Screening for atrial fibrillation in primary care by Taggar, Jaspal
Taggar, Jaspal (2017) Screening for atrial fibrillation in 
primary care. PhD thesis, University of Nottingham. 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/44379/1/JASPAL%20TAGGAR%20PHD%20WRITE%20UP
%20Post%20Viva%20Clean.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
This article is made available under the University of Nottingham End User licence and may 
be reused according to the conditions of the licence.  For more details see: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf
For more information, please contact eprints@nottingham.ac.uk
  
 
UNIVERSITY OF NOTTINGHAM 
SCHOOL OF MEDICINE 
PHD: PRIMARY CARE 
 
SCREENING FOR ATRIAL 
FIBRILLATION IN PRIMARY CARE 
 
DR JASPAL SINGH TAGGAR 
(4245881) 
  
 1 
Acknowledgments 
I would thank my supervisors – Professor Tim Coleman and 
Professor Lewis – for not only providing the support and 
supervision for this PhD, but also for the mentorship in my career 
to date.  
 
To staff at the Division of Primary Care and the Primary Care 
Education Unit, University of Nottingham – you know who you are! 
Your support helping me manage my work and PhD commitments 
was invaluable in completing this body of research. 
 
Finally to my wife and family – thank you for enduring the endless 
hours I have missed spending time with you and for your support 
enabling me to complete the PhD.  
 
 
 2 
Declarations 
The research undertaken was conceived, designed, led and 
completed by Dr Jaspal Singh Taggar (JT).  
 
PhD supervision was provided by Professor Tim Coleman (TC) and 
Professor Sarah Lewis (SL). Dr Matthew Jones (MJ) worked as part 
of the study team and provided support undertaking the research, 
data collection and assimilation. Professor Carl Heneghan (CH) 
provided expertise to help inform the design of the systematic 
reviews undertaken. 
 
Funding 
The research undertaken was funded the National Institute for 
Health Research (NIHR) GP Career Progression Fellowship and 
Nottingham City Clinical Commissioning Group.  
 
 3 
Contents 
Chapter 1. Epidemiology of atrial fibrillation ...................... 20 
1.1. Incidence and prevalence of atrial fibrillation ..................... 20 
1.1.1. Incidence and prevalence according to time and gender ... 20 
1.1.2. Incidence and prevalence according to age ..................... 24 
1.2. Risk factors for the development of atrial fibrillation ........... 25 
1.3. Consequences of atrial fibrillation ..................................... 26 
1.3.1. Morbidity from atrial fibrillation ..................................... 26 
1.3.2. Mortality from atrial fibrillation ...................................... 27 
1.3.3. Healthcare costs from atrial fibrillation ........................... 28 
1.4. Symptoms, signs and diagnosis of patients with atrial 
fibrillation ............................................................................ 29 
1.5. Stroke prevention in atrial fibrillation ................................ 30 
1.6. Silent atrial fibrillation ..................................................... 31 
1.7. Principles of screening programmes and applicability to atrial 
fibrillation screening .............................................................. 34 
Chapter 2. Screening for atrial fibrillation .......................... 40 
2.1. Literature review ............................................................ 40 
2.1.1. Search strategy ........................................................... 41 
2.1.2. Analyses ..................................................................... 43 
2.2. Results .......................................................................... 44 
2.2.1. Study characteristics .................................................... 44 
2.2.2. Organisation and implementation of interventions to detect 
silent atrial fibrillation ............................................................ 45 
2.2.2.1. Process of atrial fibrillation detection within studies ....... 45 
2.2.2.2. Periodicity of detecting silent atrial fibrillation within 
studies ................................................................................ 46 
2.2.2.3. Healthcare settings and professionals used to detect silent 
atrial fibrillation .................................................................... 48 
 4 
2.2.2.4. Selection of participants within silent atrial fibrillation 
detection studies................................................................... 48 
2.2.2.5. Age of participants within silent atrial fibrillation detection 
studies ................................................................................ 50 
2.2.2.6. Summary for the organisation and implementation of 
interventions to detect silent atrial fibrillation ........................... 50 
2.2.3. Clinical effectiveness and/or yield of interventions to detect 
silent atrial fibrillation ............................................................ 51 
2.2.3.1. Systematic review evidence for the clinical effectiveness 
and/or yield of interventions to detect silent atrial fibrillation ...... 52 
2.2.3.2. Randomised trial evidence for the clinical effectiveness of 
interventions to detect silent atrial fibrillation ........................... 55 
2.2.3.2.1. Randomised trial evidence for the clinical effectiveness 
of interventions to detect silent atrial fibrillation compared to usual 
care .................................................................................... 56 
2.2.3.2.2. Randomised trial evidence comparing the clinical 
effectiveness of systematic and opportunistic approaches of 
interventions to detect silent atrial fibrillation ........................... 58 
2.2.3.2.3. Secondary analyses of randomised trial evidence 
comparing the clinical effectiveness of systematic and opportunistic 
approaches of interventions to detect silent atrial fibrillation ....... 60 
2.2.3.3. Uncontrolled studies of atrial fibrillation case detection .. 61 
2.2.3.4. Summary of studies for the clinical effectiveness and/or 
yield of interventions to detect silent atrial fibrillation ................ 68 
2.2.3.4.1. Detecting new cases of atrial fibrillation .................... 68 
2.2.3.4.2. Risk of stroke in new cases of atrial fibrillation ........... 69 
2.2.3.4.3. Long-term clinical outcomes in new cases of atrial 
fibrillation ............................................................................ 69 
2.2.4. Cost-effectiveness of atrial fibrillation screening .............. 69 
 5 
2.2.5. Impact on the health status of patients and acceptability of 
detecting silent atrial fibrillation by patients and healthcare 
professionals ........................................................................ 75 
2.3. Conclusion and areas for further research .......................... 79 
2.3.1. Conclusion .................................................................. 79 
2.3.2. Justification for research undertaken within the thesis ...... 82 
Chapter 3. Research aims and objectives ........................... 84 
3.1. Aims ............................................................................. 84 
3.2. Objectives ..................................................................... 84 
3.3. Research methods .......................................................... 84 
Chapter 4. Systematic review and meta-analysis of methods 
for detecting pulse irregularities caused by atrial fibrillation
 .......................................................................................... 86 
4.1. Background ................................................................... 86 
4.2. Aims ............................................................................. 89 
4.3. Objectives ..................................................................... 89 
4.4. Methods ........................................................................ 90 
4.4.1. Search strategy and selection criteria ............................. 90 
4.4.1.1. Data sources ............................................................ 90 
4.4.1.2. Search terms............................................................ 90 
4.4.1.3. Inclusion and exclusion criteria ................................... 91 
4.4.2. Data extraction ........................................................... 92 
4.4.3. Assessment of study quality and risk of bias ................... 93 
4.4.4. Statistical analysis ....................................................... 96 
4.4.4.1. Primary outcome measures for diagnostic accuracy ....... 96 
4.4.4.2. Assessment of heterogeneity ...................................... 99 
4.4.4.3. Sub-group analyses .................................................. 99 
4.4.4.4. Assessment of publication bias ................................. 100 
4.5. Results ........................................................................ 102 
4.5.1. Study characteristics .................................................. 113 
 6 
4.5.2. Healthcare settings for detecting pulse irregularities caused 
by atrial fibrillation .............................................................. 114 
4.5.3. Methods used to detect pulse irregularities caused by atrial 
fibrillation .......................................................................... 114 
4.5.3.1. Detecting pulse irregularities and suspected atrial 
fibrillation .......................................................................... 114 
4.5.3.2. Reference standard for atrial fibrillation detection ....... 117 
4.5.4. Study quality and risk of bias ...................................... 118 
4.5.5. Data synthesis .......................................................... 120 
4.5.6. Sub-group analyses ................................................... 127 
4.5.7. Publication bias ......................................................... 127 
4.6. Discussion ................................................................... 129 
4.6.1. Summary of principal findings ..................................... 129 
4.6.2. Strengths and limitations ............................................ 129 
4.6.3. Findings in context of previous research ....................... 133 
4.7. Conclusion ................................................................... 135 
Chapter 5. Systematic review and meta-analysis of methods 
for diagnosing atrial fibrillation using 12-lead ECG .......... 136 
5.1. Background ................................................................. 136 
5.2. Aims ........................................................................... 139 
5.3. Objectives ................................................................... 139 
5.4. Methods ...................................................................... 140 
5.4.1. Search strategy and selection criteria ........................... 140 
5.4.1.1. Data sources .......................................................... 140 
5.4.1.2. Search terms.......................................................... 140 
5.4.1.3. Inclusion and exclusion criteria ................................. 141 
5.4.2. Data extraction ......................................................... 142 
5.4.3. Assessment of study quality and risk of bias ................. 142 
5.4.4. Statistical analysis ..................................................... 143 
5.4.4.1. Primary outcome measures for diagnostic accuracy ..... 143 
 7 
5.4.4.2. Assessment of heterogeneity .................................... 144 
5.4.4.3. Sub-group analyses ................................................ 144 
5.4.4.4. Assessment of publication bias ................................. 145 
5.5. Results ........................................................................ 146 
5.5.1. Study characteristics .................................................. 148 
5.5.2. Healthcare settings for 12-lead ECG interpretation and 
diagnosis of atrial fibrillation ................................................. 148 
5.5.3. Methods used for 12-lead ECG interpretation and diagnosis 
of atrial fibrillation ............................................................... 148 
5.5.3.1. Methods used for acquiring and interpreting 12-lead ECGs 
in the diagnosis of atrial fibrillation ........................................ 148 
5.5.3.2. Reference standard for diagnosing atrial fibrillation ..... 150 
5.5.4. Study quality and risk of bias ...................................... 154 
5.5.5. Data synthesis .......................................................... 156 
5.5.6. Sub-group analyses ................................................... 161 
5.5.7. Publication bias ......................................................... 161 
5.6. Discussion ................................................................... 163 
5.6.1. Summary of principal findings ..................................... 163 
5.6.2. Strengths and limitations ............................................ 163 
5.6.3. Findings in context of previous research ....................... 166 
5.7. Conclusions ................................................................. 168 
Chapter 6. Survey of healthcare professionals in primary 
care about AF screening ................................................... 170 
6.1. Background ................................................................. 170 
6.2. Aims ........................................................................... 173 
6.3. Objectives ................................................................... 173 
6.4. Methods ...................................................................... 174 
6.4.1. Study approach and participants.................................. 174 
6.4.2. Survey design and implementation .............................. 176 
6.4.2.1. Survey questions .................................................... 176 
 8 
6.4.2.1.1. Participant characteristics...................................... 176 
6.4.2.1.2. Existing methods for diagnosing atrial fibrillation and 
participant knowledge, skills and attitudes about atrial fibrillation 
screening ........................................................................... 176 
6.4.2.1.3. Facilitators and barriers to atrial fibrillation screening 178 
6.4.2.2. Survey piloting ....................................................... 178 
6.4.3. Survey dissemination ................................................. 179 
6.4.4. Statistical analysis ..................................................... 179 
6.4.5. Study ethics .............................................................. 181 
6.5. Results ........................................................................ 182 
6.5.1. Participant response ................................................... 182 
6.5.2. Participant characteristics ........................................... 184 
6.5.3. Existing methods for diagnosing atrial fibrillation ........... 184 
6.5.4. Knowledge, skills and attitudes (KSA) relating to atrial 
fibrillation screening ............................................................ 185 
6.5.5. Facilitators and barriers to AF screening ....................... 194 
6.5.5.1. Quantitative results ................................................. 194 
6.5.5.2. Findings from open-ended questions ......................... 197 
6.6. Discussion ................................................................... 199 
6.6.1. Summary of principal findings ..................................... 199 
6.6.2. Strengths and limitations ............................................ 199 
6.6.3. Comparison with existing literature .............................. 203 
6.7. Conclusions ................................................................. 206 
Chapter 7. Summary and recommendations..................... 207 
7.1. Summary and implications ............................................ 207 
7.2. Recommendations ........................................................ 215 
7.2.1. Recommendations for clinical practice .......................... 215 
7.2.2. Recommendations for research ................................... 217 
 
 
 
 9 
 
  
 10 
Tables 
Table 2-1: Uncontrolled studies of interventions to detect silent 
atrial fibrillation .................................................................... 64 
Table 4-1: Characteristics of included studies ......................... 104 
Table 4-2: Characteristics of eligible studies that were excluded 111 
Table 5-1: Characteristics of included studies ......................... 151 
Table 5-2: Characteristics of eligible studies that were excluded 153 
Table 6-1: Knowledge and skills in conducting atrial fibrillation 
screening actives by healthcare professionals ......................... 187 
Table 6-2: Attitudes of healthcare professionals about training for 
atrial fibrillation screening .................................................... 191 
Table 6-3: Perceived role of healthcare professionals in future atrial 
fibrillation screening ............................................................ 195 
 
 
 
 
  
 11 
Figures 
Figure 4-1: Study selection and stratification .......................... 103 
Figure 4-2: Study quality according to QUADAS-2 criteria ........ 119 
Figure 4-3: Sensitivity and specificity of blood pressure monitor 
interventions ...................................................................... 121 
Figure 4-4: Sensitivity and specificity of non-12-lead ECG 
interventions ...................................................................... 122 
Figure 4-5: Sensitivity and specificity of smartphone applications
 ........................................................................................ 123 
Figure 4-6: Sensitivity and specificity of pulse palpation .......... 124 
Figure 4-7: Summary Receiver Operating Characteristic (SROC) 
plots for methods of detecting pulse irregularities caused by atrial 
fibrillation .......................................................................... 126 
Figure 5-1: Study selection and stratification .......................... 147 
Figure 5-2: Study quality according to QUADAS-2 criteria ........ 155 
Figure 5-3: Sensitivity and specificity of 12-lead ECG interpretation 
using automated software .................................................... 157 
Figure 5-4: Sensitivity and specificity of 12-lead ECG interpretation 
by any healthcare professional ............................................. 158 
Figure 5-5: Sensitivity and specificity of 12-lead ECG interpretation 
by primary care professionals ............................................... 159 
Figure 5-6: Summary Receiver Operating Characteristic (SROC) 
plots for the accuracy of 12-lead ECG interpretation by software, 
any clinician, and primary care clinician ................................. 160 
Figure 5-7: Sub-group analyses of the sensitivity and specificity of 
12-lead ECG interpretation by GPs and practice nurses ............ 162 
Figure 6-1: Participant response to the survey ........................ 183 
 
 
 
 12 
Appendices 
Appendix 1: Chapter 4 - Electronic search strategy ................. 242 
Appendix 2: Chapter 4 - Data extraction table ........................ 252 
Appendix 3: Chapter 5 - Electronic search strategy ................. 254 
Appendix 4: Chapter 6 - Healthcare professional survey .......... 266 
Appendix 5: Research outputs .............................................. 276 
 
 
 
 13 
List of abbreviations 
AF    Atrial fibrillation 
ANOVA    Analysis of variance  
AUD    Australian dollar 
BPM    Blood Pressure monitor 
C    Cohort 
CC    Case-control 
CCG     Clinical Commissioning Group  
CI    Confidence interval 
CKD     Chronic kidney disease  
COPD    Chronic obstructive pulmonary   
    disease  
CS     Cross-sectional 
DOACS    Direct oral anticoagulants   
ECG    Electrocardiogram 
EHRA    European Heart Rhythm Association  
EORP-AF    EurObservational Research Programme -  
    Atrial Fibrillation 
EQ-5D    EuroQol five dimensions  
ES     European Society of Cardiology  
GP    General practitioner 
HCA    Healthcare assistant 
HCP    Healthcare professional 
HPV     Human Papilloma Virus  
 14 
HR     Hazard ratio 
ICER     Incremental Cost-Effectiveness Ratio 
IQR    Interquartile range 
KSA     Knowledge, skills and attitudes  
MACE    Major Adverse Cardiac Events  
MRC     Medical Research Council 
NHS     National Health Service 
NICE     National Institute for Health and Care  
    Excellence  
NIHR    National Institute for Health Research  
NLR    Negative Likelihood ratio 
NNS     Number needed to screen  
NP    Nurse Practitioner 
OR    Odds ratio 
OSA     Obstructive sleep apnoea  
PLR    Positive Likelihood ratio 
PREVEND     Prevention of Renal and Vascular End- 
    Stage Disease  
QALY    Quality-Adjusted Life Year  
QUADAS-2   Quality Assessment of Diagnostic Accuracy 
    Studies-2  
RCP     Royal College of Physicians  
RCT     Randomised controlled trial 
ROC     Receiver operating characteristic 
 15 
RR     Risk ratio 
SAFE trial    Systematic screening versus routine  
    practice for the detection of atrial   
    fibrillation in people aged 65 and over trial  
SD    Standard deviation 
SROC    Summary Receiver Operating Characteristic 
UI    Uncertainty interval 
UK     United Kingdom 
US     United states 
USA     United States of America 
USD    US dollar 
 
 16 
Abstract 
Background 
Screening for atrial fibrillation (AF) has been recommended but is 
yet to be implemented in clinical practice. However, the most 
effective approaches for screening are not known and it is unclear 
if screening could feasibly be implemented in primary care. 
   
Aims and methods 
The overall aims were to determine how AF screening might 
feasibly and effectively be introduced into primary care in the 
United Kingdom (UK). Objectives were: 1) to determine the range 
and accuracies of methods for detecting pulse irregularities 
attributable to AF, 2) to determine the range and accuracies of 
methods for diagnosing AF using 12-lead electrocardiograms 
(ECGs) and 3) to investigate the feasibility and opinions of 
healthcare professionals (HCPs) in primary care about 
implementing AF screening.  
Three studies were undertaken: 1) a systematic review and meta-
analysis of the diagnostic accuracy of methods for detecting pulse 
irregularities caused by AF, 2) a systematic review and meta-
analysis of the diagnostic accuracy of methods for diagnosing AF 
using 12-lead ECG and 3) a survey of HCPs in primary care about 
screening implementation.  
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Results 
Study 1: Blood pressure monitors (BPMs) and non-12-lead ECGs 
had the greatest accuracy for detecting pulse irregularities 
attributable to AF [BPM: sensitivity 0.98 (95% CI 0.92-1.00), 
specificity 0.92 (95% CI 0.88-0.95), positive likelihood ratio (PLR) 
12.1 (95% C.I 8.2-17.8) and negative likelihood ratio (NLR) 0.02 
(95% C.I 0.00-0.09); non-12-lead ECG: sensitivity 0.91 (95% CI 
0.86-0.94), specificity 0.95 (95% CI 0.92-0.97), PLR 20.1 (95% 
C.I 12-33.7), NLR 0.09 (95% C.I 0.06 to 0.14); there were similar 
findings for smart-phone applications although these studies were 
small in size. The sensitivity and specificity of pulse palpation were 
0.92 (95% CI 0.85-0.96) and 0.82 (95% CI 0.76-0.88), 
respectively (PLR 5.2 (95% C.I 3.8-7.2), NLR 0.1 (0.05-0.18)].  
Study 2: The sensitivity and specificity of automated software were 
0.89 (95% CI 0.82-0.93) and 0.99 (95% CI 0.99-0.99), 
respectively; PLR 96.6 (95% C.I 64.2-145.6); NLR 0.11 (95% C.I 
0.07-0.18). ECG interpretation by any HCPs had a similar 
sensitivity for diagnosing AF as automated software but a lower 
specificity [sensitivity 0.92 (95% CI 0.81-0.97), specificity 0.93 
(95% CI 0.76-0.98), PLR 13.9 (95% C.I 3.5-55.3), NLR 0.09 (95% 
C.I 0.03-0.22). Sub-group analyses of primary care professionals 
found greater specificity for General Practitioners (GPs) than nurses 
[GPs: sensitivity 0.91 (95% C.I 0.68-1.00); specificity 0.96 (95% 
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C.I 0.89-1.00). Nurses: sensitivity 0.88 (95% C.I 0.63-1.00); 
specificity 0.85 (95% C.I 0.83-0.87)].    
Study 3: 39/48 (81%) practices had an ECG machine and 
diagnosed AF in-house.  Fewer non-GP HCPs reported having 
excellent knowledge about ECG interpretation, diagnosing and 
treating AF than GPs [Proportion (95% CI): ECG interpretation = 
GPs: 5.9 (2.8-12.0); healthcare assistants (HCAs): 0; nurses: 2.0 
(0.3-13.9); Nurse practitioners (NPs): 11.8 (3.0-36.4). Diagnosing 
AF = GPs: 26.3 (17.8-37.0); HCAs: 0; nurses: 2.0 (0.3-12.9); 
NPs: 11.8 (2.7-38.8). Treating AF = GPs: 16.9 (9.9-27.4); HCAs: 
0; nurses: 0; NPs: 5.9 (0.8-34.0)]. A greater proportion of non-GP 
HCPs reported they would benefit from ECG training specifically for 
AF diagnosis than GPs [proportion (95% CI) GPs: 11.9% (6.8-
20.0); HCAs: 37.0% (21.7-55.5); nurses: 44.0% (30.0-59.0); NPs 
41.2% (21.9-63.7)]. Barriers included time, workload and capacity 
to undertake screening activities, although training to diagnose and 
manage AF was a required facilitator. 
 
Conclusions 
BPMs and non-12-lead ECG were most accurate for detecting pulse 
irregularities caused by AF. Automated ECG-interpreting software 
most accurately excluded AF, although its ability to diagnose this 
was similar to all other HCP groups. Within primary care, the 
specificity of AF diagnosis was greater for GPs than nurses. Inner-
 19 
city general practices were found to have adequate access to 
resources for AF screening. Non-GP HCPs would like to up-skill in 
the diagnosis and management of AF and they may have a role in 
future AF screening. However, organisational barriers, such as lack 
of time, staff and capacity, should be overcome for AF screening to 
be feasibly implemented within primary care.  
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Chapter 1. Epidemiology of atrial fibrillation 
Atrial fibrillation (AF) is the most common sustained heart rhythm 
disorder encountered in clinical practice and is a global public 
health burden. (1) Originating predominately from the left atrium, 
AF results in chaotic atrial activity manifesting clinically as an 
irregular cardiac rate and cardiac output. (2) AF is not benign and 
results in a hypercoagulable state predisposing to an increased risk 
of stroke. (3) A substantial proportion of patients with AF have no 
symptoms and are referred to as having asymptomatic or silent AF. 
(4, 5) Therefore, early detection and subsequent provision stroke 
preventative treatment in patients with silent AF may have 
significant public health benefits.   (4, 5) 
 
1.1. Incidence and prevalence of atrial fibrillation 
1.1.1. Incidence and prevalence according to time and 
gender 
 
The incidence and prevalence of AF have increased over time 
across different international healthcare systems and are both 
greater in men than women. A systematic review of population-
based studies from 21 Global Burden of Disease regions 
investigated changes in the incidence and prevalence of AF 
between 1980 and 2010. (6) Chugh et al. identified 184 studies (no 
 21 
age of inclusion restrictions applied) that were relevant to this 
review and estimated 33.5 million people (20.9 million men (95% 
uncertainty (i.e. confidence) interval (UI) 19.5-22.2) and 12.6 
million women (95% UI 12.0-13.7) had AF globally in 2010. (6) In 
1990, the annual age-adjusted incidence rates (95% UI) of AF 
were 60.7 (49.2-78.5) per 100,000 men and 43.8 per 100,000 
(35.9-55.0) women. (6) By 2010 the point estimates for annual 
incidence rates had increased to 77.5 (65.2-95.4) and 59.5 (49.9-
74.9) per 100,000 in men and women, respectively. (6) Similar 
trends in the point estimates for the prevalence of AF were also 
reported between 1990 and 2010 although, as for the reported 
incidence rates, the UI were overlapping; the prevalence of AF 
increased from 569.5 (95% UI 532.8-612.7) to 596.2 (95% UI 
558.4-636.7) per 100,000 men and from 359.9 (95% UI 334.7-
392.6) to 373.1 (95% UI 347.9-402.2) per 100,000 women. (6) 
Furthermore, Chugh et al. found that there were differences in the 
global distribution of AF with developed countries having a greater 
incidence and prevalence of AF than in developing regions. (1, 6) 
 
A further systematic review of studies that provided up-to-date 
epidemiological data for the estimated incidence and prevalence of 
AF in European countries found the overall prevalence of AF in 
adults has doubled over the last 20 years. (7) Zoni-Berisso et al. 
reported that the current overall prevalence of AF is between 1-2% 
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in European countries, ranging from around 1.9% in Italy, Iceland 
and England, to 2.3% in Germany and 2.9% in Sweden. (7) The 
current population incidence of AF in Europe ranged from 0.23 per 
1,000 person-years in Iceland to 0.41 per 1,000 person-years in 
Germany. (7) 
 
Studies conducted within North American populations suggest the 
recorded incidence and prevalence of AF may be higher in the 
United States (US) than European countries. (8, 9) Analyses from 
the Framingham Heart Study suggest the recorded age-adjusted 
incidence of AF has increased from 3.7 to 13.4 per 1,000 person-
years in men and 2.5 to 8.6 per 1,000 person-years in women 
between 1958 and 2007. (9) Over the same time period, the 
recorded age-adjusted prevalence of AF increased from 20.4 to 
96.2 per 1000 person-years in men and 13.7 to 49.4 per 1,000 
person-years in women. (9) This rise in prevalence over the last 50 
years is likely to be due to a multiple of interacting factors over 
time such as improvements in diagnosis and clinical coding, 
changes in the prevalence of risk factors for the development of AF 
and improved survival from AF. (9) 
 
Population based estimates from the far Eastern countries suggest 
the incidence and prevalence of AF may be lower than in Western 
countries, although differences in global healthcare systems and 
 23 
comprehensiveness of recording clinical information may contribute 
to the accuracy of such epidemiological estimates.  There does, 
however, appear to be similar trends of rising incidence and 
prevalence overtime as for other nations. A representative 
community-based study of 29,079 participants aged 30 years or 
older from 13 provinces in China found the population prevalence 
of AF, confirmed by physical examination and electrocardiography, 
was 0.65 per 100 people. (10) Analyses from a Chinese medical 
insurance database between 2001-2012 (n=471,446, 62% male, 
mean age 62 years) found the overall incidence of AF in adults over 
20 years of age was 0.05 per 100 person-years and the prevalence 
of AF was 0.2 per 100. (11) The authors also found there was 
around a 20-fold increase in AF incidence and prevalence over the 
study period. (11) Studies from Japanese populations also have 
reported similar trends in AF prevalence. Analyses of data from 
periodic health examinations in 630,138 people aged 40 years and 
over from communities, company employees and local 
governments in 2003 found the prevalence of AF was 1.35 and 
0.43 per 100 in Japanese men and women, respectively. (12) 
Moreover, Inoue et al. estimated the prevalence of AF in Japan 
would increase from 0.65 to 1.09 per 100 from 2010 to 2050. (12)  
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1.1.2. Incidence and prevalence according to age 
The incidence and prevalence of AF increase with advancing age 
and this trend has been consistently reported from a variety of 
studies across different global populations and healthcare systems. 
(6-8, 10-24)  
 
The prevalence of AF was estimated at around 0.12-0.5% in those 
under 50 years of age, 3.7%–4.2% in people between 60-70 years 
of age and this steeply rises to greater than 10% in the over 80 
year old population. (7, 13, 16, 25)  
 
The narrative systematic review by Zoni-Berisso et al. also 
suggested the incidences of AF in those aged 65–74 years were 
3.2, 10.8, and 15.5 per 1,000 person-years in Scotland, Germany 
and the USA, respectively. (7) The incidence appeared higher in 
the older age group with it being reported as 6.2, 16.8, and 33.5 
per 1,000 person-years in Scotland, Germany and the USA, 
respectively, in those aged 75–84 years. (7) These findings were 
consistent with analyses from Rotterdam population-based cohort 
study. (25) Heeringa et al. reported incidence rates of AF from 
6,432 Dutch patients aged 55 years and older who had a mean 
follow-up of 6.9 years and found the incidence rate in those aged 
55-59 years was 1.1 (95% CI 0.3–2.9) per 1,000 person-years, 
which increased to 20.7 (95% CI 16.8–25.3) per 1,000 person-
 25 
years in those aged 80-84 years. (25) The authors also found an 
increase in AF prevalence with advancing age in analyses form 
6,808 participants which rose from 0.7% (95% CI 0.4–1.4) in 
patients aged 55-59 years to 17.8% (95% CI 14.5–21.7) in those 
85 years of age and older. (25)  
 
1.2. Risk factors for the development of atrial 
fibrillation 
The lifetime risk of developing AF is around 20-25% in people over 
the age of 40 years. (11, 16, 20, 25) The point estimates for risk 
suggest this may be greater for men than women although the 
confidence around these estimates suggest the difference is likely 
borderline. (Men 26.0% (95% Confidence Interval (CI) 24.0-27.0) 
and women 23.0% (95% CI 21.0-24.0). (20) 
 
There are a number of comorbidities that are associated with the 
development of AF and the European Society of Cardiology (ESC) 
identify increasing age, hypertension, cardiac failure, 
cardiomyopathies, coronary artery disease, valvular heart disease, 
diabetes, obstructive sleep apnoea (OSA), obesity, chronic 
obstructive pulmonary disease (COPD); thyroid dysfunction and 
chronic kidney disease (CKD) as established risk factors that 
associate and/or predispose to incident AF. (16-18, 22, 26-35)  
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Furthermore, other potential risk factors for the development of AF 
include asthma, (36, 37)  Caucasian ethnicity, (38, 39) lower 
socioeconomic status, (38, 39) smoking, (40) higher levels of 
alcohol consumption (41) and excessive exercise. (42-45) There 
may also be a genetic predisposition for the development of AF. 
(16, 46-50)  
 
1.3. Consequences of atrial fibrillation 
AF is associated with substantial morbidity, mortality and 
healthcare costs, most notably from an increased risk of ischaemic 
stroke. (16, 51)  
 
1.3.1. Morbidity from atrial fibrillation 
The increased morbidity from AF predominately arises from 
symptoms of AF, the development of heart failure and AF related 
stroke. (52-55)  
 
People may experience symptoms from AF, such as palpitations 
that arise from the characteristic feature of AF presenting with an 
irregular pulse, chest pain or discomfort, shortness of breath, 
dizziness and blackouts. (16, 51) Moreover, patients with AF also 
experience greater psychological distress, depressed mood (56) 
and impaired quality of life than those without AF and these are 
independent of other comorbidities. (52, 57-60) 
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AF is associated with a 4-5 fold increased risk of ischaemic stroke, 
(55) Major Adverse Cardiac Events (MACE), (61, 62) and cardiac 
failure. (16, 63) Strokes attributable to AF have a greater severity 
than non-AF related strokes. (64, 65) Moreover, prospective 
analyses from European and Canadian population cohorts suggest 
the risk of stroke from AF is greater in women than men. (66-68)  
 
Furthermore, prospective cohort registry data suggest around 10-
40% of patients are hospitalised every year with AF (52, 55, 69) 
and AF is independently associated with cognitive decline and 
vascular dementia. (52, 70, 71)  
 
1.3.2. Mortality from atrial fibrillation 
Mortality rates are approximately double in people with AF.  
Analyses of prospective data from the Framingham Cohort Study 
found, in people aged 55-94 years (n=5,209) who developed AF 
during 40 years of follow-up, AF independently increased the risk 
of mortality (OR (95% CI) 1.5 (1.2-1.8) in men and 1.9 (1.5-2.2) 
in women). (72) 
 
 
The Scottish Renfrew/Paisley cohort study investigated 
cardiovascular outcomes in 7,052 men and 8,354 women aged 45-
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64 years over a 20-year period. (54) Stewart et al. found AF to be 
an independent predictor of all-cause mortality in both women and 
men (RR (95% CI) for women 2.2 (1.5-3.2) and men 1.5 (1.2-
2.2). (54)  
 
More recent analyses of cohort data over a mean 9.7 years of 
follow-up from 8,265 Dutch participants in the Prevention of Renal 
and Vascular End-Stage Disease (PREVEND) study suggested the 
independent risk of mortality from AF may be as much as 3-fold 
higher than those without AF (HR (95% CI) 3.02 (1.73-5.27)). (63)  
 
1.3.3. Healthcare costs from atrial fibrillation 
International studies across a variety of healthcare systems have 
demonstrated that AF is a costly public health problem, and is 
associated with greater healthcare utilisation and costs than in 
people without AF. Moreover, strokes attributable to AF incur 
greater healthcare costs than non-AF related strokes. (64, 65) A 
German study of 367 patients who were followed up for 12 months 
after a stroke investigated the direct hospital costs attributable to 
strokes and reported a greater mean direct cost per patient for 
those with a stroke caused by AF (€11,799 (SD 8,292) versus 
€8,817 (SD 7,251); p<0.001 for AF and non-AF attributable 
strokes, respectively). (64) Retrospective analyses of US claims 
data on hospital related costs from AF calculated an annual in-
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patient cost of $11,306.53 and an annual out-patient cost of 
$2,826.78 per patient when the primary diagnosis was AF. (73) 
Moreover, another US study that also used data from a claims 
database estimated the incremental cost burden of undiagnosed AF 
at $3.1 billion (95% CI 2.7-3.7). (74) A study in the United 
Kingdom (UK) investigated the projected healthcare costs directly 
related to AF and estimated that nearly 1% of the National Health 
Service (NHS) expenditure would be for AF. (75) Moreover, 
Stewart et al. found that approximately 50% of costs were related 
to hospital admissions and 20% of costs were for drug 
prescriptions. (75)  
 
1.4. Symptoms, signs and diagnosis of patients with 
atrial fibrillation 
AF results in an irregular cardiac rhythm and therefore an irregular 
pulse is the hallmark clinical sign of AF. (76-79) Patients with AF 
may present with symptoms including palpitations, shortness of 
breath, chest pain, lethargy, dizziness and/or syncope, (76) of 
which some are non-specific and may be caused by other 
conditions. The experience and severity of AF symptoms varies 
considerably between patients. The European Society of Cardiology 
(ESC) recommend using the Modified European Heart Rhythm 
Association (EHRA) symptom scale to determine the severity of 
symptoms in those with AF – the symptom scale ranges from 1 to 
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4, with 1 denoting no symptoms and a score of 4 representing 
disabling symptoms. (52)  
 
An irregularly irregular pulse is usually the first clinical finding in 
patients with suspected AF. Once suspected, AF is diagnosed by an 
electrocardiogram (ECG), with a 12-lead ECG interpreted by a 
competent professional being recognised as the gold standard 
diagnostic test. (51, 52, 80) 
 
1.5. Stroke prevention in atrial fibrillation 
The prevention of stroke in patients once AF has been diagnosed is 
imperative to reduce the morbidity, mortality and healthcare costs 
associated with AF. (16, 51) Anti-thrombotic therapy to prevent AF 
related stroke is the only treatment that has been shown to reduce 
mortality associated with AF. (16)   
 
The risk of stroke in AF is heterogeneous and increases with age, 
the number of AF-associated co-morbidities and is higher in women 
than men. (16) Patients with AF should have their risk of stroke 
and systemic thromboembolism calculated using the established 
and validated Congestive cardiac failure, Hypertension, Age ≥75 
years, Diabetes and Stroke (CHADS2) and/or the Congestive 
cardiac failure, Hypertension, Age ≥75 years, Diabetes, Stroke, 
Vascular disease, Age 65-74 and Sex category (CHA2DS2VASc) 
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schemata. (16, 51) The National Institute for Health and Care 
Excellence (NICE) and the European Society of Cardiology (ESC) 
recommend patients scoring ≥2 points on either risk scale should 
be offered stroke preventative therapies, and men with a 
CHA2DS2VASc score of 1 should be considered for such treatments. 
(16, 51)  
 
Oral anticoagulation using vitamin K antagonists (VKAs), such as 
warfarin, has been shown to reduce the risk of stroke. A meta-
analysis of 29 randomised trials (n=28,044; mean age 71 years) 
found, as compared to control, adjusted dose warfarin reduced the 
risk of stroke by around 64% (95% CI 49-74). (81) More recently 
direct oral anticoagulants (DOACS) have been developed and these 
appear to overcome difficulties in safe prescribing and monitoring 
of VKAs, and randomised trial evidence has found DOACS to have 
at least a similar efficacy for stroke prevention and similar or lower 
risk of haemorrhagic complications as VKAs. (82-84) Consequently, 
the prescription of the DOACS Dabigatran, Apixaban and 
rivaroxaban have been recommended, alongside the use of VKAs, 
for the prevention of stroke in patients with AF. (16, 51)  
 
1.6. Silent atrial fibrillation  
Patients with AF may present to healthcare professionals with 
symptoms as described previously. However, a substantial number 
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of patients with AF have no symptoms and are described as having 
either asymptomatic or silent AF, (16) and these terms are used 
interchangeably. 
 
The EurObservational Research Programme - Atrial Fibrillation 
(EORP-AF) registry enrolled consecutive inpatients and outpatients, 
from 67 centres in nine countries that presented with AF to 
cardiologists. (85) Patients with AF had their symptoms scored 
using the EHRA symptom scale to distinguish symptom severity 
and impairment in daily activity. (16, 85) Analyses of data from the 
EORP-AF pilot registry found that, of 3,119 patients enrolled, 1,237 
(39.7%) had an EHRA score of one and were therefore classified as 
being asymptomatic. (86) Asymptomatic patients with AF were 
more likely to be male, older, and have a previous history of 
myocardial infarction. (86) Moreover, one-year mortality was 
around twice higher in patients with asymptomatic AF than those 
with symptoms. (86)  
 
Data from studies of pacemaker interrogation to detect silent AF 
suggest that asymptomatic AF may be occurring in 10.1-30% of 
patients with cardiac pacemakers. (87-89) However the true 
prevalence of silent AF may be higher or lower in unselected 
community populations as estimates have been derived 
predominately from patients in secondary care settings.  
 33 
 
There has been an abundance of studies that have also 
investigated the proportion of hospital inpatients with newly 
detected AF after first presenting with an ischaemic stroke. Most 
studies within this setting have used serial ECGs or cardiac holter 
monitors to detect asymptomatic AF. (90-106) Up to 45% of 
patients presenting with stroke had undiagnosed AF although there 
was substantial variation in detection rates due to the method, 
duration and definition of AF within each study. A more recent 
analysis of data from 55,551 patients aged 18 years or over from a 
national Danish stroke registry found 9,482 (17.1%) of patients 
with an acute ischaemic stoke were found to have AF. (107)   
 
Given the high prevalence of AF in asymptomatic patients and 
those first presenting with an ischaemic stroke, combined with the 
increasing prevalence of AF in an ageing population, AF and its 
consequences pose a significant public health burden. Early 
detection of AF and the subsequent provision of stroke 
preventative therapies could result in significant population health 
benefits.  Consequently, screening for AF has been recommended 
by the European Society of Cardiology (ESC) and the Royal College 
of Physicians (RCP) as a method to improve the detection of AF 
and subsequent prevention of stroke in people over 65 years of 
age. (16, 80, 108)  
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In the following section the extent to which it would be appropriate 
to introduce screening for AF will be assessed and the context(s) in 
which this should be done.  
 
1.7. Principles of screening programmes and 
applicability to atrial fibrillation screening 
Published by the World Health Organisation in 1968, Wilson and 
Jungner identified the following 10 criteria for appraising the 
validity of screening programmes: (109)  
1. The condition being screened for should be an important 
health problem. 
2. The natural history of the condition should be well 
understood. 
3. There should be a detectable early stage. 
4. Treatment at an early stage should be of more benefit than 
at a later stage. 
5. A suitable test should be devised for the early stage. 
6. The test should be acceptable. 
7. Intervals for repeating the test should be determined 
8. Adequate health service provision should be made for the 
extra clinical workload resulting from screening. 
9. The risks, both physical and psychological, should be less 
than the benefits. 
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10. The costs should be balanced against the benefits. 
 
AF screening aligns with many of the principles of screening 
programmes set by Wilson and Jungner. (109) As discussed in 
previous sections, AF is highly prevalent and an important health 
problem (criteria one). The natural history from the development of 
AF to the occurrence of thromboembolic complications is 
understood (criterion two). A substantial proportion of patients with 
AF are asymptomatic and AF is easily detectable during this early 
stage (criterion three). Moreover, treatments exist, are widely 
available and, if provided early, reduce the risk of thromboembolic 
complications arising from AF (criterion four). The proposed 
screening process, by first conducting pulse palpation (the 
screening test) and then diagnosing AF using ECG (the diagnostic 
test), is available (criterion five). However, the evidence to support 
screening implementation is less robust when mapped to the other 
screening criteria. 
 
As AF screening fulfils many of the screening criteria, consensus 
from the Royal College of Physicians of Edinburgh suggested that 
the most cost-effective approach to detect AF in the UK is to 
opportunistically screen people aged 65 years or older by radial 
pulse palpation followed by a 12-lead ECG in those with an 
irregular pulse, and that this should be done in primary care. (80)  
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As screening aims to detect asymptomatic patients with AF prior to 
the development of thromboembolic complications, it is likely that 
non-hospital settings – such as primary healthcare and/or non-
healthcare community (e.g. care homes, community health 
campaigns, community education groups) settings - would be the 
most appropriate contexts for screening implementation. However, 
of these two settings it is probable the primary healthcare would be 
the more relevant setting for AF screening. Within healthcare it is 
estimated that up to 90% of NHS contact occurs within primary 
care (110, 111) and consultation rates in GP practices are high in 
the elderly (111) - a group most likely to have a highest 
prevalence of AF. There is access to 12-lead ECG diagnosis of AF 
within primary care, with GP practices recording and interpreting 
ECGs. (112) Many patients with AF are already managed in primary 
care (21, 113) and, with an increasing amount of healthcare 
services being delivered in primary care alongside the increasing 
elderly population, (114) it is likely that the number of patients 
with AF that are managed by primary care services is set to rise. 
However, there have been no studies that have investigated the 
views of healthcare professionals in GP practices (e.g. General 
Practitioners (GPs) and/or nurses) about feasibly implementing AF 
screening and their abilities to accurately detect this arrhythmia. 
Indeed, understanding the views of professionals that could be 
expected to undertake screening would be an important priority to 
 37 
ensure adequate health service provisions are in place for the extra 
clinical workload that would arise from screening.  
 
Following consensus statements to implement AF screening, a 
review of the evidence for screening was published in 2014 for the 
United Kingdom (UK) National Screening Committee and the 
evidence was assessed against the criteria for screening 
programmes. (115) The review found that despite AF screening 
meeting many of the screening criteria there were sufficient gaps 
in the evidence-base to not support national implementation of an 
AF screening programme.  The reported gaps and limitations 
highlighted within this report are provided below and I have 
mapped these to the screening criteria that were not fulfilled: 
(115)  
 Although many approaches to screening may exist, the 
optimal methods for detecting and diagnosing AF were 
unclear (criterion five).  
 An assessment of adequate staffing and facilities for the 
testing, diagnosis, treatment of an AF screening programme 
had not been undertaken. It was unclear if adequate service 
provision was available for the increased workload that would 
arise from screening implementation and, therefore, the 
feasibility of implementing screening was not known. 
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Moreover, consensus on the quality assurance measures of 
an AF screening had not been derived (criterion eight).  
 The optimal time interval(s) for repeating AF screening and 
the impact of using different age thresholds for screening 
were not known (criterion seven). 
 Treatment uptake in patients with AF was sub-optimal. 
Therefore, improvement in the provision of stroke 
preventative therapies to those with AF was needed before 
screening could be implemented (criterion four). 
 It was unclear if people with screen-detected AF had better 
long-term outcomes for morbidity and mortality than those 
with AF diagnosed through routine care. Therefore, it was 
unclear if the clinical benefits from AF screening outweighed 
the clinical risks  (criterion four). 
 There was little research that investigated the views of 
patients, healthcare professionals and other key stakeholders 
about AF screening. Therefore, it was unclear whether 
screening was acceptable (criterion six) and if the benefits, 
both physical and psychological, outweighed the risks of 
screening (criterion nine). 
 There was insufficient evidence for the cost-effectiveness of 
screening. Moreover, the affordability and opportunity cost of 
implementing screening were not established (criterion ten).  
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Consequently, despite the expert consensus recommendations 
made for AF screening in primary care, this is yet to be 
implemented into routine clinical practice, and research that 
develops our understanding of how AF screening could feasibly and 
effectively be introduced within primary care is warranted.   
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Chapter 2. Screening for atrial fibrillation 
2.1. Literature review 
The review in 2014 for the UK National Screening Committee did 
not support the implementation of AF screening and a number of 
gaps were highlighted in the evidence-base for this intervention 
when appraised against the criteria for screening programmes. 
(115) Research gaps included understanding better the optimal 
methods for detecting AF, the feasibility of implementing screening 
into clinical practice and translating the detection of patients with 
AF into improved long-term clinical outcomes.  
 
A broad literature review was conducted with the aim of assessing 
the current evidence base for or against AF screening (i.e. 
detecting silent AF) in primary healthcare and/or community-based 
settings, and to further characterise the research required before 
screening could be introduced into routine clinical practice. A 
secondary aim of the review was to describe how screening was 
organised in studies conducted within the UK, as different 
contextual factors might be relevant to screening within the 
National Health Service (NHS).  
 
The objectives for this review were to characterise how 
interventions to detect silent AF within primary healthcare and/or 
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community-based (i.e. non-hospital) settings have i) been 
organised and implemented, ii) to determine the effectiveness 
and/or yield of interventions to detect silent AF, iii) to determine 
the cost-effectiveness of interventions to detect silent AF, iv) to 
determine the impact on health status of patients and the 
acceptability of interventions to detect silent AF by patients and 
healthcare professionals.  
 
2.1.1. Search strategy 
The MEDLINE and EMBASE databases were searched for studies 
until January 2016 using the following Medical Subject Headings 
(MeSH) terms, keywords and associated wildcard terms: 
 Atrial fibrillation  
 Atrial flutter  
 Auricular fibrillation 
 Irregular pulse 
 Irregular heart  
 Irregular rhythm 
 Screening 
 Mass screening  
 Detect 
 Identify 
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The National Institute for Health Research (NIHR), European 
Society of Cardiology (ESC) and Royal College of Physicians (RCP) 
guidelines, the Cochrane Library, Cochrane Controlled Trials 
Register, and the AF Screen International Collaboration were also 
searched. 
  
Using a systematic search strategy, studies were included that 
were published in English and addressed the topic of detecting 
silent AF in adults aged 18 years or over in non-hospital settings. 
Studies were included that recruited participants from primary 
healthcare (e.g. GP practices, pharmacies, opticians), non-
healthcare community (e.g. care homes, community health 
campaigns, community education groups) and/or outpatient clinic 
settings. Outpatient clinic settings were included in the definition of 
non-hospital settings as outpatient services are increasingly being 
delivered out of hospitals and studies within this setting may be 
translatable to the delivery of screening in primary care. Studies 
conducted using hospital inpatients or in emergency care settings 
were not included. Empirical research studies of any study design, 
with the exception of case reports and case series, that reported 
clinical outcomes (e.g. number of new cases of AF, stroke risk in 
those with new AF, number of strokes after AF detection, harms 
from the treatment of AF) for the effectiveness and/or yield, cost-
effectiveness, impact and/or acceptability on patients or healthcare 
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professionals from AF screening interventions were included. 
Effectiveness was defined as clinical outcomes from interventions 
to detect silent AF when compared to other interventions or routine 
care. Yield was defined as clinical outcomes from interventions to 
detect silent AF when there were no comparator groups in studies.   
Review articles were also eligible for inclusion. Studies that 
investigated intensive methods of detecting silent AF after an acute 
stroke (e.g. cardiac holter monitoring, implantable reveal devices) 
were not reviewed as these are not translatable to mass screening 
of asymptomatic patients in the general population.  
 
The titles and abstracts of potentially relevant papers were initially 
screened (by JT) and only studies felt likely to meet the inclusion 
criteria were obtained for full-text review. The reference lists of 
review articles were also screened for relevant citations.  
 
2.1.2. Analyses 
Studies were grouped and data extracted under the relevant 
themes of i) how interventions to detect silent AF were organised 
and implemented, ii) the clinical effectiveness and/or yield and iii) 
cost-effectiveness of interventions to detect silent AF, and iv) the 
impact on health status of patients, and acceptability of AF 
screening by patients or healthcare professionals. The description 
of studies and outcomes were narratively reported. 
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2.2. Results  
2.2.1. Study characteristics 
The database search identified 2,229 citations and, after removal 
of duplicate records, there were 1,927 citations for further 
assessment. After considering titles and abstracts there were 55 
potentially relevant articles that were extracted for full-text review. 
Subsequently, 30 articles met the selection criteria and were 
included in the final literature review. These included two 
systematic reviews, (116, 117) three randomised controlled trials, 
(118-121) one secondary analysis of trial data, (122) and 20 
uncontrolled studies of case finding from AF screening 
interventions. (35, 123-141) Another two studies exclusively 
reported economic analyses from AF screening interventions (142, 
143) and one study exclusively reported outcomes for the 
acceptability of AF screening by patients and healthcare 
professionals. (144) Of the 20 uncontrolled studies of AF case 
finding, there were two studies that retrospectively analysed 
baseline cohort data for new diagnoses of AF in participants. (128, 
135) Therefore, these two studies were not designed a priori as AF 
screening intervention studies. 
 
Of the individual studies (i.e. non-systematic reviews) identified by 
the literature search, 10 were conducted in Europe, (35, 121, 123, 
124, 126, 127, 129, 138, 139, 142) 8 in the UK, (118-120, 122, 
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130, 131, 137, 141) 5 in the US, (128, 132, 133, 135, 136) 4 in 
Australia or New Zealand (125, 134, 140, 144) and one in Japan. 
(143) 
 
2.2.2. Organisation and implementation of 
interventions to detect silent atrial fibrillation 
2.2.2.1. Process of atrial fibrillation detection within studies 
Two processes for detecting silent AF were identified – systematic 
and opportunistic detection. Most studies investigated a systematic 
approach for detecting AF (invitation of all people within a target 
population at risk of AF) as the method for detecting new cases of 
AF. (35, 118-121, 123, 125, 127, 128, 130, 131, 133, 135, 137-
139, 141) Fewer studies used opportunistic case detection of AF 
where participants were usually opportunistically screened for AF 
during encounters with healthcare professionals for other reasons. 
(118-120, 124, 126, 129, 132, 134, 136, 140)   
 
Only two studies were found that directly compared outcomes from 
the systematic and opportunistic processes of AF detection, (118-
120) both of which were randomised trials conducted in the UK. 
The remaining UK studies investigated systematic approaches to AF 
detection. (130, 131, 137, 141) 
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2.2.2.2. Periodicity of detecting silent atrial fibrillation 
within studies  
There were two periodicities (i.e. frequencies of attempts made) for 
detecting new cases of AF within studies – multiple intermittent 
attempts made prospectively to detect AF made over a defined 
time-period (121, 127, 129, 139) or only one attempt in total for 
AF detection. (35, 118-120, 123-126, 128, 130-135, 137, 138, 
140, 141)  
 
Of the studies that used an intermittent approach for detecting AF, 
two used twice-daily ECG recordings made every day over a two 
week period, (127, 139) one used twice-daily ECG recordings made 
every day over four weeks, (129) and another used patient self-
assessment for pulse irregularities once every month and then six-
monthly clinical assessments by healthcare professionals, including 
12-lead ECG, over a total study duration of two years. (121) 
 
Of studies using single time-point AF detection there were two 
further methods used to identify silent AF. Studies used either a 
recording of one ECG to detect AF (‘one-step’ method) (35, 118-
120, 123-125, 128, 130-132, 134, 135, 141) or firstly identifying 
pulse irregularities before performing a diagnostic ECG in those 
with suspected AF (‘two-step’ method). (118-120, 126, 133, 136-
138, 140) 
 47 
 
The majority of studies that used the one-step approach for single 
time-point screening used 12-lead ECG, (35, 118, 119, 125, 128, 
130, 135, 141) and others used single-lead ECG, (120, 124, 132, 
134) three-lead ECG, (123) four-lead ECG, (131) and/or seven-
lead ECG (135) for detecting silent AF. 
 
The studies that used a two-step approach used pulse palpation 
(118-120, 136-138) and/or single-lead ECG (126, 133, 140) for 
the first-step of identifying those with suspected AF. For the 
second-step of confirming AF nearly all studies used 12-lead ECG, 
(118, 119, 126, 133, 137, 138, 140) whilst one used single-lead 
ECG, (120) and another used self-reported outcomes from self-
referral to a medical practitioner after an irregular pulse was 
identified. (136)  
 
All of the UK studies used the single time-point approach for 
detecting silent AF. (118-120, 130, 131, 137, 141) The majority of 
these used the one-step method of screening using an ECG. (118-
120, 130, 141) Others used a two-step method of pulse palpation 
followed by ECG confirmation of AF. (118-120, 137)    
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2.2.2.3. Healthcare settings and professionals used to detect 
silent atrial fibrillation 
Most studies of interventions for the detection of silent AF were 
conducted in family/GP practices and involved their practice staff 
(such as GPs and/or nurses) for conducting screening activities. 
(118-120, 123, 124, 130, 131, 137, 138, 141) Three studies 
involved patient self-recording of ECGs (127, 129, 139) and two 
studies were conducted in pharmacies and involved pharmacists 
undertaking screening activities. (134, 140) 
 
For the vast majority of studies a trained cardiac specialist 
interpreted ECGs to make the final diagnosis of AF. (35, 118-120, 
123, 125-127, 129, 131-135, 137, 139-141) Two studies used 
automated analysis (124, 128) and one study used only family 
physician interpretation of ECGs for AF diagnosis. (138)   
 
All UK studies were conducted in GP practices and involved practice 
staff, mostly GPs and/or nurses, undertaking screening activities. 
(118, 119, 130, 131, 137, 141) 
 
2.2.2.4. Selection of participants within silent atrial 
fibrillation detection studies  
For the studies that investigated systematic detection of AF, most 
identified participants through either random (35, 118-121, 123, 
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128, 135, 139) or total population sampling. (125, 127, 130, 131, 
133, 138, 141) Random selection of participants was from either 
patient lists at primary healthcare centres and/or GP practices 
(118-121, 123) or lists of community residents. (35, 128, 135, 
139) Total population sampling of participants was from all eligible 
people at primary healthcare centres and/or GP practices, (130, 
131, 138, 141) all inhabitants of communities, (127, 133) or all 
attendees at an outpatient clinic. (125) One study systematically 
screened all patients ≥65 years of age that attended an influenza 
clinic within primary care in the UK. (137)  
 
Within studies of opportunistic AF detection, participants either 
self-selected to participate or were screened opportunistically when 
consulting healthcare professionals about other health problems. 
(118-120, 124, 126, 129, 132, 134, 136, 140) Participants were 
opportunistically identified within primary care medical centres 
and/or outpatient clinics, (118-120, 124, 126, 129, 132) 
community pharmacies, (134, 140) and one study detected silent 
AF in people that attended an education group about AF. (136) All 
of the UK studies that investigated opportunistic approaches to 
screening were undertaken in primary healthcare settings.    
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2.2.2.5. Age of participants within silent atrial fibrillation 
detection studies  
The range of age thresholds for including participants in studies of 
detecting silent AF was broad. The majority of studies included all 
people ≥65 years old. (118-121, 123, 127, 128, 130, 131, 134, 
137-139, 141) Of these studies, there were two that included 
participants between 75-76 years of age (127, 139) and one 
included those ≥70 years old. (123)  
 
One study included people ≥55 years of age. (140) The age of 
inclusion for the remaining studies were ≥45 years, (135) ≥40 
years, (124, 125, 132) 35-75 years, (35) ≥18 years, (126) and 12-
99 years. (133) All studies conducted in the UK setting included 
participants ≥65 years of age. (118-120, 130, 131, 137, 141)  
 
2.2.2.6. Summary for the organisation and implementation 
of interventions to detect silent atrial fibrillation 
Most studies of interventions to detect silent AF were conducted in 
primary healthcare settings. Two processes – systematic and 
opportunistic screening – were identified for detecting silent AF. 
The majority of studies investigated the detection of AF in people 
≥65 years of age and investigated AF detection at a single-time 
point. There were two subsequent approaches for detecting AF; the 
one-step approach where AF was directly diagnosed using ECGs, or 
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the two-step approach where an irregular pulse were firstly 
identified and then diagnostic ECG performed in those with 
suspected AF.  
 
All UK studies were conducted in GP surgeries, involving practice 
staff, and screened for AF in patients ≥65 years of age. All studies 
investigated single-time point screening, using either a one or two-
step approach to screening.  
 
2.2.3. Clinical effectiveness and/or yield of 
interventions to detect silent atrial fibrillation 
There were 27 studies that reported outcomes for the clinical 
effectiveness and/or yield of interventions to detect silent AF – two 
systematic reviews, (116, 117) three randomised trials (reported 
across four articles), (118-121) 20 uncontrolled studies of AF case 
detection, (35, 123-141) and one secondary analysis of 
randomised trial data.  (122) 
 
The clinical effectiveness and/or yield of interventions was primarily 
reported as the number of new cases/proportion of AF detected, 
incident AF and/or screen-detected AF. Some studies also reported 
the risk of stroke in patients with screen-detected AF using the 
established CHADS2 and/or CHA2DS2VASc risk stratifying 
schemata; consequently, these studies also provided data for the 
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effectiveness and/or yield of screening interventions to detect AF 
cases that could also be eligible for stroke preventative treatment. 
Only one study provided data for longer-term clinical outcomes 
arising from the treatment of those with new AF. Within this 
section, all such clinical outcomes (i.e. screen detected AF, stroke 
risk scores and longer-term clinical outcomes) arising from 
interventions to detect silent AF have been provided under the 
domain of clinical effectiveness and/or yield and have been 
reported together for the individual studies that provided such 
data.   The following sections provide information for the clinical 
effectiveness and/or yield of interventions to detect silent AF 
according to study design - notably systematic reviews, 
randomised trials, secondary analyses of randomised trial data and 
uncontrolled studies of AF case finding. 
  
2.2.3.1. Systematic review evidence for the clinical 
effectiveness and/or yield of interventions to detect silent 
atrial fibrillation  
Individual studies that were included in the two systematic 
reviews, that also met the selection criteria for the current 
literature review, have been individually appraised in subsequent 
sub-sections of this chapter.  However, where relevant the point 
estimates for clinical outcomes (as defined above) from the two 
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systematic reviews that are not reported within individual studies 
have been provided in this sub-section.      
 
One of the systematic reviews was a Cochrane review of 
randomised trials, controlled before and after, and interrupted time 
series studies that investigated the effectiveness of AF screening 
programmes for the detection of new AF when compared to routine 
practice. (117) Only one randomised trial met the selection criteria 
for the Cochrane review and this study has been appraised in the 
following sub-section of chapter two. (117-119)  
 
The other systematic review investigated the prevalence of AF and 
incidence of unknown AF from studies of single time-point 
screening in ambulatory populations using either ECG or pulse 
palpation. (116) The review identified 31 studies (26 prospective 
cohort studies, two retrospective cohort studies and two 
randomised controlled trials) from nine countries that included 
122,571 patients (mean age 64 years, 54% male).  
There was an attrition of included studies with data to enable 
calculation of point estimates for the incidence of new AF from 
interventions to detect silent AF. Many of the studies were 
uncontrolled studies of AF case finding and these have been 
described in greater detail in the subsequent section of this 
chapter.  (116) Overall, the incidence of previously undiagnosed AF 
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from interventions [14 studies, n=67,772] was 1.0% (95% CI 
0.89-1.04). Sub-group analyses determined the incidence of 
undiagnosed AF from studies conducted in both GP/outpatient 
clinics, non-healthcare related community settings (e.g. screening 
from community advertisements or population screening) and in 
people ≥65 years of age. The incidence of new AF was higher in 
studies conducted within a GP/outpatient clinic setting [5 studies 
(n=13,533)] than other non-healthcare related community settings 
[8 studies; n=54,239; 1.2% versus 0.9% (p<0.001)]. 
Furthermore, the incidence of AF was greatest at 1.4% (95% CI 
1.2–1.6%) when analyses were restricted to studies that included 
participants ≥65 years of age (8 studies, n=18,189). (116)  
 
Secondary outcomes of this review were to determine the stroke 
risk scores and eligibility for oral anticoagulation in those with new 
AF. Four studies (n=5,676) reported outcomes for anticoagulation 
eligibility but only two of these reported CHADS2 or CHA2DS2VASc 
scores; (125, 127) point estimates for the risk of stroke in those 
with new AF were not calculated in this systematic review. 
However, the two studies that provided stroke risk scores have 
been included in the current literature review and their clinical 
outcomes are provided in subsequent sections of this chapter.   
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Although this systematic review included more studies than the 
Cochrane review, these were of various and weaker designs, and 
the review aggregated data mostly from uncontrolled studies of AF 
case finding. Consequently, this increases the risk of bias when 
determining point estimates and the findings from this review 
mostly provide data for the yield of interventions to detect 
undiagnosed AF.  
 
2.2.3.2. Randomised trial evidence for the clinical 
effectiveness of interventions to detect silent atrial 
fibrillation  
Three randomised trials investigated the effectiveness of 
interventions to detect incident AF and all were conducted in 
primary healthcare settings. (117-121) Two were conducted in the 
UK (118-120) and one is Spain. (121) One trial compared the 
effectiveness of two interventions with usual care whilst also 
providing a comparison of the effectiveness between the two 
interventions. (117-119) Another trial only compared the 
effectiveness of an intervention with usual care, (121) and the 
remaining trial only compared the effectiveness of two 
interventions with one other. (120)  
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2.2.3.2.1. Randomised trial evidence for the clinical 
effectiveness of interventions to detect silent atrial 
fibrillation compared to usual care 
The largest trial of detecting silent AF was the systematic screening 
versus routine practice for the detection of atrial fibrillation in 
people aged 65 and over (SAFE) study. (117-119) This cluster-
randomised trial set within primary care recruited patients ≥65 
years of age across 50 practices in England, UK. This three-arm 
trial compared two single time-point AF detection interventions 
with AF detection arising from usual care. (117-119) Practices 
within the intervention arms of the study (n=25) were randomly 
allocated to implement either systematic screening (systematic 
invitation to all patients for the one-step approach of ECG 
recording) or opportunistic screening (two-step approach of 
checking for an irregular pulse with confirmatory ECG, as required) 
by GPs and/or nurses. (117-119) The study recruited 14,802 
patients (mean (SD) age 75.3 (7.2) years; 42.6% male) that were 
equally distributed across each study arm. (117-119) The overall 
detection rate of new cases of AF was 1.63% a year in the 
intervention practices and 1.04% in control practices (difference 
0.59%; 95% CI 0.20-0.98). (118, 119) Compared to usual care, 
systematic screening was 57% [OR 1.57 (95% CI 1.08-2.26)] 
more likely to detect incident AF; similarly, opportunistic screening 
was 58% [OR 1.58 (95% CI 1.10-2.29)] more likely to detect 
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incident AF than usual care. (117) Consequently, the number 
needed to screen (NNS) to detect one additional case of AF was 
172 (95% CI 94-927) for systematic screening and 167 (95% CI 
92-806) for opportunistic screening when compared to routine 
practice. (117) 
 
Another randomised trial set within primary care in Spain 
investigated the effectiveness of a two-year AF detection 
programme. (121) Randomly selected patients, with at least one 
risk factor for AF (age ≥65 years, hypertension, ischaemic heart 
disease, valvular heart disease, diabetes and/or congestive cardiac 
failure) were invited to participate from an urban primary 
healthcare centre. Excluded participants included those with 
pacemakers and those unable to attend the health centre.  
Participants (n=928) were randomised to receive either a screening 
intervention or usual care (the control group) for detecting new AF. 
(121) The intervention was intermittent screening and comprised, 
after instruction by a trained nurse at the baseline visit, monthly 
patient self-assessment for pulse irregularities, and six-monthly 
healthcare professional assessments of a full medical history, 
physical examination and an ECG. (121) The primary outcome for 
this trial was newly diagnosed AF at 6 months and secondary 
outcomes included patients diagnosed with AF at 2-years follow-up 
and the complications arising from AF and its treatment. (121) At 
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six-months follow-up more cases of new AF were detected in 
screened participants than from usual care (8 (1.7%) versus 1 
(0.2% cases; p=0.018). (121) At two-years there were similar 
rates of new AF detection in both trial arms (11 (2.5%) 
intervention versus 6 (1.3%) usual care; p=0.132). (121) Time to 
first diagnosis of AF was shorter in the intervention group (median 
(IQR) time to diagnosis 7 (192) days versus 227 (188.5) days for 
the intervention and controls groups, respectively; p=0.029).  
The risk of stroke for patients with new AF were not reported but at 
two years 90.9% of patients with new AF had at least two risk 
factors for stroke in the intervention group as compared to 66.7% 
of controls. (121) 
At two years of follow-up 10/11 patients with new AF in the 
intervention group were started on anticoagulation therapy 
compared to 2/6 patients in the control group. Only two patients 
were reported to have mild treatment related complications, one 
patient from each trial group. (121) 
 
2.2.3.2.2. Randomised trial evidence comparing the clinical 
effectiveness of systematic and opportunistic approaches of 
interventions to detect silent atrial fibrillation  
The SAFE study, described previously, also compared as part of its 
primary study design the effectiveness of systematic and 
opportunistic screening for detecting new cases of AF. (117-119) 
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This found that both approaches for screening detected similar 
numbers of new cases of AF (1.62% v 1.64%, respectively; 
difference 0.02%, −0.5% to 0.5%). (117-119)  
 
The third randomised trial of AF screening included 3,001 patients 
aged 65-100 years from four general practices within the Medical 
Research Council (MRC) general practice framework, UK. (120) 
Patients were randomised to single time-point AF detection of 
either systematic nurse-led screening (systematic invitation for 
patients to attend for pulse palpation and a single-lead ECG) or 
opportunistic case finding for AF (prompts entered into patient 
notes to conduct two-step screening that comprised a pulse check 
during consultations with healthcare professionals and then 
undertake single-lead ECG if appropriate). (120) There was no trial 
arm to determine AF detection from routine practice. There was a 
greater detection of any AF in systematic screened patients (n=67; 
4.5%) compared to those exposed to opportunistic case finding 
(n=19; 1.3%); OR (95% CI) 3.7 (2.2-6.1). The yield of new AF 
was lower with 12 (0.8%) new cases of AF in the systematic 
screening arm and seven (0.5%) in the opportunistic case-finding 
arm. It was estimated that the NNS to detect one case of AF was 
31 (95% CI 23-50). (120) This trial also found that 47/67 (70%, 
95% CI 58-81) patients with AF that were identified by systematic 
screening had, other than AF, at least one other risk factor 
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(previous stroke or transient ischaemic attack, hypertension or 
diabetes) for stroke. (120) Combined with the age threshold of 
≥65 years for inclusion of patients into this study, one can 
reasonably assume the majority of patients with AF detected in this 
trial would have had a risk score sufficiently high to warrant further 
stroke preventative treatment.  
 
2.2.3.2.3. Secondary analyses of randomised trial evidence 
comparing the clinical effectiveness of systematic and 
opportunistic approaches of interventions to detect silent 
atrial fibrillation 
A secondary analysis of the SAFE trial data was conducted and 
reported the risk of stroke, using baseline trial data, in those 
diagnosed with new AF from the intervention practices. (122) As 
baseline data to enable the calculation of stroke risk were not 
available for patients in the control arm there was no comparison 
of stroke risk in patients with screen-detected AF and those with AF 
detected through routine practice. (122) The majority of patients 
with screen-detected AF had a CHADS2 score≥1 and there were no 
significant differences in the proportions of patients with these 
scores between the two intervention arms (Proportion (95% CI) 
with CHADS2 scores≥1 82.7% (72.6-89.6) and 78.4 (67.7-86.2); 
p=0.51 in the opportunistic and systematic screening arms, 
respectively). (122) There were also a substantial proportion of 
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patients with CHADS2 scores≥2 (Proportion (95% CI) with CHADS2 
scores≥2 29.3% (20.2-40.4) and 43.2% (32.6-54.6); p=0.077 in 
the opportunistic and systematic screening arms, respectively). 
(122)  
 
2.2.3.3. Uncontrolled studies of atrial fibrillation case 
detection  
There were 20 uncontrolled case finding studies for the detection of 
silent AF. (35, 123-141) These studies have been described in 
chronological order to enable appreciation of any changes in study 
design over time and are summarised in table 2-1.  
 
There were two studies that reported AF detection as part of 
baseline data collection within a cohort study (128, 135) and, 
therefore, these studies have limited applicability to screening than 
the other case finding studies, as they were not designed a priori to 
screen for silent AF.  
 
Most studies used single time-point screening to detect AF; (35, 
123-126, 128, 130-138, 140, 141) eleven studies used a one-step 
approach of recording an ECG to detect AF, (35, 123-125, 128, 
130-132, 134, 135, 141) six used two-step screening of firstly 
identifying an irregular pulse with confirmatory ECG in those with 
suspected AF. (126, 133, 136-138, 140) The remaining three 
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studies used intermittent screening at multiple time-points. (127, 
129, 139)  
 
It appears that more recently non-12-lead ECGs, particularly 
single-lead ECG, have been used more often to detect AF than in 
earlier studies of AF detection. (127, 129, 131, 133, 139, 140) 
Moreover, recent studies have investigated the yield of intermittent 
screening using single-lead ECG over multiple time-points to detect 
AF. (127, 129, 139) Consequently, there appears to be greater 
prominence on using non-12-lead ECGs for detecting suspected AF 
than other approaches, such as pulse palpation, in more recent 
studies.  
No studies provided comparative estimates for the number of AF 
cases detected from routine clinical practice or usual care. Only 
eight of these studies provided data for the stroke risk in patients 
with newly diagnosed AF. (35, 123, 125, 127, 129, 134, 137, 139) 
Therefore, these studies only provide data for the yield of clinical 
outcomes from interventions to detect silent AF. 
 
All studies showed to a variable extent that undiagnosed AF exists 
and interventions to detect silent AF, irrespective of method used, 
were able to identify new cases of AF. The yield of new AF 
detection from the uncontrolled studies ranged from 0.2-9.0% 
although the majority of studies reported at least 1.0% new AF 
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detection. The studies that reported stroke risk scores suggest the 
likelihood of treating those with new AF would affect clinical 
outcomes. No studies provided data for longer-term clinical 
outcomes, such as changes in stroke burden or complications from 
treatment.  
 
There were only four UK studies of uncontrolled AF case finding. 
(130, 131, 137, 141)  Three studies only provided data for new 
cases of AF detected. (130, 131, 141) All UK studies were 
conducted in GP surgeries and investigated systematic AF detection 
in patients ≥65 years of age. Three used the one-step method of 
identifying AF at a single time-point. (130, 131, 141) The yield of 
patients with new AF in UK studies ranged from 0.3-1.2%.  
 
Many of the uncontrolled studies had low response rates from 
people that were invited to participate in screening and this is a 
source of non-response bias in their findings. Combined with the 
uncontrolled study design the findings from these studies have 
limited utility beyond understanding the potential methods that 
could be used for AF screening.    
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Table 2-1: Uncontrolled studies of interventions to detect silent atrial fibrillation 
Study Country Setting & 
HCPs 
involved a 
Age Screening 
process 
Method of 
AF 
detection 
Number 
screened 
(n) 
RR 
(%) b 
New AF 
(%) c 
Stroke risk: d 
(CHADS2/ 
CHA2DS2VASc)  
Hill  
1987 (130) 
UK GP surgery 
(n=1); 
nurses 
 
≥65 Systematic: 
Single time-
point 
One step: 
12-lead ECG 
819 80.7 1.2 n/a 
Furberg  
1994 (128) 
USA Community 
(Cohort 
study); n/r 
 
≥65 Systematic: 
Single time-
point  
One step: 
12-lead ECG 
5,151 n/r 1.5 n/a 
Lavenson  
1998 (132) 
USA Community 
(outpatient 
clinic); n/r 
>40 Opportunistic: 
Single time-
point  
One step: 
Single lead 
ECG or 
apical pulse 
auscultation 
176 n/r 9.0* n/a 
Wheeldon  
1998 (141) 
UK GP surgery 
(n=1); 
technician 
 
≥65 Systematic: 
Single time-
point 
One step: 
12-lead ECG 
1,207 84.9 0.4 n/a 
Munchauer  
2004 (136) 
USA Community 
(281 group 
education 
sessions); 
n/r 
>50 Opportunistic: 
Single time-
point  
Two step: 
Pulse 
palpation +/- 
self referral 
for 
healthcare 
professional 
assessment 
1,839 42.5 0.5 n/a 
Doliwa  
2009 (126) 
Sweden Community 
(publically 
attended 
≥18 Opportunistic: 
Single time-
point 
Two step: 
Single lead 
ECG +/- 12-
606 n/r 1.0 n/a 
 65 
ESC 
congress); 
self-recorded 
 
lead ECG 
Meschia  
2010 (135) 
USA Community 
(Cohort 
study); n/r 
 
≥45 Systematic: 
Single time-
point:  
One step: 
12-lead or 7 
lead ECG 
29,861 49 0.6 n/r 
Claes  
2012 (124) 
Belgium Primary care 
medical 
centres 
(n=69); 
nurses 
 
≥40 Opportunistic: 
Single time-
point 
One step: 
Single lead 
ECG 
10,758 n/r 1.6 n/r 
Schnaebel  
2012 (35) 
Germany Community; 
n/r 
35-75 Systematic 
Single time-
point  
One step: 
12-lead ECG 
5,000 64.0 0.5 2.0/3.0 
Deif  
2013 (125) 
Australia Out-patients 
(retrospectiv
e analysis of 
pre-surgical 
ECGs); n/r 
≥40 Systematic: 
Single time-
point  
One step: 
12-lead ECG 
2,808 n/r All ages: 
0.4  
 
 
≥65 
years: 
0.6  
All ages:  
1.9 (1.5)/3.3 
(2.2)  
 
≥65 years:  
2.2 (1.5)/3.8 
(2.0)  
Sanmartain  
2013 (138) 
Spain Primary care 
medical 
centres 
(n=3) & out-
patients 
(n=1); 
nurses 
 
≥65 Systematic: 
Single time-
point  
Two step: 
Pulse 
palpitation 
+/- 12-lead 
ECG 
1,532 17.3 1.1 n/r 
Hendrikx  Sweden Family n/r Opportunistic: Intermittent: 928 93.6 3.8 (2.7- 2 (1-4) / - 
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2013 (129) practices 
(n=8) & out-
patients 
(n=2); self-
recorded 
 
Multiple time-
points 
Single lead 
ECG twice 
daily over 4 
weeks 
5.2) 
Rhys  
2013 (137) 
UK GP surgery 
(n=1); 
nurses and 
GPs 
 
≥65 Systematic: 
Single time-
point 
Two step: 
Pulse 
palpation +/- 
12-lead ECG  
573 33.4 0.3 - / 5 
Engdahl  
2013 (127) 
Sweden Community; 
self-recorded 
75-76 Systematic: 
Multiple time-
points  
Intermittent: 
Twice daily 
single lead 
ECG 
recording 
over 2 weeks 
403 47.5 7.4 (5.2-
10.4) 
2.5 / - 
Walker  
2014 (140) 
New 
Zealand 
Pharmacy; 
(n=1); 
pharmacists 
≥55 Opportunistic: 
Single time-
point  
Two step: 
Single-lead 
ECG +/- 12 
lead ECG  
121 n/r 1.7 n/r 
Javed  
2014 (131) 
UK GP surgery 
(n=15); 
practice staff 
 
≥65 Systematic 
Single time-
point 
One step: 
Four lead 
ECG 
6,856 30.7 0.8 n/r 
Lowres  
2014 (134) 
Australia Pharmacy 
(n=10); 
pharmacists 
 
≥65 Opportunistic: 
Single time-
point  
One step: 
Single lead 
ECG 
1,000 n/r 1.5 (0.8-
2.5) 
3.7 (1.1) / - 
Bury  
2015 (123) 
Ireland GP surgery 
(n=25); 
practice staff 
 
≥70 Systematic: 
Single time-
point 
One step: 
Three-lead 
ECG 
566 56.4 2.1 - / 4 (1-7) 
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Le Page  
2015 (133) 
US Community 
(hospital 
foyer); 
doctors and 
nurses 
 
12-99 Opportunistic: 
Single time-
point 
Two step: 
Single-lead 
ECG +/- 12 
lead ECG 
954 n/r 0.2 n/r 
Svennberg  
2015 (139) 
Sweden Community; 
self-recorded 
75-76 Systematic: 
Multiple time-
points 
Intermittent: 
Twice daily 
single lead 
ECG 
recording 
over 2 weeks  
7,173 53.8 3.0 (2.7-
3.5) 
3.5 (1.2) / - 
n/r = Not reported; *study only reported proportion of arrhythmias detected and new AF not specified; a = setting from which 
participants were recruited (community settings refer to non-healthcare settings in the community; out-patients refers to hospital based 
out-patient clinics; GP surgery refers to General Practices and HCPs refers to healthcare professionals involved in screening; b = RR 
(Response rate) is the number of people screened from those invited for screening; c = Proportion (95% CI) of new cases of AF identified 
by the intervention;   d = Values presented as means (SD), with the exception of Hendrikx 2013 and Bury 2015 where median (IQR) 
stroke risk scores are provided 
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2.2.3.4. Summary of studies for the clinical effectiveness 
and/or yield of interventions to detect silent atrial 
fibrillation 
2.2.3.4.1. Detecting new cases of atrial fibrillation 
There were two systematic reviews and three randomised trials 
that reported clinical outcomes for the detection of new AF. Data 
from one systematic review and two randomised trials (one of 
which was the only study in the systematic review) suggest that AF 
screening, as compared to routine practice, is likely to be effective 
at detecting new cases of AF. It remains unclear which 
interventions have the greatest effectiveness for detecting AF when 
compared to one another. However, the largest trial of AF 
screening interventions, the SAFE trial, suggested that there is no 
difference between systematic and opportunistic processes of AF 
screening for the detection of new AF.  
 
Most evidence for the ability of interventions to detect new cases of 
silent AF has been derived from uncontrolled studies of AF case 
finding. These studies suggest that undiagnosed AF exists and that 
screening interventions detect silent AF to a variable extent. The 
other systematic review, which mostly included uncontrolled case 
finding studies, suggested the yield of AF case finding may be 
greatest in those aged ≥65 years old and when conducted in 
primary healthcare settings. 
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2.2.3.4.2. Risk of stroke in new cases of atrial fibrillation 
Of the studies that reported stroke risk scores for patients with 
incident AF, most calculated the risk using either the CHADS2 
and/or CHA2DS2VASc risk stratifying schemata. Patients with 
screen-detected new AF have stroke risk scores sufficiently high to 
justify the subsequent treatment of AF using stroke preventative 
therapies. However, most studies that reported the risk of stroke in 
patients with screen-detected AF did not provide a comparison of 
the stroke risk in those with AF detected from usual care.  
 
2.2.3.4.3. Long-term clinical outcomes in new cases of atrial 
fibrillation 
The literature review found only one study that reported long-term 
clinical outcomes from the treatment of those with newly diagnosed 
AF; this study found minor adverse effects arising from the 
treatment of those with screen-detected AF and outcomes were 
similar in those with AF diagnosed and treated from routine 
practice. However, there was a clear lack of evidence for longer-
term clinical outcomes arising from the treatment of patients with 
screen-detected AF, such as the progression of AF, changes in 
stroke burden and/or consequences of stroke preventative 
treatments.  
 
2.2.4. Cost-effectiveness of atrial fibrillation screening 
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There were seven articles that reported economic analyses from six 
studies of AF screening; data were reported from two randomised 
trials, (119, 120) three uncontrolled case finding studies (134, 137, 
139, 142) and one modelled economic analyses using simulated 
epidemiological data. (143)  
 
The SAFE study, the largest RCT of AF screening, reported 
outcomes from within trial and model based economic analyses. 
(119) From an NHS only perspective the within trial analyses 
found, compared to no screening (i.e. routine care), the overall 
incremental costs for detecting new cases of AF within 
opportunistic and systematic screening trial arms were £9,429 and 
£40,882, respectively. As the number of new AF cases detected 
were similar in both intervention arms, opportunistic screening 
provided greater cost-effectiveness than systematic screening; the 
Incremental Cost-Effectiveness Ratio (ICER) for opportunistic 
screening was of £337 per additional new case of AF detected; this 
assumed an acceptable Incremental Cost-Effectiveness Ratio 
(ICER) per additional case of AF being set at this value. (119) 
Using both NHS and patient costs, the incremental cost of 
detecting an additional case of AF increased to £363 from 
opportunistic screening yet this remained the more cost-effective 
approach than systematic screening. (119) A number of model-
based analyses were conducted that evaluated the effects of 
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screening on long-term consequences arising from the treatment of 
those with screen-detected AF, and the impact of different 
screening configurations for detecting AF. (119) Compared to 
routine care, opportunistic screening increased the percentage of 
people with newly detected AF which was most marked by annual 
screening. Combined with the effects of stroke risk reduction and 
complications arising from treatment, economic modelling 
suggested opportunistic AF screening would at worst be cost-
neutral and at best produce a small reduction in overall costs. 
(119)  
 
The other RCT compared the effectiveness of systematic nurse-led 
screening with opportunistic case finding of AF but only provided 
data for within trial economic analyses from the systematic 
screening intervention arm. (120) Comparisons for the cost-
effectiveness of systematic with opportunistic screening were not 
reported. (120) As a result of systematic screening, one additional 
patient with atrial fibrillation was detected for every 31 screened 
(95% CI 23-50) and, using a cost estimate of £6 per consultation 
with a practice nurse, the reported cost per atrial fibrillation case 
detected of £186 (95% CI = £138 to £300). (120) The number 
needed to screen to detect a new case of AF was 91 with a 
minimum cost estimate per case identified (based on practice 
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nurse time) at £550 but confidence around these estimates were 
not reported. (120) 
A smaller uncontrolled study by Rhys et al. provided estimates for 
the cost of systematic screening during influenza clinics. (137) The 
authors reported the cost of identifying a new case of AF as 
approximately £234 and estimated the total annual cost to prevent 
one stroke using oral anticoagulation as approximately £9,911. 
(137) However, the authors did not conduct further economic 
analyses for cost-effectiveness beyond the estimation of incurred 
screening costs. (137)  
 
Economic analyses were also reported from the search-AF study – 
an uncontrolled study of AF detection using single-lead ECGs at 
community pharmacies in Australia. (134) Assuming a 50% 
screening participation rate and 55% treatment adherence, 
opportunistic screening using single-lead ECGs was associated with 
an Incremental Cost-Effectiveness Ratio (ICER) per Quality-
Adjusted Life Year (QALY) gained of $AUD 5,988 (95% CI 1,613-
13,435) [€3,142; $USD 4,066]. The ICER per stroke avoided was 
$AUD 30,481  (95% CI 8,210-68,384) [€15,993; $USD 20,695]. 
(134) Lowres et al. reported that opportunistic screening using this 
approach to AF screening was cost-effective. (134) 
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Two studies reported economic analyses from the STROKE-STOP 
study. (127, 139) The uncontrolled STROKE-STOP study 
investigated silent AF detection using intermittent ECG recording 
over two weeks. Within trial analyses suggested this approach to 
AF detection was associated with a cost of €4,164 per QALY 
gained. (139) Subsequent economic analyses using the 
STROKESTOP data and a simulated Markov model for 1,000 
patients assessed cost-effectiveness. (142) Aronsson et al. found 
that this approach to screening would result in eight fewer strokes, 
11 more life-years, and 12 more QALYs per 1,000 population 
screened. (142) Moreover, this approach to screening resulted in 
an incremental cost of €50,012, a cost of €4,313 per QALY gained 
and €6,583 per avoided stroke. (142) The authors concluded that 
systematic AF screening using intermittent ECG recording was cost-
effective assuming the willingness to pay around €5,000 per QALY 
gained. (142)   
 
Maeda et al. reported their findings of a simulated analysis that 
used epidemiological data from the Framingham Study data and 
applied this to a hypothetical population of Japanese patients 
receiving healthcare from the ages 65-85 years. (143) Using a 
Markov model, Maeda et al. compared the cost-effectiveness of 
annual screening using either systematic ECG recording or pulse 
palpation followed by ECG in those with an irregular pulse, with no 
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screening. (143) The authors found that both screening approaches 
were similar in effectiveness and cost-effectiveness. The ICERs in 
males and females per QUALY were $8,000 and $10,000, 
respectively. Medea et al. concluded that both approaches to 
screening were feasible and cost-effective for the prevention of 
stroke. (143) 
 
In summary, research data suggests AF screening may be cost-
effective and randomised trial data suggests the more cost-
effective approach is opportunistic AF case detection. Data from 
uncontrolled case finding studies provide information about the 
incurred costs of AF detection; these studies suggest detecting 
silent AF could be cost-effective but assume the costs incurred are 
acceptable to healthcare providers. The uncontrolled studies, 
however, do not provide comparative estimates of the costs of 
detecting AF that would have occurred from routine practice.  
Furthermore, none of the studies reported modelled outcomes for 
the affordability of AF screening when delivered at a population 
level. Although AF screening may be cost-effective, the overall 
costs to healthcare systems and providers could potentially be 
large and deemed uneconomical when considered alongside the 
delivery of equitable population health.    
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2.2.5. Impact on the health status of patients and 
acceptability of detecting silent atrial fibrillation by 
patients and healthcare professionals 
Despite the large number of studies investigating the clinical 
effectiveness and/or yield of interventions for detecting silent AF, 
there were few studies that reported outcomes about the impact 
and/or acceptability of AF detection for patients and/or healthcare 
professionals. Only four studies reported outcomes for the impact, 
acceptability, opinions and/or training requirements about AF 
screening by patients or healthcare professionals. (119, 134, 140, 
144)   
As part of the cluster-randomised SAFE trial, the impact of 
screening interventions on patient health status and the 
acceptability of screening were assessed using baseline, post 
screening and post study surveys. (118) Self-reported data were 
collected for anxiety (using the Spielberger 6-item Anxiety 
Questionnaire), quality of life (using the EuroQol five dimensions 
(EQ-5D) questionnaire), and surveys also asked about patient 
views of screening. (119) However, comparisons were not reported 
for the health status and acceptability of AF detection from patients 
with AF identified from routine care. (118) 
 
All patients that attended for an ECG in the intervention arms 
(n=2,595) received a post-screening survey; there were 1,940 
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(74.8%) participants that responded with a completed survey. 
Data for anxiety scores were skewed with nearly 40% of all 
patients reporting the lowest anxiety score. (119) There were no 
significant differences in the anxiety scores between those that 
received opportunistic and systematic screening. (119) Hobbs et al. 
also reported, from other domains in the post screening survey, 
that 1,810/1,897 (95.4%) of patients felt screening was important 
and that the minority of patients would have wanted ‘someone to 
discuss it more first’ (91/1,892 (4.8%)), ‘to talk about the tests 
with doctor first’ (60/1,892 (3.2%)) or ‘to come to a clinic 
appointment for more information’ (74/1,892 (4.0%)). 
Furthermore, only 17/1,897 (3.7%) felt that screening was 
inconvenient. (119)  
 
Finally, randomly selected participants in the intervention arms 
that also received baseline questionnaires about anxiety and 
quality of life were also sent an end of study survey. From 777 
surveys distributed, there were 630 (81.1%) responses, of which 
535 (68.9%) were completed. There were no significant differences 
in anxiety scores between the intervention arms at the end of the 
study. The anxiety and quality of life scores were similar for survey 
respondents at baseline and at the end of the study, but the 
authors did not report a direct statistical comparison between the 
two. (119) Sub-group analyses did however find that the end of 
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study anxiety scores were significantly higher (mean (95% CI) 
anxiety score 38.12 (35.89-40.35) versus 34.61 (32.41-36.81); 
p=0.028) and the quality of life scores were significantly lower 
(mean (95% CI) EQ-5D score 0.66 (0.62-0.70) versus 0.73 (0.68-
0.77); p=0.020) for screen-positive than screen-negative patients. 
(119) However these findings have limited utility for the effects of 
screening on the health status of patients, as there were no 
comparisons made with the health impact of AF detection from 
routine care.  
As part of the SEARCH-AF study pharmacists received training 
about AF. (134) Knowledge of AF was assessed before training and 
at end of the study using a survey of eight questions and analysis 
of ECGs to give a cumulative maximum score of 23 points. The 
questionnaire ascertained data about general AF knowledge, 
associated health risks, symptoms, risk factors, stroke risk, 
screening modes and medications. (134) Lowres et al. reported 
that the mean (SD) percentage scores for pharmacist knowledge 
about AF improved from 49% (25) at baseline to 86% (8) post-
study (p<0.001). (134) The SEARCH-AF study was also evaluated 
by a qualitative sub-study; nine pharmacists were interviewed to 
explore their experiences of implementing an AF screening service. 
(144) Lowres et al. reported that screening for AF was well 
accepted in pharmacies and could be linked to the efficient delivery 
of other healthcare services. (144) Four broad themes were 
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identified that related to service provision; i) there was interest 
and engagement in AF screening by pharmacists, customers, and 
doctors; ii) pharmacists reported perceived benefits from screening 
that included increased job satisfaction, better customer relations 
and a raised pharmacy profile; iii) barriers were identified that 
included managing workflow and allocating time to discuss the 
screening process and fears; and iv) there was potential for future 
implementation within this setting with remuneration linked to 
government or pharmacy incentives by combining AF screening 
with cardiovascular screening, and automating risk-assessments 
using touch-screen technology. (144) 
 
The other pharmacy based AF screening study by Walker et al. 
investigated single-lead ECG screening. (140) All patients that 
undertook screening (n=121) completed a questionnaire. Patients 
with screen-detected AF were referred to their usual GP for further 
management. Walker et al. reported that ‘pharmacists and 
participants found the heart monitor easy to use, and participating 
GPs had overwhelmingly positive feedback on the study.’ (140) 
However, the authors did not report any methodological or 
outcome data to support these conclusions. (140)  
 
Although these studies report a positive impact and acceptability of 
AF screening by patients and pharmacists, there were no studies 
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that evaluated the views of other healthcare professionals who are 
more likely to be responsible for delivering AF screening in a 
primary care setting, such as General Practitioners and nurses. 
Moreover, there were no studies that investigated the feasibility of 
implementing screening within primary care settings.      
 
In summary, these studies suggest that AF screening is likely to be 
acceptable to patients and healthcare professionals, such as 
pharmacists, but no studies were found that investigated the 
acceptability of AF screening by GP or nurses. There were no 
studies that reported comparisons between the impact and/or 
acceptability of AF screening in those who had AF detected from 
screening interventions and those with AF identified from routine 
practice. 
 
2.3. Conclusion and areas for further research 
2.3.1. Conclusion 
A broad literature review was conducted to provide greater 
understanding of the research gaps, as previously highlighted by 
the review by Allaby in 2014 (chapter one), and characterise 
research priorities before screening implementation.  
 
There have been few randomised trials that have compared the 
effectiveness of interventions to detect silent AF with AF detection 
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from routinely delivered primary care.  Most evidence for 
interventions to detect incident AF has been derived from 
uncontrolled studies of AF case finding. Moreover, there have also 
been few trials comparing the effectiveness of different screening 
approaches with one another.  
 
Studies used opportunistic and systematic approaches for 
screening and the abundance of research investigated AF detection 
at a single time-point. Within studies of single time-point screening 
there were two further methods for detecting AF – one-step 
screening (where patients receive an ECG) or two-step screening 
(where patients are checked for a pulse irregularity and those with 
suspected AF receive an ECG). For the vast majority of studies the 
final AF diagnosis was made using ECGs that were interpreted by 
cardiac specialists.  
 
The limited evidence does suggest AF screening is likely to be 
effective at detecting incident AF and comparisons suggest the 
most cost-effective approach may be opportunistic AF detection. 
The yield of detecting silent AF appears greater in primary 
healthcare settings (such as GP practices or out-patient clinics) and 
in older patients, particularly ≥65 years of age. Patients with 
screen-detected AF have stroke risk profiles that would warrant 
treatment with oral anticoagulation. However, there was little data 
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from one study that reported longer-term clinical outcomes from 
the treatment of patients with screen-detected AF; this showed no 
difference in minor adverse effects from the treatment of AF in 
those with screen-detected AF and those with routinely detected 
AF. There were no studies that reported outcomes such as the 
disease progression of AF and changes in stroke burden in those 
with screen-detected AF. Economic modelling from randomised trial 
data suggests the most cost-effective approach to screening may 
be opportunistic screening using the two-stage method AF 
detection. Furthermore, it appears that AF screening in primary 
care is acceptable to patients and community pharmacists. 
 
The UK studies of interventions to detect silent AF comprised two 
randomised trials, one secondary analysis of trial data and four 
uncontrolled studies of AF case finding. The UK studies investigated 
single time-point screening in patients ≥65 years of age and 
involved mostly GPs and/or nurses for undertaking screening 
activities within GP practices. One of these studies was the SAFE 
study, the largest randomised trial of AF screening interventions; 
this found that screening, irrespective of approach used, was both 
effective and cost-effective at detecting incident AF and secondary 
analyses suggested that patients with screen-detected had stroke 
risk scores sufficiently high to warrant anticoagulation treatment. 
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Moreover, SAFE trial data suggested that screening was acceptable 
by patients. 
 
2.3.2. Justification for research undertaken within the 
thesis 
Areas for further research that are specific to the work undertaken 
within this PhD are provided below.   
 
Recommendations currently advocate the two-step approach for AF 
screening at a single time-point using pulse palpation followed by 
confirmatory 12-lead ECG.  
 
These recommendations may assume pulse palpation to be the 
optimal method of detecting pulse irregularities attributable to AF. 
However, more recently it appears that other methods, such as 
single-lead ECGs, are increasingly being used for detecting 
suspected AF. There were no studies that compared the 
effectiveness of different methods for detecting pulse irregularities 
as part of the first-step within screening interventions. Indeed, 
comparing the diagnostic accuracies and effectiveness of different 
methods for detecting pulse irregularities attributable to AF would 
help inform our understanding of how this first-step of proposed AF 
screening could be optimally organised.  
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The second-step of recommended AF screening is to diagnose AF 
using 12-lead ECG interpreted by a competent professional - the 
gold-standard test for AF diagnosis. The majority of studies 
investigating the detection of silent AF used ECGs interpreted by 
trained cardiac specialists for the diagnosis of AF. Few studies used 
other healthcare professionals, such as primary care physicians, for 
interpreting ECGs when making the final diagnosis of AF. As 
primary care is a likely setting for AF screening, an important 
consideration would be to understand the range and accuracies of 
other methods for interpreting ECGs, such as automated software 
ECG analysis and primary care physician ECG interpretation. This 
would enable greater understanding of how AF diagnosis, the 
second-step of AF screening, could be better organised and 
implemented within a primary care setting.  
 
Furthermore, it is unclear whether AF screening could be feasibly 
implemented within primary care. A few studies evaluated the 
opinions of pharmacists about screening implementation but most 
screening studies in primary care involved GPs and/or nurses. It is 
likely that GPs and/or practice nurses would be expected to have a 
major role in screening activities within primary care. However, 
there have been no studies evaluating the opinions of these 
healthcare professionals about feasibly implementing AF screening 
within General Practice.   
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Chapter 3. Research aims and objectives 
3.1. Aims 
The overall aims of this work were to determine how AF screening 
might feasibly and effectively be introduced into primary care in 
the UK.  
 
3.2. Objectives 
The objectives for this work were: 
 To determine the range and accuracies of methods for 
detecting pulse irregularities attributable to AF. 
 To determine the range and accuracies of methods for 
diagnosing AF using 12-lead ECG. 
 To investigate the feasibility and opinions of healthcare 
professionals in primary care about the implementation of 
AF screening. 
 
3.3. Research methods 
Three complimentary studies were undertaken to investigate each 
of the three objectives and overall aims: 
 A systematic review and meta-analysis of methods for 
detecting pulse irregularities caused by AF. 
 A systematic review and meta-analysis of methods for 
diagnosing AF using 12-lead ECG. 
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 A survey of healthcare professionals in primary care about 
the implementation of AF screening. 
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Chapter 4. Systematic review and meta-
analysis of methods for detecting pulse 
irregularities caused by atrial fibrillation 
4.1. Background 
Screening for AF in primary care has been recommended (80, 108, 
145) but is yet to be implemented into routine clinical practice. 
(115) Current recommendations advocate screening to be 
undertaken as a two-stage process. (80, 108) The first step of this 
process is to identify patients with a pulse irregularity (i.e. 
suspected AF) and recommendations advocate using pulse 
palpation as the method for doing this. (16, 80, 108)  
 
The accuracy of methods for detecting pulse irregularities that are 
caused by silent AF is particularly important for this first-step of AF 
screening.  
 
Evaluating the accuracy of diagnostic tests requires knowledge of 
sensitivity and specificity. (146) Sensitivity and specificity are 
measures defined according to disease status; the sensitivity of a 
test is the probability that the index test result will be positive in a 
person with the disease (or the true positive rate) and the 
specificity of a test is the probability that the index test result will 
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be negative in a person without the disease (or the true negative 
rate). (146) 
 
A high sensitivity would ensure people are appropriately referred 
for diagnostic 12-lead ECG but a low sensitivity would result in a 
high false negative rate and mean excessive AF diagnoses are 
missed. A high specificity is also important and ensures people 
without AF are correctly identified, but a low specificity would result 
in a high false positive rate of suspected AF with many patients 
subsequently having unnecessary ECG examinations.  
 
A systematic review in 2006 by Cook et al. investigated the 
accuracy of pulse palpation for the detecting AF. (147) Cook et al. 
identified three studies (n=2,385 patients) that compared the 
accuracy of pulse palpation with ECG diagnosed AF. (147) Pulse 
palpation was found to have a pooled sensitivity (95% CI) of 94% 
(84–97) and pooled specificity (95% CI) of 72% (69–75). (147) 
Therefore, this review found that despite pulse palpation having a 
high accuracy for correctly identifying those with AF, this method 
was less accurate in correctly identifying people without AF 
resulting in substantial false positive cases of suspected AF. (147) 
 
More recently, new methods for detecting suspected AF have been 
developed including non-12-lead ECG (e.g. single lead ECG), (126, 
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133, 140, 148) modified blood pressure monitors (148) and pulse 
oximeters. (148) To date there has been no systematic evaluation 
of the range and accuracies of newer methods for detecting pulse 
irregularities attributable to AF and how these compare to pulse 
palpation. Indeed, this would inform how the first-step of proposed 
AF screening could be optimally organised. 
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4.2. Aims 
To describe and compare the diagnostic accuracies of different 
methods for identifying pulse irregularities caused by AF. 
 
4.3. Objectives 
 To describe the healthcare settings and professionals 
involved the detection of an irregular pulse and potential AF. 
 To describe different methods used for detecting pulse 
irregularities caused by AF. 
 To determine the accuracy of different methods used for the 
detection of an irregular pulse and potential AF as compared 
to ECG diagnosed AF. 
 
 90 
4.4. Methods 
4.4.1. Search strategy and selection criteria 
This study was conducted in accordance with guidelines and 
methods for systematic reviews and meta-analyses of diagnostic 
tests. (146, 149-151) A comprehensive search strategy was used 
to maximise the sensitivity of literature searching and ensure all 
relevant citations were identified.  
 
4.4.1.1. Data sources 
The databases MEDLINE, EMBASE, Cumulative Index to Nursing & 
Allied Health (CINAHL) and Latin American and Caribbean Health 
Sciences Information System (LILACS) were searched in all 
languages (150) published until 16th March 2015 (Appendix 1). 
Additionally, the Cochrane Register of Diagnostic Test Accuracy 
Studies and the reference lists of national guidelines, review 
articles and included studies were hand-searched to identify 
potentially eligible studies.  (150) 
 
4.4.1.2. Search terms  
Studies of diagnostic test accuracy investigate the performance of 
tests in the context of population, disease state and setting. The 
search criteria therefore included specified terms to encompass 
these domains and related to participants, settings, target 
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condition, index test(s) and reference standard (Appendix 1). (149, 
150)  
 
4.4.1.3. Inclusion and exclusion criteria 
After the removal of duplicate records, two reviewers (JT and MJ) 
independently screened citations for relevance and reviewed full-
text articles using predetermined eligibility criteria. Any 
disagreements were resolved by consensus with a third reviewer 
(TC).  
 
The inclusion criteria for studies in the review were:  
 All randomised trials and observational studies 
 Studies which recruited participant’s ≥18 years of age. 
 Studies that involved healthcare professionals identifying 
patients with an irregular pulse (the participants) 
 Studies investigating any method of identifying patients with 
an irregular pulse or suspected AF (the index test and target 
condition).  
 Studies that compared the index test with any ECG 
interpreted by a competent professional (the reference 
standard). 
 Studies that reported sufficient data to enable the calculation 
of diagnostic accuracy.  
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The exclusion criteria for studies in the review were: 
 Studies that were case reports and case-series. 
 Studies using invasive or echocardiographic methods of 
identifying AF, as these could not feasibly be used in 
population screening. 
 
4.4.2. Data extraction 
Two reviewers (JT and MJ) independently extracted data from 
eligible studies using a pre-specified data extraction form. 
(Appendix 2) Any disagreements were resolved by consensus with 
a third reviewer (TC). Data were extracted for study characteristics 
and for true positive, true negative, false positive and false 
negative cases of suspected AF. 
 
Where studies reported findings using multiple thresholds for the 
same intervention, only the data where thresholds maximised the 
sensitivity of the index test were extracted in order to avoid 
duplicate inclusion of the same index test. This would have 
minimised the effects of including duplicate data from the same 
study within the analyses, which would have inappropriately 
overinflated the estimates of diagnostic accuracy for an individual 
test.  
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The lead author(s) of studies for which the reported data were 
insufficient to calculate diagnostic accuracy were contacted to 
ascertain missing data. Studies were excluded from the review if 
no additional data were identified or if the authors failed to 
respond.  
 
4.4.3. Assessment of study quality and risk of bias 
The assessment of methodological quality and bias is an essential 
component of systematic reviews as errors in the design, conduct 
and/or reporting of studies are potential sources of bias. (151) 
There are three broad types of tools that can be used for the 
assessment of study quality and bias in systematic reviews – 
checklists, scales and levels of evidence. (151) Scales provide 
numerical scores that are attributed to domains based upon 
perceived importance of the individual domains, but weighting of 
each item within such scales is often ignored. (152, 153)  
Consequently, quality-rating scores may not accurately reflect 
study quality. (152, 153) Levels of evidence amalgamate quality 
item scores into recommendations and it is therefore not possible 
to differentiate the individual quality aspects of study. (151) The 
guidance provided by the Cochrane collaboration for the 
methodological assessment of study quality within reviews of 
diagnostic test accuracy advocate using checklists, as this enables 
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full reporting of study characteristics without assumptions being 
made or emphasis being placed on individual quality items. (151) 
 
A systematic review by Whiting e al. identified over 90 instruments 
that have previously been used to assess study quality in reviews 
of diagnostic test accuracy. (154) This review found that there 
were large variations in the items used within the tools for 
assessing study quality and that most tools were developed for 
specific use within an individual review. Furthermore, none of the 
tools have been systematically evaluated. (151, 154) 
  
Therefore, study quality in the current review was appraised using 
the Quality Assessment of Diagnostic Accuracy Studies-2 
(QUADAS-2) instrument. (151, 155-157) The QUADAS-2 tool was 
first developed through expert consensus, informed by empirical 
evidence, (155, 157) and is recommended by the Cochrane 
Collaboration for assessing the risk of bias in systematic reviews of 
diagnostic test accuracy. It was recently updated to ensure it 
remained fit for purpose. (155) The QUADAS-2 tool currently rates 
study quality across two broad areas – the ‘risk of bias’ within the 
study methods and ‘applicability’ of the research question to the 
study methods. Within these two areas of assessment, there are 
four domains that are evaluated - patient selection, the index test, 
the reference standard, study flow and timing.  To make a 
 95 
judgment about these four domains there are a number of 
‘signalling questions’ that enable each domain to be judged by 
consensus from question responses. (155)  
 
The QUADAS-2 does not explicitly evaluate studies investigating 
multiple tests. When studies in the current review investigated 
multiple index tests, the QUADAS-2 tool was applied separately for 
each test to ensure the risk of bias was assessed for every test 
being evaluated.  
 
One of the limitations of the QUADAS-2 tool is that is does not 
enable grading and sub-group analyses according to study quality. 
To enable sub-group analyses according the study quality, the 
studies included in the review were also graded using a four-point 
quality scale that has been derived from the QUADAS-2 criteria and 
has been previously reported by Van den Bruel et al. (158) Studies 
were rated as grade A if they fulfilled all QUADAS-2 criteria. 
Studies were graded D if there was no or unclear verification of the 
index test findings with the reference standard, or if the index test 
results were interpreted un-blinded to the results of the reference 
test. Studies where there was an unduly long time delay between 
index and reference tests, or where the reference test was not 
independent of the index test, or where the reference test was 
interpreted un-blinded to the results of the index test were graded 
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C.   Remaining studies which did not fall in to these categories 
were graded B. (158) 
 
4.4.4. Statistical analysis 
Analyses were conducted using Stata Version 11.0 and Review 
Manager 5.2 for quality assessments.   
 
4.4.4.1. Primary outcome measures for diagnostic accuracy 
Data extracted were used to construct 2x2 contingency tables and 
primary outcomes were the pooled sensitivity, specificity, Positive 
likelihood ratios (PLR) and negative likelihood ratios (NLR) of each 
method for detecting suspected AF. (146)  
 
Unlike sensitivity and specificity, likelihood ratios make explicit the 
impact of the test result on the probability of disease and therefore 
provide a more obvious expression of test performance. (159) A 
PLR describes how many times more likely the positive index test 
results are in the diseased group than the non-diseased group. 
Conversely, a NLR describes how many times less likely the 
negative index test results are in those with the disease than those 
without disease. (146) As a guide, a PLR over 10 suggests a useful 
increase in probability of disease after a positive test result and a 
NLR of less than 0.1 is a useful decrease in probability of disease 
after a negative test result. (160) 
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Sensitivity and specificity are inherently related, and vary by the 
threshold used for diagnostic tests and heterogeneity between 
studies. (146, 161) Univariate meta-analysis of these measures is 
therefore inappropriate, as it does not take into account the 
correlation between these measures and results in an 
underestimation of test accuracy. (161) The most rigorous 
approach for deriving point estimates of sensitivity, specificity, PLR 
and NLR requires fitting of random effects hierarchical models of 
meta-analysis. (146)  
 
A number of statistical models are available for conducting meta-
analyses of diagnostic test accuracy. The Moses Littenberg model, 
although the oldest and widely used, is a fixed effects model and 
does not take into account the heterogeneity between studies. 
(146) This has been superseded by random effects models of 
meta-analysis. Consequently, the bivariate hierarchical method was 
used for the primary analyses as this provides greater precision of 
point estimates for diagnostic accuracy. (146, 162) This model 
involves statistical distributions at two levels. At a lower level, the 
cell counts in the 2×2 tables are extracted from each study using 
binomial distributions and logistic (log-odds) transformations of 
proportions. At a higher level, random study effects are assumed 
to account for heterogeneity in diagnostic test accuracy between 
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studies beyond that accounted for by sampling variability at the 
lower level. (146) The bivariate parameterization models 
sensitivity, specificity and the correlation directly between them. 
The inclusion of a correlation parameter in the model allows for the 
expected trade off in sensitivity and specificity as the test positivity 
threshold varies across studies. Where variation between studies 
arises through such a trade off this correlation is expected to be 
negative, but the correlation may be positive if there are other 
sources of heterogeneity. (146) 
 
Using this statistical method, the average operating points (pooled 
estimates) for sensitivity and specificity were calculated and this 
enabled the construction of Summary Receiver Operating 
Characteristic (SROC) plots with 95% prediction regions. (146)  
 
SROC plots provide a visual display of the results from individual 
studies in Receiver Operating Characteristic (ROC) space; each 
study is plotted within the SROC plot as a single sensitivity 1-
specificity point and the size of the point represents the sample 
size of the study.  (146) Therefore, SROC plots provide a visual 
scatter of study results. A diamond within the SROC plots 
represents the pooled sensitivity and specificity, and a 95% 
prediction region can also be calculated and displayed which can be 
used as a method of visually assessing heterogeneity. (146, 163) A 
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greater test accuracy is observed when the pooled sensitivity-
specificity plot is closer to top left hand corner within the SROC 
plot.  
 
4.4.4.2. Assessment of heterogeneity 
Heterogeneity is presumed in meta-analyses of diagnostic test 
studies as this will arise from differences in study design, patient 
characteristics, test methods and other unknown factors.  (146, 
164) To minimise heterogeneity the results were analysed a priori 
in groups of each method for identifying an irregular pulse.  
Univariate tests of heterogeneity in sensitivity and specificity, such 
as the I2 statistic, cannot be reliably used for the assessment of 
heterogeneity in reviews of diagnostic test accuracy. (165) 
Alternatively, it is recommended that heterogeneity can be 
assessed by visual inspection of the SROC plot 95% prediction 
regions and how close individual studies were to the predicted ROC 
curve within SROC plots. (146, 163, 164)  
 
4.4.4.3. Sub-group analyses 
Sub-group analyses were planned according to study quality and 
studies conducted within a primary care setting providing there 
were ≥4 studies within sub-groups. (146) The bivariate hierarchical 
model assumes the inclusion of at least four studies and sub-
 100 
groups with fewer studies results in failure of the hierarchical 
model to converge and greater statistical error. (146) 
 
4.4.4.4. Assessment of publication bias 
The assessment of publication bias using conventional funnel plot 
asymmetry, as for systematic reviews of interventions, is not 
recommended; application of these methods to reviews of 
diagnostic test accuracy may lead to inaccuracy and increase the 
risk of inappropriately detecting publication bias. (166) It is well 
established that the accuracy of conventional tests for assessing 
funnel plot asymmetry is reasonable if odds ratios are close to one 
(as in the case for many randomised trials), but this deteriorates 
as the odds ratios move away from one. (146, 166) For diagnostic 
test accuracy reviews the odds ratios are expected to be large. 
Applying conventional tests for funnel plot asymmetry in diagnostic 
test accuracy reviews is therefore likely to result in publication bias 
being incorrectly indicated more often. (146, 166) Consequently, a 
more appropriate method of assessing publication bias has been 
developed. (146, 166) Deeks’ funnel plot asymmetry tests for the 
association between the diagnostic accuracy and the ‘effective 
sample size’, a simple function of the number of diseased and non-
diseased individuals. This test has been shown to have a moderate 
power for detecting funnel plot asymmetry. (146, 166) Therefore, 
an assessment for publication bias was made within each category 
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of method for detecting suspected AF using Deeks’ Funnel plot 
asymmetry test; a P-value<0.10 was used to signify the presence 
of publication bias. (166)  
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4.5. Results 
After the removal of duplicate records, there were 5,418 potential 
citations identified. From these, 69 studies were identified for 
detailed evaluation (figure 4-1).  After full-text review, 21 studies 
were included in the final analyses (Table 4-1). (119, 120, 126, 
134, 167-183) Five studies met the selection criteria, but reported 
insufficient outcome data and were excluded (Table 4-2). (137, 
184-187) 
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Figure 4-1: Study selection and stratification 
 
 
 
Contact with 
authors 
1 citation 
21 studies included in final 
review 
 7242 titles or abstracts identified and screened for retrieval 
 
Reference 
List 
4 citations 
MEDLINE 
3194 
citations 
LILACS 
61 citations 
EMBASE 
3344 
citations 
CINAHL 
638 
citations 
69 full-text articles 
48 excluded: 
- 31 not detection studies 
- 3 editorials or reviews 
- 9 not relevant to study 
design 
- 5 insufficient data 
 
7173 excluded: 
- 1824 duplicate records 
- 5349 not relevant  
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Table 4-1: Characteristics of included studies 
Study Setting, 
population & 
sample size 
Prevalence/ 
proportion 
(%) of AF 
Study 
Design† 
Index test(s) Reference test Outcomes Quality 
grading 
Bourdillon 
1978 (167) 
UK; secondary 
care; 221 ECGs 
of adult subjects 
18.6 CS Software 
interpretation of 
three lead ECG 
12-lead ECG 
interpreted by two 
clinicians 
Sensitivity 0.66, 
specificity 0.99 
C 
Caldwell 
2012 (168) 
UK; secondary 
care; 157 
patients 
recruited from 
anticoagulation 
clinic 
49.7 CC 1. Five second 
conventional 6-lead 
ECG from 4 limb 
leads 
 
2. Five second 6-
lead frontal plane 
ECG from four 
electrodes in a 
supine, undressed 
patient using a 
prototype recorder 
 
3. Five second 6-
lead frontal plane 
ECG using four 
electrodes in a 
sitting, dressed 
patient using a 
prototype recorder  
 
Cardiologist 
interpretation (all 
tests) 
12-lead ECG 
interpreted by 
three cardiologists 
Test 1: sensitivity 
0.96; specificity 
0.97 
 
Test 2: sensitivity 
0.96; specificity 
0.97 
 
Test 3: sensitivity 
0.95; specificity 
0.97 
B 
Doliwa Sweden; 51 CC Bipolar single-lead 12-lead ECG Sensitivity 0.92; D 
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2009 (126) secondary care; 
100 patients 
recruited from 
cardiology 
outpatient clinic 
ECG placed on the 
patient’s thumbs 
 
Cardiologist 
interpretation 
interpreted by a 
cardiologist 
specificity 0.96 
Gregg 
2008 (169) 
UK; secondary 
care; database of 
50,000  hospital 
ECGs; 1,785 
randomly 
selected  
6.1 CS 1.  Reconstructed 
12-lead ECG from 
limb leads and 
leads v1 and v4.  
 
2. Reconstructed 
12-lead ECG from 
limb leads and 
leads v2 and v5 
 
All index tests 
interpreted by 
computer software 
12-lead ECG 
interpreted by two 
cardiologists 
Test 1: sensitivity 
0.84; specificity 
0.99 
 
Test 2: sensitivity 
0.88; specificity 
0.99 
D 
Haberman 
2015 (170) 
USA; secondary 
care; 381 
subjects 
recruited from 
university 
athletics society, 
medical 
students, and 
cardiology clinic 
4.7 CS iPhone based single 
lead ECG (AliveCor) 
interpreted by 
software and two 
electrophysiologists 
12-lead ECG 
interpreted by 
automated 
software and two 
electrophysiologists 
Sensitivity 0.94; 
specificity 0.99 
D 
Hobbs 
2005 (119) 
UK; primary 
care; 9,866 
patients aged≥ 
65 years 
Test 1: 8.6 
 
Test 2: 8.5  
 
Test 3: 8.2 
 
RCT 1. Pulse palpation 
(nurse) 
 
2. Single-lead ECG 
(nurse 
interpretation) 
12-lead ECG 
interpreted by two 
cardiologists; third 
cardiologist for 
arbitration 
Test 1: sensitivity 
0.87; specificity 
0.81 
 
Test 2: sensitivity 
0.69; specificity 
C 
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Test 4: 9.1  
 
Test 5: 9.4 
 
3. Single-lead ECG 
(GP interpretation) 
 
4. Limb-lead ECG 
(nurse 
interpretation) 
 
5. Limb-lead ECG 
(GP interpretation) 
0.83 
 
Test 3: sensitivity 
0.85; specificity 
0.86 
 
Test 4: sensitivity 
0.72; specificity 
0.83 
 
Test 5: sensitivity 
0.83; specificity 
0.89  
Kaleschke 
2009 (171) 
Germany;  
secondary care; 
508 patients  
attending AF 
specialist centres  
25.4 C Single-lead ECG 
Omron Heartscan 
801)  
 
Cardiologist 
interpretation 
12-lead ECG 
interpreted by a 
cardiologist. 
Sensitivity 0.99; 
specificity 0.96 
B 
Kearley 
2014 (172) 
UK, primary 
care; 999 
patients aged 
≥75 years 
Test 1: 7.7 
 
Test 2: 7.9 
 
Test 3: 7.9 
 
Test 4: 7.9 
 
Test 5: 7.9 
CS 1. Pulse palpation 
(nurse) 
 
2. Automated BP 
monitor (WatchBP) 
 
3. Single-lead ECG 
with automated 
analysis (OMRON 
HCG-801) 
 
4. Single-lead ECG 
with cardiologist 
interpretation 
12-lead ECG 
interpreted by two 
cardiologists; third 
cardiologist for 
arbitration 
Test 1: sensitivity 
0.97; specificity 
0.86 
 
Test 2: sensitivity 
0.95; specificity 
0.90  
 
Test 3: sensitivity 
0.99; specificity 
0.76  
 
Test 4: sensitivity 
0.94, specificity 
B 
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(OMRON HCG-801) 
 
5.Single-lead ECG 
with cardiologist 
interpretation 
(Merlin) 
0.95 
 
Test 5: sensitivity 
0.94, specificity 
0.90 
Lau  
2012 (173) 
Australia; 109 
patients; setting 
unknown 
35.8 CC Single-lead ECG 
using smart phone 
(i-phone) 
 
ECGS interpreted 
by automated 
software and 
cardiologist 
12-lead ECG 
interpreted by a 
cardiologist 
Software 
interpretation: 
sensitivity 1; 
specificity 0.96  
 
Cardiologist 
interpretation:  
sensitivity 0.97; 
specificity 0.91 
B 
Lowres 
2015 (134) 
Australia; 
primary care; 
972 patients 
recruited from 10 
pharmacies 
6.9 CS Pulse palpation 
conducted by 
trained pharmacist 
iPhone based single 
lead ECG (AliveCor 
heart monitor) 
interpreted by 
cardiologist 
Sensitivity 0.76; 
specificity 0.93 
D 
Marazzi 
2012 (174) 
Italy; Secondary 
care; 550 
patients 
attending 
hypertension 
clinic  
20.1 
20.4 
CS 1. Automated BP 
monitor (Microlife 
BP A200 Plus) 
2. Automated BP 
monitor (Omron 
M6)  
12-lead ECG 
interpreted by a 
cardiologist.  
Microlife BP A200 
Plus: sensitivity 
0.92; specificity 
0.97 
 
Omron M6: 
sensitivity 1; 
specificity 0.96 
B 
McManus 
2013 (175) 
USA; Secondary 
care; 76 patients 
with AF 
attending  
elective 
50 CS The index test was 
the Smart phone 
application to 
detect fingertip 
pulse waveform i-
12-lead ECG or 
telemetry, 
interpreted by a 
trained physician 
RMSSD: sensitivity 
0.98; specificity 
0.91 
  
Shannon entropy: 
D 
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cardioversion phone 4S) 
 
Analysis by three 
methods of 
automated 
software (RMSSD, 
Shannon entropy 
and combination of 
the two) 
sensitivity 0.98; 
specificity 0.82 
 
RMSSD + Shannon 
entropy: Sensitivity 
of 0.96; specificity 
0.95. 
Morgan 
2002 (120) 
UK; Primary 
care; 3001 
patients from 
four general 
practices 
6.1 RCT Pulse palpation 
(nurse)  
Single-lead ECG 
interpreted by a 
physician 
Sensitivity 0.91; 
specificity 0.74 
A 
Renier 
2012 (176) 
Belgium; 
secondary care; 
244 patients 
attending 
emergency 
department or 
hospital wards 
7.3 CS Non-12 –lead 
(Omron Heartscan 
- a wireless device 
which creates a 
ECG on a display 
representing leads 
v3 and v4 of a 
conventional 12-
lead ECG)  
 
Interpretation by 
two GPs and 
automated 
software  
12-lead ECG 
interpreted by a 
cardiologist.  
GP interpretation: 
sensitivity 0.69; 
specificity 0.95  
 
Software 
interpretation: 
sensitivity 0.92; 
specificity of 1 
B 
Somerville 
2000 (177) 
UK; Primary 
care; 86 patients 
recruited from 
one general 
practice 
Pulse 
palpation: 
31.4 
 
Bipolar ECG: 
CC 1. Pulse palpation 
(nurse) 
 
2. Bipolar ECG 
(nurse 
12-lead ECG 
interpreted by a 
consultant 
cardiologist 
Test 1: sensitivity 
0.97; specificity 
0.79 
 
Test 2:  Sensitivity 
C 
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30.2 interpretation) 
 
3. Bipolar ECG (GP 
interpretation)  
0.94; specificity 
0.93 
 
Test 3: Sensitivity 
0.96; specificity 
0.98  
Stergiou 
2009 (178) 
Greece; 
Secondary care; 
73 patients 
recruited from 
both outpatient 
and inpatient 
settings 
36.9 CC Automated BP 
monitor (Microlife 
BPA100 Plus)  
12-lead ECG 
interpreted by the 
lead investigator 
and a cardiologist  
Sensitivity 1; 
specificity 0.85 
D 
Sudlow 
1998 (179) 
UK; primary 
care; 1235 
patients from 
nine general 
practices.  
4.4 CC Pulse palpation 
(nurse)  
Limb-lead ECG 
(interpreter 
unclear)  
Sensitivity 0.93; 
specificity 0.71 in 
women, and 1 and 
0.86 in men 
respectively 
D 
Vaes  
2014 (180) 
Belgium; primary 
care; 181 
patients from 
general practices 
53 CC Single lead ECG 
(MyDiagnostick) 
with automated 
software analysis 
12-lead ECG 
interpreted by 
cardiologist 
Sensitivity 0.94; 
specificity 0.93 
B 
Wiesel 
2004 (181) 
USA; secondary 
care; 450 
patients 
recruited from 
outpatient clinic 
12.6 CS Automated BP 
monitor (Omron 
712C) 
 
12-lead ECG 
(interpreter 
unclear)  
Sensitivity 1; 
specificity 0.91 
D 
Wiesel 
2009 (182) 
USA; secondary 
care; 405 
patients 
recruited from 
outpatient clinic  
23.0 CS Automated BP 
monitor (Microlife 
BP3MQ1-2D) 
 
12-lead ECG 
interpreted by a 
cardiologist 
Sensitivity 0.95; 
specificity 0.86 
B 
Wiesel USA; secondary 5.7 C Automated BP ECG event monitor Sensitivity 1; B 
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2013 (183) care; 160 
patients ≥65 
years recruited 
from internist’s 
office and home 
monitoring 
performed. 
monitor (Microlife 
BP3MQ1-2D) 
(Heartrak 2)  
 
A 60 second ECG 
interpreted by a 
cardiologist  
specificity 0.94 
†CC = Case-control study; CS = cross-sectional study; RCT = Randomised controlled Trial; C = Cohort study 
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Table 4-2: Characteristics of eligible studies that were excluded 
Author/Year Setting, 
population & 
sample size 
Study 
design 
Intervention Comparator Reported 
outcomes 
Reason for 
exclusion 
Boyle  
2013 (184) 
USA; 1334 patients; 
screening 
performed at 
community events 
CS Pulse palpation 
(Nurse) 
 
 
Single lead ECG 
rhythm strip 
interpreted by 
consultant 
cardiologist 
Pulse palpation: 
Sensitivity 0.43;  
Positive predictive 
value 0.16 
Only the number 
of true AF cases 
were reported 
Harrington  
2013 (185) 
USA; 93 patients; 
setting unknown 
C Smart phone 
application (i-
Phone 4S with 
three algorithms) 
Smart phone 
application (i-
Phone 4S with 
three interpretation 
algorithms): 
 
Algorithm 1: 
Poincare 
Plot+RMSSD+ ShE 
 
Algorithm 2: 
Poincare 
Plot+RMSSD+ 
SampE 
 
Algorithm 3: 
Poincare 
Plot+RMSSD+ 
ShE+SampE 
Algorithm 1: 
Sensitivity 1; 
specificity 0.88  
 
Algorithm 2: 
Sensitivity 1; 
specificity 0.87  
 
Algorithm 3: 
sensitivity 1; 
specificity 0.98  
Unsure of 
comparator 
intervention, and 
true positive 
cases of AF not 
known  
Lewis  
2011 (186) 
UK and USA; 
secondary care; 
594 patients ≥60 
years recruited 
CC Finger probe that 
recorded pulse 
waveform 
(automated 
12-lead ECG 
interpreted by a 
consultant 
cardiologist 
Sensitivity 1; 
specificity 0.91 
The number of 
true positive and 
true negative 
cases not 
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outpatient clinics  software analysis)  reported  
Rhys  
2013 (137) 
UK; primary care; 
patients ≥65 years 
recruited from flu 
clinics 
CS Pulse palpation 
(Nurse) 
12-lead ECG 
interpreted by a 
consultant 
cardiologist 
23 patients were 
detected as 
having AF 
Only true 
positive cases of 
AF reported 
Sawant  
2014 (187) 
USA; secondary 
care; 103 patients 
from cardiology 
outpatient clinic 
CS Smartphone ECG 
interpreted by 
cardiologist 
12-lead ECG 
interpreted by two 
cardiologists 
Sensitivity 0.88; 
specificity 0.91 
Number of 
patients with 
true AF not 
reported 
†CC = Case-control study; CS = cross-sectional study; RCT = Randomised controlled Trial; C = Cohort study 
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4.5.1. Study characteristics 
Of the 21 studies included, (table 4-1) there were two randomised-
trials, (119, 120) seven case-control, (126, 168, 173, 177-180) 
two cohort, (171, 183) and 10 cross-sectional studies. (134, 167, 
169, 170, 172, 174-176, 181, 182)  
 
Although the majority of studies avoided a case-controlled design, 
only four were prospective and there were seven studies conducted 
in a primary care setting.(119, 120, 134, 172, 177, 179, 180) AF 
prevalence ranged from 5.7% to 25.4% in studies with a 
prospective design. (119, 120, 171, 183) There was substantial 
variation in the proportion and/or prevalence of AF in studies within 
each category of detection method.     
  
Five studies excluded participants if they were <65 years of age 
and for two studies the age of inclusion was 75 years. (119, 134, 
172, 177-179, 183) Six studies included participants who were ≥18 
years old. (120, 171, 174-176, 181) Nine studies excluded patients 
that had been fitted with pacemakers and/or implantable 
defibrillators. (134, 169, 172, 174, 178, 180-183)  
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4.5.2. Healthcare settings for detecting pulse 
irregularities caused by atrial fibrillation 
Of the 21 included studies eight were conducted in the UK (119, 
120, 167-169, 172, 177, 179) and six in non-UK European 
countries. (126, 171, 174, 176, 178, 180) Five studies were 
conducted in the United States (170, 175, 181-183) and two in 
Australia. (134, 173)  
 
Most studies were conducted in secondary care settings (126, 167-
171, 174-176, 178, 181-183) with only seven being conducted in 
primary care. (119, 120, 134, 172, 177, 179, 180) Five of these 
were in UK primary care. (119, 120, 172, 177, 179) The healthcare 
setting for one study was not reported. (173) 
 
4.5.3. Methods used to detect pulse irregularities 
caused by atrial fibrillation  
4.5.3.1. Detecting pulse irregularities and suspected atrial 
fibrillation 
The 21 studies investigated 39 interventions (n=15,129 pulse 
assessments) which were categorised as blood pressure monitors 
(BPMs) [six studies; seven interventions], (172, 174, 178, 181-
183) non-12-lead ECG [10 studies; 20 interventions], (119, 126, 
167-169, 171, 172, 176, 177, 180) pulse palpation [six studies; six 
interventions], (119, 120, 134, 172, 177, 179) and smartphone 
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applications [three studies; six interventions]. (170, 173, 175) The 
five studies which were excluded due to insufficient reporting of 
outcome data investigated pulse palpation, pulse oximetry, smart 
phone applications and single-lead ECG as methods for detecting 
AF.  
 
Of the studies investigating BPMs, three did not report the 
professional used to obtain readings, (174, 178, 181) one study 
used a nurse, (172) one used a trained technician (182) and 
another used patient self-recording of automated blood pressures. 
All of the studies of BPMs (172, 174, 178, 181-183) used 
integrated automated analysis within the BPM to determine the 
presence of suspected AF. (183) Most of these studies described 
the software algorithms used; blood pressure monitors analysed 
the differences in time between successive pulse waveforms during 
blood pressure cuff deflation and suspected AF was indicated when 
a pre-specified irregularity index was exceeded. (174, 178, 181-
183)   
 
Of the studies that investigated smart phone devices for detecting 
an irregular pulse, two required patients to self-administer the 
device to detect AF (170, 175) and for one study the method used 
to obtain a reading was not reported. (173) All of the studies of 
smart phone technology used software algorithms, as for BPMs, to 
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detect pulse irregularities caused by AF. (170, 173, 175) One study 
however combined software and electrophysiologist analysis of the 
readings to determine suspected AF. (170)  
 
There was a broader range of approaches for indicating the 
presence of suspected AF in studies that used non-12-lead ECGs. 
(119, 126, 167-169, 171, 172, 176, 177, 180) To obtain the non-
12-lead ECGs there were two studies where patient’s self- recorded 
ECGs. (126, 171) Nurses recorded ECGs in three studies (119, 172, 
177) but for the remainder of studies the person recording ECGs 
was not reported. (167-169, 176, 180) Seven of the non-12-lead 
ECG studies used clinical expertise of clinicians to interpret ECGs – 
four studies used cardiologists (126, 168, 171, 172) and three 
studies used GPs and/or nurses. (119, 176, 177) Only one study 
reported a one-hour training session that was provided to clinicians 
to standardise ECG interpretation. (119) However, none of the 
studies provided information about the criteria used to rule in or 
out the presence of suspected AF and this classification threshold 
was based on clinical expertise.   
The remaining studies used automated software analysis of non-
12-lead ECGs but the algorithms and the cut-offs used to 
determine the presence of suspected AF were not reported. (167, 
169, 172, 180) 
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In studies that used pulse palpation for detecting pulse 
irregularities caused by AF (119, 120, 134, 172, 177, 179) most 
used nurses to perform pulses palpation (119, 120, 172, 177, 179)  
and one used community pharmacists. (134) All studies relied on 
the clinical expertise of healthcare professionals to make 
judgments about the degrees of pulse irregularity when 
determining the presence of suspected AF. Two studies classified 
the pulse as either regular or irregular, the latter being used to 
determine the presence of AF. (119, 177) One study defined 
suspected AF as being any pulse that was not regular. (179) One 
study required nurses to palpate the pulse for at least 20 seconds 
and then classify the pulse as either regular, occasional ectopics, 
frequent ectopics or continuously irregular; suspected AF was then 
defined as any pulse irregularity. (120) Two studies did not report 
how pulses were classified to determine suspected AF. (134, 172) 
Only one study reported training provided to nurses about 
detecting an abnormal pulse. (119) 
 
4.5.3.2. Reference standard for atrial fibrillation detection 
For the majority of studies, the reference standard was 12-lead 
ECG interpreted by at least one trained physician/cardiologist. One 
study did not specify the training of the clinician interpreting 
reference ECGs. (167) Five studies reported other reference 
standards; (120, 134, 175, 179, 183) one study used either 12-
 118 
lead ECG or ECGs derived from cardiac telemetry; (175) three 
studies used single or limb-lead ECG; (120, 134, 179) one study 
used ECGs derived from Holter monitors. (183)  
 
4.5.4. Study quality and risk of bias 
The methodological quality of included studies using QUADAS-2 
criteria is presented in figure 4-2. Study quality was generally low. 
Using the additional quality grading system, we classified one study 
as A-grade having met all QUADAS-2 criteria. (120) Eleven studies 
were graded category C or D. (119, 126, 134, 167, 169, 170, 175, 
177-179, 181) Studies with the lowest methodological quality (D-
grade) were classified as this due to either the interpretation of the 
reference standard being unclear or at high risk of bias, or due to 
the index test being interpreted un-blinded to the results of the 
reference standard. Category C studies were graded as such 
because it was unclear whether there was an appropriate time 
interval between the index test and reference standard. The 
remaining nine studies were categorised as grade-B in 
methodological quality. (168, 171-174, 176, 180, 182, 183) 
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Figure 4-2: Study quality according to QUADAS-2 criteria 
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4.5.5. Data synthesis 
Forest plots for diagnostic accuracies of the four methods for 
detecting AF are presented in figures 4-3, 4-4, 4-5 and 4-6. Blood 
pressure monitors (BPMs) had a pooled sensitivity of 0.98 (95% CI 
0.92-1) and specificity of 0.92 (95% CI 0.88-0.95); PLR of 12.1 
(95% C.I 8.2-17.8) and NLR of 0.02 (95% C.I 0.00-0.09). There 
were similar diagnostic accuracies for studies that investigated 
smartphone applications, sensitivity 0.97 (95% CI 0.95-0.99), 
specificity 0.95 (95% CI 0.88-0.98), PLR 19 (95% C.I 8-45), NLR 
0.03 (95% C.I 0.01-0.05); and non-12-lead ECGs, sensitivity 0.91 
(95% CI 0.86-0.94), specificity 0.95 (95% CI 0.92-0.97), PLR 20.1 
(95% C.I 12-33.7), NLR 0.09 (95% C.I 0.06 to 0.14). Although 
pulse palpation had a sensitivity that was comparable to the other 
methods for detecting suspected AF (sensitivity of 0.92 (95% CI 
0.85-0.96), there was a substantially lower specificity for this 
method (specificity 0.82 (0.76-0.88); PLR and NLRs for pulse 
palpation were 5.2 (95% C.I 3.8-7.2) and 0.1 (0.05-0.18), 
respectively. 
 
 121 
Figure 4-3: Sensitivity and specificity of blood pressure monitor interventions 
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Figure 4-4: Sensitivity and specificity of non-12-lead ECG interventions 
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Figure 4-5: Sensitivity and specificity of smartphone applications 
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Figure 4-6: Sensitivity and specificity of pulse palpation 
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SROC plots for the methods of detecting AF are presented in figure 
4-7. Visual inspection of the plots confirms the accuracy of pulse 
palpation was lower than other methods for detecting AF. There 
was substantial variation in outcomes of the studies investigating 
non-12-lead ECG from the predicted ROC curve and suggests the 
heterogeneity amongst these studies was greatest.  In contrast, 
the heterogeneity was lowest amongst studies that investigated 
smart phone applications and BPMs for detecting pulse 
irregularities caused by AF. 
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Figure 4-7: Summary Receiver Operating Characteristic 
(SROC) plots for methods of detecting pulse irregularities 
caused by atrial fibrillation 
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4.5.6. Sub-group analyses 
There were only sufficient studies to perform bivariate sub-group 
analyses according to study quality for BPM, non-12-lead ECG and 
pulse palpation interventions. After exclusion of studies with the 
lowest (D-grade) quality, there were no substantial differences to 
the primary findings. [BPMs: sensitivity 0.96 (95% C.I 0.91-0.98), 
specificity 0.93 (95% C.I 0.89-0.96); non-12-lead ECG: sensitivity 
0.92 (95% C.I 0.86-0.95), specificity 0.94 (95% C.I 0.91-0.97); 
pulse palpation: sensitivity 0.93 (95% C.I 0.86-0.97), specificity 
0.81 (95% C.I 0.76-0.85)].   
 
Sufficient studies to perform bivariate sub-group analyses for 
primary care studies were available for pulse palpation and non-
12-lead ECG interventions. The findings were similar to our primary 
analyses, although the specificity of non-12-lead ECGs was slightly 
lower  [Non-12-lead ECGs: sensitivity 0.91 (95% C.I 0.83-0.95), 
specificity 0.89 (95% C.I 0.85-0.92); pulse palpation: all studies 
were conducted in primary care and findings already presented 
above].   
 
4.5.7. Publication bias 
There was no evidence of publication bias; Deeks’ Funnel test 
p=0.34, p=0.11, p=0.14 and p=0.27 for studies investigating 
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BPMs, non-12-lead ECG, smart phone applications and pulse 
palpation, respectively.  
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4.6. Discussion 
4.6.1. Summary of principal findings 
Modified blood pressure monitors (BPMs), non-12-lead ECGs, smart 
phone applications and pulse palpation were identified as methods 
for detecting pulse irregularities caused by AF. Most studies 
investigating these methods were conducted in secondary care 
settings although most primary care studies were from the UK. 
Healthcare professionals were often involved in the detection of 
suspected AF. Automated analysis was used by BPMs and smart 
phone applications to detect cases of suspected AF, but for pulse 
palpation and non-12-lead ECGs the presence or absence of 
possible AF was often determined by clinician expertise.  Modified 
BPMs and non-12-lead ECG devices were found to have the 
greatest diagnostic accuracy for detecting pulse irregularities 
caused by AF. Although the sensitivities of all methods for 
identifying those with suspected AF were similar, the specificity of 
pulse palpation was lower which gives rise to more false positive 
test results.   
 
4.6.2. Strengths and limitations 
This study supersedes the previous review by Cooke et al. (147) 
that provided evidence for the accuracy of pulse palpation for 
detecting suspected AF. The current study is also the first 
systematic review and meta-analysis of different interventions for 
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the detection of suspected AF and provides evidence comparing the 
diagnostic accuracy of newer interventions to pulse palpation.  
 
A strength of this study was the use of a standardised protocol that 
is consistent with published guidelines for systematic reviews of 
diagnostic test studies.  A comprehensive search strategy was used 
that included contacting authors of potentially relevant studies, 
although no additional data were obtained from author 
correspondence.   The results also supported the lack of publication 
bias and it is likely that relevant small studies with less significant 
findings were included.  
There were four studies that were excluded due to insufficient 
reporting of outcome data to enable meta-analysis and this could 
influence the findings. However, the outcomes that were reported 
from these studies were consistent with the primary outcomes from 
the review and the effect of excluding these studies is likely to be 
minimal.  
 
Only four of the 21 included studies adopted a prospective design 
and there were a number of inherent methodological weaknesses 
in most studies as reflected by the assessments of study quality. 
Only one study was judged to have met all QUADAS-2 criteria. 
Consequently, the internal validity of the findings may be limited.  
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Most studies that investigated methods for identifying patients with 
an irregular pulse were conducted in a secondary care setting and 
there was substantial variation in the proportion of patients with 
AF. Combined with the abundance of low quality of studies in the 
review, the generalisability of the findings to primary care 
populations that AF screening is intended for is limited. Healthcare 
professionals in secondary care may have greater training and 
experience for detecting patients with AF – either using pulse 
palpation or newer technologies - than those in primary care, and 
patients in secondary care are more likely to have cardiovascular 
disease and AF detected than unselected primary care populations. 
Consequently this limits the translation of findings from the review 
to screening conducted within primary care settings.  
 
As the prevalence of AF increases with age and it is greater in men 
than women, it is possible that the performance of methods for 
detecting pulse irregularities could be affected by the different ages 
and distribution of gender between study populations. A limitation 
of this study was that these potential interacting factors could not 
be accounted for as the included studies did not provide sufficient 
data for such analyses to be conducted. However, the measures of 
diagnostic accuracy used in the review are prevalence independent 
and therefore the impact of age within studies on test performance 
is likely to be mitigated.  
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For some studies the time between conduct of index and reference 
tests was unclear.  Patients with paroxysmal AF could have been 
missed as AF identified by initial testing may have resolved by the 
time verification testing had been performed. Consequently, this 
could have reduced the diagnostic accuracy of the index test(s) 
under investigation.  
 
As expected, there was heterogeneity amongst the studies within 
all intervention categories and this is likely to be attributable to 
differences in study population and design. This variation was 
greatest for studies that investigated non-12-lead ECG for 
detecting suspected AF. This may be due to differences in the 
detection methods within this category; the non-12-lead ECG 
interventions included single-lead, three-lead and reconstructed 
ECG for detecting pulse irregularities caused by AF, and such 
technological differences may account for some of the greater 
observed heterogeneity than other methods. In addition, there 
would have been differences in the abilities of clinicians, such as 
GPs or nurses, to verify the presence or absence of disease in 
these studies and the criteria used to interpret non-12-lead ECGs 
to rule in or out suspected AF were often undefined and reliant 
upon clinical expertise.  
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4.6.3. Findings in context of previous research 
A narrative literature review was conducted to inform the Royal 
College of Physicians about how to best detect AF. This review also 
identified, in addition to pulse palpation and single-lead ECGs, 
modified blood pressure monitors and pulse oximeters as methods 
for detecting pulse irregularities caused by AF. (148) Harris et al. 
suggested that pulse palpation may have the lowest accuracy for 
detecting an irregular pulse caused by AF than other methods due 
to its lower specificity and these findings are consistent with those 
in my review. However, the review by Harris et al. only included 
studies from 2006 onwards, did not provide point estimates for the 
diagnostic accuracies or compare the accuracies of different 
methods for detecting suspected AF, and the risk of bias of 
included studies were not appraised. (148) Therefore, the internal 
validity of findings from this earlier review are limited and the 
findings from my review supersede it.  
 
The systematic review by Cooke et al. only investigated the 
accuracy of pulse palpation for detecting AF.  (147) My review 
identified a greater number of studies that investigated pulse 
palpation for detecting AF and investigated other methods of 
detecting pulse irregularities. The findings from my review are 
consistent with those by Cooke et al. and support the assertion 
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that pulse palpation, despite having a high sensitivity, has a low 
specificity for the detection of pulse irregularities caused by AF.   
 
More recently, studies have tended to evaluate newer technologies 
for detecting suspected AF. My review identified three methods – 
non-12-lead ECG, modified blood pressure monitors, smart phone 
applications – as alternative methods for detecting an irregular 
pulse caused by AF. Of all interventions analysed, pulse palpation 
was found to have the lowest diagnostic accuracy for detecting 
pulse irregularities attributable to AF as reflected by its lower 
specificity. This could be due to differences between the cut-off 
points of each method to rule in or out the presence of suspected 
AF. Electronic methods, such as modified blood pressure monitors 
or smart phone applications, use software algorithms to determine 
the severity of pulse irregularity and only those patients meeting a 
pre-determined cut-off point are classified as having AF. In 
contrast, studies investigating pulse palpation required clinicians to 
classify the pulse as being regular or irregular. It is therefore 
conceivable that pulse palpation is more likely to result in a greater 
number of false positive cases of suspected AF arising from the 
detection of patients who have a slight irregularity in pulse that is 
not attributable to AF, such as atrial or ventricular extra-systoles, 
that software algorithms would have excluded. 
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4.7. Conclusion 
Modified blood pressure monitors and non-12-lead ECG devices 
were found to have a greater accuracy than pulse palpation for 
detecting pulse irregularities attributable to AF. These methods 
could be pragmatic alternatives to the currently recommended 
pulse palpation for identifying patients with suspected AF as part of 
national screening programmes.  
 
This study investigated and compared the accuracies of different 
methods that could be used for the first-step of proposed AF 
screening. In the next chapter, I will investigate and compare the 
accuracies of different methods that could be used to interpret 12-
lead ECGs – the proposed second-step of AF screening. 
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Chapter 5. Systematic review and meta-
analysis of methods for diagnosing atrial 
fibrillation using 12-lead ECG 
5.1. Background 
After firstly identifying patients with a pulse irregularity (i.e. 
suspected AF), the second-step of recommended AF screening is to 
confirm or exclude the presence of AF. (80, 108)  The gold 
standard test for diagnosing AF is 12-lead ECG that is interpreted 
by a competent professional. (51, 80, 108)  
 
The accuracy of interpreting 12-lead ECGs for the diagnosis of AF is 
fundamental to the effectiveness of AF screening, and has 
significant implications for health service resources and patient 
safety. A high sensitivity would result in patients being correctly 
diagnosed with AF and appropriately assessed for stroke 
preventative therapies, but a low sensitivity would result in 
excessive false negative diagnoses of AF and patients incorrectly 
being reassured and not offered treatment. Conversely, a high 
specificity would result in those without AF being correctly 
reassured, but a low specificity would result in high numbers of 
false positive AF diagnoses and patients inappropriately offered 
stroke preventative treatment.   
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A sub-study of the systematic screening versus routine practice for 
the detection of atrial fibrillation in people aged 65 and over (SAFE) 
trial investigated the accuracy of different methods for 12-lead ECG 
interpretation and diagnosis of AF. (188) The SAFE sub-study 
compared the accuracy of ECG interpretation by GPs, practice 
nurses and automated software to cardiologist ECG interpretation. 
(188) This found that, compared to ECG diagnoses of AF made by 
cardiologists, interpretive software had a significantly greater 
specificity than the other methods of ECG interpretation. However, 
the sensitivities for GPs, nurses and software for AF diagnosis were 
substantially lower and similar across all groups. [Sensitivities 
(95% CI) and specificities (95% CI) for GPs: 79.8% (70.5-87.2) 
and 91.6% (90.1-93.1); practice nurses: 77.1% (67.4-85.0) and 
85.1% (83.0-86.9); automated software: 83.3% (78.3-88.2) and 
99.1% (98.7-99.5)]. Consequently, Mant et al. suggested the 
accuracy of ECG interpretation and diagnosis of AF in primary care 
using any single method may be insufficient for screening 
implementation within this setting.  (188)  
 
To date there has been no systematic evaluation of the accuracies 
of different methods for interpreting 12-lead ECGs in the diagnosis 
of AF. A greater understanding of this fundamental step of AF 
screening, with a focus of AF diagnosis in primary care, would 
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inform how the second-step of screening could be organised and 
implemented. 
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5.2. Aims 
To describe and compare the diagnostic accuracies of different 
methods for 12-lead ECG interpretation in the diagnosis of AF, with 
a focus on ECG interpretation in primary care. 
 
5.3. Objectives 
 To describe the healthcare settings and professionals 
involved in the interpretation of 12-lead ECGs for AF 
diagnosis. 
 To describe different methods used for interpreting 12-lead 
ECGs in the diagnosis of AF. 
 To determine the accuracy of different methods used for 
making diagnoses of AF, with a focus on healthcare 
professionals in primary care, by comparing the 
interpretation of 12-lead ECGs by trained cardiac specialists 
to other methods of 12-lead ECG interpretation.  
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5.4. Methods 
The methods used for this systematic review were the same as 
those in the previous systematic review of interventions for 
detecting pulse irregularities attributable to AF. Justification for the 
methodological and statistical approaches used has therefore been 
provided in the relevant sub-sections of chapter four. 
 
5.4.1. Search strategy and selection criteria 
This study was conducted in accordance with guidelines and 
methods for systematic reviews and meta-analyses of diagnostic 
tests. (146, 150, 151, 164) A comprehensive search strategy was 
used to ensure all relevant citations were identified. 
 
5.4.1.1. Data sources 
The databases MEDLINE, EMBASE, Cumulative Index to Nursing & 
Allied Health (CINAHL) and Latin American and Caribbean Health 
Sciences Information System (LILACS) were searched in all 
languages published from inception until 24th March 2014 
(Appendix 3). (150) Additionally, the Cochrane Register of 
Diagnostic Test Accuracy Studies and the reference lists of national 
guidelines, review articles and included studies were hand-
searched to identify potential studies. (150)   
 
5.4.1.2. Search terms 
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The search criteria included specified terms to encompass domains 
related to the participants, settings, target condition, index test(s) 
and reference standard (Appendix 3). (149, 150)  
 
5.4.1.3. Inclusion and exclusion criteria 
After the removal of duplicate records, two reviewers (JT and MJ) 
independently screened citations for relevance and reviewed full-
text articles using predetermined eligibility criteria. Any 
disagreements were resolved by consensus with a third reviewer 
(TC).  
 
The inclusion criteria for studies in the review were: 
 All randomised trials and observational studies. 
 Studies that recruited participant’s ≥18 years of age. 
 Studies that investigated any method for interpreting 12-lead 
ECGs to show AF (the index test and target condition.)  
 Studies that compared the index test to 12-lead ECG 
diagnoses of AF made by a trained cardiac specialist (the 
reference standard).  
 Studies that involved healthcare professionals in making AF 
diagnoses.  
 Studies that reported sufficient data available to enable the 
calculation of diagnostic accuracy.  
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The exclusion criteria for studies in the review were: 
 Studies that were case reports or case-series. 
 Studies using invasive or echocardiographic methods for 
diagnosing AF, as these could not feasibly be used in 
population screening.  
 
5.4.2. Data extraction 
Two reviewers (JT and MJ) independently extracted data from 
eligible studies using a pre-specified data extraction form 
(Appendix 2). Any disagreements were resolved by consensus with 
a third reviewer (TC). Data were extracted for study characteristics 
and for true positive, true negative, false positive and false 
negative diagnoses of AF. The lead author(s) of studies for which 
reported data were insufficient to calculate diagnostic accuracy 
were contacted to ascertain missing data. 
 
5.4.3. Assessment of study quality and risk of bias 
Study quality was appraised using the Quality Assessment of 
Diagnostic Accuracy Studies-2 (QUADAS-2) instrument. (151, 155-
157) Additionally, the studies were graded using the quality scale 
reported by Van den Bruel et al; (158) studies were rated as grade 
A if they fulfilled all QUADAS-2 criteria. Studies were graded D if 
there was no or unclear verification of the index test findings with 
the reference standard, or if the index test results were interpreted 
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un-blinded to the results of the reference test. Studies where there 
was an unduly long time delay between index and reference test, 
or where the reference test was not independent of the index test, 
or where the reference test was interpreted un-blinded to the 
results of the index test were graded C.   Remaining studies which 
did not fall in to these categories were graded B.  
 
5.4.4. Statistical analysis 
Analyses were conducted using Stata Version 11.0 and Review 
Manager 5.2 for quality assessments.  
 
5.4.4.1. Primary outcome measures for diagnostic accuracy 
Data extracted were used to construct 2x2 contingency tables. This 
enabled the calculation of sensitivity and specificity for each 
method of diagnosing AF. Positive likelihood ratios (PLR) and 
negative likelihood ratios (NLR) were calculated for each method of 
diagnosing AF. Unlike sensitivity and specificity, likelihood ratios 
make explicit the impact of a positive or negative test result on the 
probability of/absence of disease and therefore are a more obvious 
expression of test performance. (152) As a guide, a PLR over 10 
suggests a useful increase in probability of disease after a positive 
test result and a NLR of less than 0.1 is a useful decrease in 
probability of disease after a negative test result. (153) 
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Primary outcomes were the pooled sensitivity, specificity, PLR and 
NLR for each method of diagnosing AF using 12-lead ECG. The 
bivariate hierarchical random effects method was used to 
determine the average operating points for sensitivity, specificity, 
PLRs and NLRs which enabled construction of Summary Receiver 
Operating Characteristic (SROC) plots with 95% prediction regions. 
(146) Diagnostic accuracy was assessed by comparison of average 
operating points and respective 95% confidence intervals. 
 
5.4.4.2. Assessment of heterogeneity 
Heterogeneity is presumed in meta-analyses of diagnostic test 
studies and the I2 statistic cannot be reliably used for its 
assessment. (146) Heterogeneity was therefore described by the 
variation in the outcomes from included studies and our pooled 
estimates by visual inspection of the SROC plots and how close 
individual studies lie to the predicted ROC curve. To minimise 
heterogeneity the results were analysed a priori grouped according 
to method of diagnosing AF. 
 
5.4.4.3. Sub-group analyses 
Sub-group analyses were planned according to study quality and 
groups of healthcare professionals within a primary care setting. It 
was expected that sub-groups would be small; therefore univariate 
random effects meta-analysis was used to derive pooled estimates 
 145 
for sensitivity and specificity when there were less than four 
studies within sub-groups as the bivariate model is unreliable in 
this context. (146) 
 
5.4.4.4. Assessment of publication bias 
An assessment of publication bias was made according to 
categories of method for detecting AF using Deeks’ Funnel plot 
asymmetry test; a P-value<0.10 was used to signify the presence 
of publication bias. (146, 166)  
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5.5. Results  
After the removal of duplicate records there were 4,426 potential 
citations, of which 62 were identified as relevant for detailed 
evaluation (figure 5-1).  After full-text review, 10 studies were 
included in the final analyses (table 5-1). (119, 137, 167, 169, 
177, 189-193) There was one study that met selection criteria for 
which there were insufficient data for reported outcomes (table 5-
2). (194) 
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Figure 5-1: Study selection and stratification 
 
 
62 full-text articles 
CINAHL 
347 citations 
EMBASE 
2700 
citations 
LILACS 
26 citations 
MEDLINE 
2982 
citations 
Reference List 
4 citations 
 10 studies included in final review 
 6059 titles or abstracts identified and screened for retrieval 
52 excluded: 
  - 40 not diagnosis 
studies  
 - 3 editorials or reviews 
 - 8 not relevant to study 
design 
 - 1 insufficient data 
 5997 excluded: 
 - 1633 duplicate records 
 - 4364 not relevant 
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5.5.1. Study characteristics 
Of the 10 studies included in the review (table 5-1), there was one 
randomised trial, (119) two case-control (177, 193) and seven 
cross-sectional studies. (137, 167, 169, 189-192) Excluding case 
control designs, across studies the prevalence of AF ranged from 
6.7% to 18.6% (Table 5-1).  
 
5.5.2. Healthcare settings for 12-lead ECG 
interpretation and diagnosis of atrial fibrillation  
There were five studies conducted in the UK, (119, 137, 167, 169, 
177) three in the USA, (189, 191, 192) one in Europe, (190) and 
one in Israel. (193) Three studies were conducted in a primary care 
setting (119, 137, 177) and included participants over 65 years of 
age; patients were recruited that would have been eligible for AF 
screening if it were implemented. (119, 137, 177) However, the 
remainder of studies were conducted using patients with existing 
cardiac pathologies in secondary care.  
 
5.5.3. Methods used for 12-lead ECG interpretation and 
diagnosis of atrial fibrillation 
5.5.3.1. Methods used for acquiring and interpreting 12-lead 
ECGs in the diagnosis of atrial fibrillation  
The 10 studies investigated a total of 16 methods of diagnosing AF 
(a total of 55,376 participant ECGs), which were categorised into 
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two intervention groups: 1) automated software (eight studies; 
nine diagnostic methods) (119, 137, 167, 169, 189-192) and, 2) 
any healthcare professional (five studies; seven diagnostic 
methods). (119, 137, 177, 190, 193) Sub-groups of healthcare 
professional were defined as: secondary care physicians (two 
studies; two diagnostic methods) (190, 193) and primary care 
professionals (three studies; five diagnostic methods), (119, 137, 
177) the latter comprising GPs (three studies) (119, 137, 177) and 
practice nurses (two studies). (119, 177)  
 
Of the included studies, four reported nurses or nurse assistants as 
the healthcare professionals who performed and acquired ECGs 
from patients. (119, 137, 177, 190) For the remainder of studies 
the professionals used to obtain ECGs was not reported.   
 
With the exception of one study, (191) all studies that investigated 
automated software analysis of ECGs reported the software used to 
diagnose AF. Both studies that investigated secondary care 
physician ECG interpretation (190, 193) relied on the clinical 
experience of the professionals involved to diagnose AF, and one of 
these studies reported each secondary care physician to have over 
30 years of expertise. (190) All studies that investigated ECG 
interpretation by primary care professionals relied on their clinical 
experience; (119, 137, 177) one of these studies involved training 
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being providing to healthcare professionals to improve ECG 
interpretation prior to study initiation. (119) 
 
5.5.3.2. Reference standard for diagnosing atrial fibrillation 
For five studies, the reference standard was 12-lead ECG 
interpreted by at least two cardiologists. (119, 169, 189, 190, 193) 
Of the remaining studies, four used ECG interpretation by a single 
cardiologist as the reference standard and one study used two 
trained secondary care clinicians. (167)   
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Table 5-1: Characteristics of included studies 
Study Setting, population & 
sample size 
AF Prevalence/ 
proportion (%) 
Study 
Design† 
Index test(s) Reference test Outcomes Quality 
grading 
Bourdillon 
1978 (167) 
UK; secondary care; 
221 ECGs of adult 
subjects 
18.6 CS Software 
interpretation 
(Mount Sinai) 
2 clinicians, 
independent 
interpretation 
Sensitivity 0.85; 
specificity 0.98 
 
C 
Davidenko 
2007 (189) 
USA; secondary care; 
35,508 consecutive 
ECGs were reviewed 
7.9 CS Software 
interpretation 
(Marquettes) 
Interpretation by 
several 
cardiologists with 
a group consensus 
Sensitivity 0.97; 
specificity 1.00 
D 
Gregg 
2008 (169) 
UK; secondary care; 
database of 50,000  
hospital ECGs; 1,785 
randomly selected 
6.1 CS Software 
interpretation 
(Philips) 
Interpreted by 2 
cardiologists 
Sensitivity 0.89; 
specificity 0.99 
D 
Hakacova 
2012 (190) 
Sweden; secondary 
care; total of 576 
ECGs from 503 
participants with a 
mean age of 64 years 
10.4 CS Test 1: Non 
expert secondary 
care clinician 
 
Test 2: Software 
A (Philips) 
 
Test 3: Software 
B (Philips) 
Interpreted by 2 
expert 
cardiologists 
Test 1: Sensitivity 
0.86; specificity 0.99 
 
Test 2: Sensitivity 
0.92; specificity 0.99 
 
Test 3: Sensitivity 
0.68; specificity 0.98 
B 
Hobbs 
2005 (119) 
UK; primary care; 
9,866 patients aged≥ 
65 years, 2595 ECGs 
were reviewed 
6.8 
6.7 
8.4 
RCT Test 1: General 
practitioner 
interpretation 
 
Test 2: Practice 
nurse 
interpretation 
 
Test 3: Software 
Interpreted by 2 
consultant 
cardiologists 
independently, 
with a third if 
arbitration was 
needed 
Test 1: Sensitivity 
0.80; specificity 0.92 
 
Test 2: Sensitivity 
0.77; specificity 0.85 
 
Test 3: Sensitivity 
0.83; specificity 0.99 
B 
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interpretation 
(Biolog)  
Poon  
2005 (191) 
USA; secondary care; 
4,297 consecutive 
ECGs were reviewed 
6.3 CS Software 
interpretation 
(not specified) 
Cardiologist 
interpretation 
Sensitivity 0.91; 
specificity 0.99 
D 
Reddy 
1998 (192) 
USA; secondary care; 
10,352 ECGs were 
reviewed 
8 CS Software 
interpretation 
(Mac-rhythm)  
Cardiologist 
interpretation 
Sensitivity 0.88; 
specificity 0.99 
D 
Rhys  
2013 (137) 
UK; primary care; 
patients ≥65 years 
recruited from flu 
clinics; 32 ECGs 
reviewed 
6.3 CS Test 1: Software 
interpretation 
(Cardioview) 
 
Test 2: General 
practitioner 
interpretation 
ECG interpreted 
by cardiologist  
Test 1: Sensitivity 1; 
specificity 1 
 
Test 2: Sensitivity 1; 
specificity 1 
D 
Shiyovich 
2010 (193) 
Israel; secondary 
care; 268 patient’s 
ECGs 
81.7 CC Secondary care 
clinician 
interpretation 
Interpretation by 
2 senior 
cardiologists 
Sensitivity 0.97; 
specificity 0.31 
B 
Somerville 
2000 (177) 
UK; Primary care; 86 
patients recruited from 
one general practice, 
86 ECGs reviewed 
31.5 
30.2 
CC Test 1: Practice 
nurse 
interpretation 
 
Test 2: General 
practitioner 
interpretation 
Interpreted by 
consultant 
cardiologist 
Test 1: Sensitivity 
0.97; specificity 0.88 
 
Test 2: Sensitivity 1; 
specificity 0.98 
B 
†CC = Case-control study; CS = Cross-sectional study; RCT = Randomised controlled Trial; C = Cohort study 
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Table 5-2: Characteristics of eligible studies that were excluded 
Author/Year Setting, 
population & 
sample size 
Study 
design 
Intervention Comparator Reported 
outcomes 
Reason for 
exclusion 
Bogun  
2004 (194) 
USA; secondary 
care; database of 
2298 ECGs from 
1085 patients 
Cross 
sectional 
Software interpretation 
using GE Marqutte 12 
SE or MACR programs, 
overread by 
cardiologists 
Interpretation by 2 
electrophysiologists 
442 (19%) of 
the 2298 ECGs 
had an 
incorrect 
computer 
interpretation 
of AF in 382 
(35%) of 
patients 
Number of true 
AF, false AF, 
missed AF, and 
non AF were not 
reported 
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5.5.4. Study quality and risk of bias 
Figure 5-2 shows the methodological quality of included studies 
according to QUADAS-2 criteria was generally low. There were no 
studies graded as having the highest (A-grade) methodological 
quality. Five studies with the lowest methodological quality (D-
grade) were due to the methodological interpretation of the 
reference standard being unclear or at high risk of bias. One study 
was graded as category C because it was unclear whether the 
reference standard was interpreted without knowledge of the index 
test. 
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Figure 5-2: Study quality according to QUADAS-2 criteria 
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5.5.5. Data synthesis 
Automated software was found to have a pooled sensitivity of 0.89 
(95% CI 0.82-0.93) and specificity of 0.99 (95% CI 0.99-0.99) for 
diagnosing AF using 12-lead ECG. (Figure 5-3) This corresponded 
with a PLR of 96.6 (95% C.I 64.2-145.6) and NLR of 0.11 (95% C.I 
0.07-0.18). In contrast, the pooled specificity for the accuracy of 
any healthcare professional diagnosing AF (Figure 5-4) was lower 
than automated software although there was a similar sensitivity of 
this method for interpreting ECGs; sensitivity 0.92 (95% CI 0.81-
0.97), specificity 0.93 (95% CI 0.76-0.98), PLR 13.9 (95% C.I 3.5-
55.3), NLR 0.09 (95% C.I 0.03-0.22). Figure 5-5 shows the 
sensitivity and specificity for diagnosing AF by any primary care 
professionals was similar to any healthcare professionals  
[sensitivity 0.96 (95% CI 0.66-1.00), specificity 0.94 (95% CI 
0.85-0.98), PLR 15.4 (95% C.I 5.9-40.3), NLR 0.05 (95% C.I 0.00 
to 0.49)].   
 
Visual inspection of the SROC plots (figure 5-6) confirms there was 
substantial variation in the outcomes from studies investigating the 
accuracy of clinicians’ 12-lead ECG diagnosis and suggests 
heterogeneity amongst these studies was greater than the 
automated software studies. 
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Figure 5-3: Sensitivity and specificity of 12-lead ECG interpretation using automated software 
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Figure 5-4: Sensitivity and specificity of 12-lead ECG interpretation by any healthcare professional 
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Figure 5-5: Sensitivity and specificity of 12-lead ECG interpretation by primary care professionals 
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Figure 5-6: Summary Receiver Operating Characteristic 
(SROC) plots for the accuracy of 12-lead ECG interpretation 
by software, any clinician, and primary care clinician 
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5.5.6. Sub-group analyses 
The sub-group analyses for categories of GPs and nurses (figure 5-
7) suggest the accuracy of primary care clinician diagnosed AF may 
be driven by a greater specificity of GPs’ AF diagnoses than nurses 
[GPs: sensitivity 0.91 (95% C.I 0.68-1.00); specificity 0.96 (95% 
C.I 0.89-1.00); nurses: sensitivity 0.88 (95% C.I 0.63-1.00); 
specificity 0.85 (95% C.I 0.83-0.87)].  
 
Bivariate sub-group analyses were similar after exclusion of studies 
with the lowest (D-grade) quality [Software: sensitivity 0.82 (95% 
C.I 0.73-0.88), specificity 0.99 (95% C.I 0.98-0.99); any 
healthcare professionals: sensitivity 0.92 (95% C.I 0.81-0.97), 
specificity 0.91 (95% C.I 0.70-0.98); any primary care 
professionals: sensitivity 0.93 (95% C.I 0.67-0.99), specificity 0.92 
(95% C.I 0.85-0.96)].   
 
5.5.7. Publication bias 
There was no evidence of publication bias for studies of any 
clinician (p=0.29) or any primary care clinician diagnosis (p=0.19). 
However, studies of software ECG interpretation suggested the 
presence of publication bias (p=0.02), with the possible 
underrepresentation of smaller studies with a lower accuracy of 
diagnosing AF.  
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Figure 5-7: Sub-group analyses of the sensitivity and specificity of 12-lead ECG interpretation by GPs 
and practice nurses 
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5.6. Discussion 
5.6.1. Summary of principal findings 
This systematic review found automated software and healthcare 
professional interpretation of 12-lead ECGs as methods for ECG 
interpretation in the diagnosis of AF. Of the 10 studies, only five 
were conducted in the UK. Most studies investigated automated 
software analysis of ECGs and were conducted in secondary care 
settings. Automated software analysis had a borderline greater 
specificity for AF diagnosis than healthcare professional 
interpretation of 12-lead ECGs. The sensitivities of automated 
software, any healthcare professionals and primary care 
professionals for interpreting 12-lead ECGs to diagnose AF were 
similar. 
 
5.6.2. Strengths and limitations 
To my knowledge, this study is the first systematic review and 
meta-analysis of different methods for interpreting 12-lead ECGs to 
diagnose AF. A strength of the study was the use of a standardised 
protocol that is consistent with published guidelines for systematic 
reviews of diagnostic test studies.  Moreover, a comprehensive 
search strategy was used that included contacting authors of 
potentially relevant studies. The findings indicated a probable lack 
of publication bias for studies of clinicians’ 12-lead ECG diagnoses 
of AF. However, there was the possibility of publication bias for 
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studies investigating automated software and this may limit the 
validity of the findings for this diagnostic modality.  
 
One study was excluded due to the insufficient reporting of 
outcome data to enable meta-analysis and this could have 
influenced the findings. However, the number of overall 
misdiagnoses of AF was similar to that of other studies 
investigating the accuracy of automated software for making ECG 
diagnoses of AF and the impact of excluding this study is likely to 
be minimal.  
 
Only one of the 10 included studies adopted a prospective design 
and there were a number of inherent methodological weaknesses 
in other studies as reflected by the appraisal of study quality. No 
studies were judged to have met all QUADAS-2 criteria and this 
was predominately due to the unclear reporting of study methods. 
This limits the internal validity of findings. However, the bivariate 
sub-group analyses that excluded studies judged to have the 
lowest (grade D) methodological quality found similar outcomes to 
the primary analyses, and supports these findings. Indeed, 
prospective higher quality studies would improve the internal 
validity of future research and provide greater confidence in the 
translation of findings to AF screening.    
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Most studies were conducted in a secondary care setting and there 
was substantial variation in the proportion of patients with AF. 
Healthcare professionals in secondary care are more likely to 
encounter patients with cardiovascular disease and may have 
greater experience in conducting and interpreting ECGs. 
Consequently the weight of evidence limits the generalisability and 
translation of review findings to unselected primary care settings 
that AF screening is intended for. However, the method of 
automated software to interpret ECGs is not reliant on clinical 
expertise and the findings for this method are likely to be 
transferable to primary care settings.  
 
There was heterogeneity amongst the studies within all categories 
of methods for diagnosing AF and this is likely to be attributable to 
differences in study populations. Heterogeneity was greatest for 
the category of any healthcare professionals’ interpretation of 12-
lead ECGs and is likely to arise from differences in professional 
groups and clinical expertise (e.g. healthcare professionals in 
primary and secondary care).  This variation was least for studies 
of automated software and strengthens the internal validity of 
findings for this approach to AF diagnosis. 
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5.6.3. Findings in context of previous research 
The current gold-standard test for diagnosing AF is 12-lead ECG, 
(51, 108) and consensus recommends competent healthcare 
professionals should interpret this as part of AF screening. (51, 80, 
108) Both systematic and opportunistic screening for AF using 12-
lead ECG in patients over 65 years were found to be an effective 
approach for improving the detection of this arrhythmia. (118)  
 
Harris et al. conducted a narrative literature review of studies from 
2006 onwards to inform the Royal College of Physicians about how 
to best detect AF. (148) Harries et al. only identified four studies 
that reported outcomes for the accuracy of methods for 
interpreting 12-lead ECGs. (148) The review by Harris et al. 
identified GP, nurse and automated software methods for 
interpreting ECGs and the range of sensitivities and specificities 
were broad for all methods [GPs (n=2 studies): sensitivity 80-
100% and specificity 92-98%; nurses (n=2 studies): sensitivity 
77-97% and specificity 85-88%; automated software (n=2 
studies): sensitivity 83-91% and specificity 91%]. This review, 
however, did not provide point estimates for the diagnostic 
accuracies or compare the accuracies of different methods for ECG 
interpretation, and the risk of bias of included studies were not 
appraised. (148) Therefore, the internal validity of findings from 
the review by Harris et al. are limited and my systematic review 
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provides up-to-date evidence with greater internal validity within 
findings.  
 
My review identified automated software and healthcare 
professional interpretation of 12-lead ECGs as methods for 
diagnosing AF. Furthermore, the interpretation of ECGs in a 
restricted group of primary care professionals was also analysed. 
The findings for automated software, using sensitivity and 
specificity as measures of diagnostic accuracy, are consistent with 
those from the SAFE sub-study. (118, 119, 188) Due to the 
significantly higher specificity of this diagnostic modality, my 
findings suggest software is the best method for correctly 
identifying patients with normal 12-lead ECGs whilst minimising the 
risk of false positive diagnoses of AF.  
 
Review findings also suggested the sensitivities of all methods for 
diagnosing AF were similar, although these may be sufficiently low 
to give rise to false negative AF diagnoses in clinical practice. As 
compared to any healthcare professionals’ ECG interpretation, the 
point estimates for sensitivity were similar for AF diagnoses made 
by primary care professionals. However, the sub-group analyses 
suggested this may be attributable to better 12-lead ECG 
interpretation by GPs; in comparison to GPs, nurses were found to 
have a significantly lower specificity for diagnosing AF. Although 
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data from the SAFE trial, the largest, pragmatic study of AF 
screening in primary care, (118) were included in the review it is 
possible that the pooled estimates for diagnostic accuracy in the 
review have been over-estimated.  Practices that undertake 
cardiovascular research in primary care may be self-selecting with 
an interest in AF and it is possible that the accuracy of diagnosing 
arrhythmias by primary care professionals in routine clinical 
practice could be lower than that found in my review.   
 
5.7. Conclusions 
Automated software had the greatest specificity for AF diagnosis 
using 12-lead ECG than healthcare professional diagnosis of this 
arrhythmia. Although the accuracy of diagnosing AF in primary care 
may be reassuring, this is driven by GP’s diagnosis of AF. If a 
national AF screening programme is introduced into primary care it 
is possible that the skills of GPs and nurses for making 12-lead ECG 
diagnoses of AF would need improving to ensure the effectiveness 
of screening is not undermined.  
 
This study investigated and compared the accuracies of different 
methods that could be used for the second-step of proposed AF 
screening. In the next chapter, I will investigate the feasibility of 
introducing AF screening within GP practices and the views of 
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healthcare professionals in this setting about their abilities to 
undertake screening activities. 
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Chapter 6. Survey of healthcare professionals 
in primary care about AF screening 
6.1. Background 
Although AF screening has been recommended, and a likely setting 
for any screening programme would be in primary care, the 
feasibility of introducing AF screening within this setting has not 
been established. 
 
National screening programmes require quality assurance of 
screening procedures to ensure standards are met and both the 
effectiveness of screening is maintained whilst patient safety 
upheld. (195) This includes ensuring screening is delivered by 
healthcare professionals who are appropriately trained, qualified 
and competent.   (195)  
 
The effectiveness of AF screening is dependent upon accurate 12-
lead ECG interpretation for diagnosing AF. (51, 80, 108) Studies 
that have evaluated the competencies of healthcare professionals 
in primary care to accurately interpret ECGs have focussed 
objectively on the skills of GPs. (196-198) Survey data suggest 
there is substantial variation in the accuracy of correctly 
interpreting ECGs, (197) with only 67% of GPs correctly identifying 
ECGs as normal and 65% correctly diagnosing AF. (197) Moreover, 
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another study of the accuracy of 12-lead ECG interpretation for any 
cardiac abnormalities found, as compared to cardiologist ECG 
interpretation, the sensitivity and specificity of GP diagnoses were 
69.8% and 85.7%, respectively. (196) It is therefore conceivable 
that prior to screening implementation, the knowledge and skills of 
GPs to interpret 12-lead ECGs would need improving. It is also 
likely that other healthcare professionals, such as practice nurses, 
may have a role in future AF screening as studies have involved 
nurses in undertaking screening activities (e.g. performing pulse 
palpation and ECGs). (119, 137, 177)  
 
It is still unclear whether GPs and other primary care professionals 
feel adequately skilled and if they are prepared to improve their 
skills, and whether they have the appropriate facilities to acquire 
and interpret ECGs. Therefore, understanding current practise and 
the views of healthcare professionals in primary care about AF 
screening are important priorities before considering its 
implementation. This would enable greater understanding of the 
perceived knowledge, skills and attitudes of those expected to 
undertake AF screening specific activities, such as performing and 
interpreting ECGs. This would also enable the identification of 
important facilitators, barriers and training needs of key 
stakeholder groups in order to deliver safe and effective screening.  
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To date, there have been no studies that have investigated the 
views of healthcare professionals in General Practice about the 
potential implementation of AF screening and their perceived 
abilities to undertake screening related activities.  
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6.2. Aims 
To determine existing methods used for detecting AF within 
General Practices in the UK, and to determine and compare the 
knowledge, skills and attitudes, (KSA) and opinions of healthcare 
professionals (HCPs) about AF screening within this setting.   
 
6.3. Objectives 
 To determine the current practise for detecting pulse 
irregularities attributable to AF and diagnosing AF using 12-
lead ECG in UK General Practice.  
 To determine the knowledge, skills and attitudes of HCPs in 
primary care with respect to identifying patients with an 
irregular pulse and making 12-lead ECG diagnoses of AF.  
 To determine the learning needs (current training and 
potential training requirements) of HCPs in primary care with 
respect to identifying patients with an irregular pulse and 
making 12-lead ECG diagnoses of AF, and to determine 
opinions about how these could be improved. 
 To identify any foreseeable barriers experienced by HCPs to 
detecting and diagnosing AF in primary care. 
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6.4. Methods 
The survey protocol was designed and written by JT. JT developed 
the survey, conducted the analyses and wrote the report. MJ 
supported JT in survey dissemination and data collection. 
 
6.4.1. Study approach and participants 
Surveys are a time-efficient approach of ascertaining large 
quantities of data, conveniently, from a large cohort of people. 
(199) As the aims and objectives of the study were broad and 
involved different professional groups across multiple sites, a 
cross-sectional survey of HCPs in Nottingham City Clinical 
Commissioning Group (CCG) was deemed an appropriate 
methodological approach and was conducted between October-
December 2014 (Appendix 4). This was based on the assumption 
that screening would be conducted in a primary care setting. As 
there has been very little research investigating the views of HCPs 
in primary care about AF screening, conducting a survey in one 
CCG was considered a reasonable starting point to provide an 
initial understanding of this research theme. A census-sampling 
frame was deemed appropriate and feasible for the target 
population (i.e. all HCPs in Nottingham City CCG were surveyed). 
(200) Combined methods, using postal and web-survey, were used 
to maximise response rates, reduce the effects of non-responder 
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bias, and to improve the time and cost-efficiency of the survey. 
(200)  
 
Nottingham City CCG comprised 67 inner-city GP practices serving 
340,000 patients; (201)  although the CCG has similar prevalences 
of long-term conditions to national estimates, there is greater 
mortality from cardio-respiratory diseases and greater potential 
years of life lost from causes amenable to healthcare than average 
estimates for England. (202)  
 
Prior to survey implementation, information from on-line public 
resources and Nottingham City CCG were used to create a list of 
HCPs working at each practice. Eligible participants were GPs, 
nurses (nurses or nurse practitioners) and healthcare assistants 
(HCAs). Non-permanent staff (e.g. locum doctors) were not 
included. Practice managers were then contacted by telephone to 
check record accuracy. The final triangulated list of eligible 
participants was used as the denominator for survey responses. 
(199)   
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6.4.2. Survey design and implementation 
6.4.2.1. Survey questions 
6.4.2.1.1. Participant characteristics  
Participant characteristics were ascertained for professional group, 
the number of years practising as a HCP, whether participants 
worked full-time (number of days worked in those not working full-
time), if ECG training had been received since graduation and the 
time since training in those previously receiving ECG training 
(Appendix 4).  
 
6.4.2.1.2. Existing methods for diagnosing atrial fibrillation 
and participant knowledge, skills and attitudes about atrial 
fibrillation screening 
As current recommendations advocate two-step AF screening, 
using pulse palpation followed by 12-lead ECG in those with 
suspected AF, the survey questions ascertained information about 
existing methods for detecting and diagnosing AF, with a focus on 
pulse palpation, conducting and interpreting ECGs.  Likert scale 
questions were developed to ascertain information about existing 
methods for detecting and diagnosing AF, and participant 
knowledge, skills and attitudes (KSA) for AF screening activities. 
The survey also included questions to ascertain participant views 
on training needs and potential roles in future AF screening.   
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The domains of KSA were used to assess the perceived abilities of 
HCPs to undertake screening activities as these directly relate to 
Bloom’s taxonomy of learning objectives and can also be mapped 
to Millers Pyramid of educational theory for developing clinical 
competencies. (203)  
 
Ordered Likert scale questions were used as they enable the 
efficient completion of multiple questions as part of a survey, 
enable the structured analysis of responses, enable comparisons 
between groups to be easily made and, if designed appropriately, 
are easy to navigate by respondents. (200) The number of ordinal 
points is an important consideration when designing survey Likert 
scale questions; too many options results in clustering of responses 
around certain points on the scale and too few points results in 
skipping of response items or marking of two adjacent answers. 
(200, 204) It has been suggested that Likert scales have optimal 
reliability and validity when 5-7 points are used, for bidirectional 
scales, and 3-5 points used for unidirectional scales. (200, 204)   
Therefore, this survey consisted predominately of three and five-
point Likert scale closed questions for unidirectional and 
bidirectional questions, respectively (Appendix 4). Bidirectional 
scales used centrally placed neutral responses to provide balance 
within scales. (200)  
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6.4.2.1.3. Facilitators and barriers to atrial fibrillation 
screening 
Barriers and training related facilitators for AF screening were 
ascertained using a combination of Likert scale questions (as 
above) and open questions requiring free-text responses (Appendix 
4). This enabled deeper understanding of participant beliefs, 
attitudes and motivation within these contexts. (200) Open 
questions used were: ‘Are there any specific areas about the 
diagnosis of AF using 12-lead ECGs that you would like training?’ ‘If 
such a screening program was introduced, what further training 
would you need to be able to undertake this role?’ ‘If a screening 
program for AF was introduced, are there any problems you think 
might prevent it working effectively at your surgery?’ 
 
6.4.2.2. Survey piloting 
Piloting surveys is an essential component to survey design and 
improves the comprehensibility, face validity, participant burden, 
layout and the skip patterns used in surveys. (199) The survey was 
therefore piloted on HCPs from a different CCG than the intended 
population (five GPs, four Nurses and one HCA) and only minor 
modifications were subsequently required. 
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6.4.3. Survey dissemination 
To improve response rates the survey was disseminated using an 
approach advocated by Dillman et al. and Safdar et al. (199, 200) 
Postal contact was made before survey implementation to inform 
individual participants about the research. A postal survey was 
then sent to all individuals; a web-link was also provided to enable 
on-line completion, if preferred. Two postal reminders (after four 
and eleven weeks from initial survey dissemination) were sent to 
non-responders. To promote greater awareness and further 
improve response, the research team attended two CCG led 
practice learning time events during the survey period to promote 
the survey. 
 
6.4.4. Statistical analysis 
Analyses were conducted using Stata version 11.0. 
There have been no studies that investigate and compare the views 
of HCPs in primary care about AF screening. Consequently, there 
were no data to inform sample size calculations. Moreover, as this 
study was an initial exploration of views by HCPs, a power 
calculation was deemed unnecessary and data from this study 
could be used to inform future research design.  
    
Participants were anonymised and given a unique ID code; this 
enabled monitoring and the identification of duplicate survey 
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responses; in cases where duplicate surveys were submitted it was 
pre-planned to contact participants to clarify any discordant 
responses. 
 
Responses to survey questions, stratified by professional group, 
were summarised using proportions for categorical data and mean 
(SD) for parametric data, respectively. GPs have a lead role in 
practice management and are likely to have the most accurate 
knowledge of existing methods for detecting AF; for questions that 
related to existing methods of diagnosing AF within the practice, 
analyses were therefore conducted at a practice level and used 
only GP responses. Remaining questions were analysed within HCP 
occupation categories ascertained from the survey (GPs, nurses, 
nurse practitioners (NPs) and HCAs). NPs are registered nurses 
that work at a level well beyond initial registration with greater 
competencies and autonomy in patient care. (205) 
 
Differences in participant characteristics across HCP groups were 
determined using chi-squared test, for categorical data, and 
analysis of variance (ANOVA) for parametric continuous data. 
Participant responses to questions about KSA to AF screening were 
summarized using proportions and 95% confidence intervals (CI) 
within HCP categories and allowed for the effects of clustering by 
practice using robust standard errors. Significance of associations 
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between HCP groups was determined, when cell sizes were 
sufficient, using logistic or multinomial regression, for dichotomous 
or categorical variables respectively.   
 
Open-ended questions were read independently by one researcher 
(JT) and a thematic analytical approach was used to determine 
major themes for the barriers and facilitators for AF screening. 
(206)  
 
6.4.5. Study ethics 
Ethical approval was gained before survey piloting.  
 
Implied consent was provided by participants through completion 
and submission of the survey; separate written or verbal consent 
was not obtained as implied consent was deemed appropriate and 
approved. Approval of study materials and procedures was granted 
by the University of Nottingham Research & Ethics Committee 
(REF: B11092014 14085 SoM PC) and Nottingham City CCG 
Research and Development  (REF: 159703). 
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6.5. Results 
6.5.1. Participant response 
Participant response is shown in Fig 6-1. Of 67 practices registered 
within Nottingham City CCG, 59 were eligible for the survey; eight 
were excluded as they had closed, had no permanent staff, or 
shared staff with another practice. From 59 practices, there were 
434 potentially eligible HCPs; 16 individuals were excluded because 
they were no longer employed by the CCG or had retired since 
initial contact was made. The final survey population was therefore 
418 HCPs (229 GPs; 129 nurses; 60 HCAs). At least one GP 
responded from 48/59 (81%) practices; from all HCPs there were 
212 (51%) respondents. [GPs: 52% (118/229); nurses: 52% 
(67/129); HCAs: 45% (27/60)]. Of the 67 nurse respondents, 17 
were NPs. No duplicate surveys were returned. 
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Figure 6-1: Participant response to the survey 
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6.5.2. Participant characteristics 
GPs had worked for a mean (SD) 20.1 (9.2) years and the time in 
practice was similar for nurses and NPs. HCAs had worked for a 
significantly shorter time (mean (SD) of 11.2 (8.5) years; 
p<0.001). Full-time working was similar across categories of HCPs.   
However, of participants working part-time, there were significant 
differences in the number of days worked across HCP groups; 
mean (SD) days worked were 3.1 (0.7), 3.8 (1.1), 3.5 (1.1) and 
3.7 (0.8) for GPs, HCAs, nurses and NPs (p=0.009). Significantly 
more GPs (62.7%) and nurse practitioners (76.5%) received ECG 
training since graduation than nurses (50.0%) and HCAs (23.1%); 
p=0.005. However, of those receiving ECG training since 
graduation, a greater proportion of GPs (66.2%), HCAs (83.3%) 
and NPs (69.2%) received it within the last five years compared to 
nurses (28.0%); p=0.014). 
 
6.5.3. Existing methods for diagnosing atrial fibrillation  
From 48 practices with at least one GP respondent, 39 (81%) 
reported having an ECG machine. In practices without an ECG 
machine, all (100%) reported using another NHS GP practice to 
obtain ECGs and a few (12.5%) also used NHS hospitals. In 
practices with an ECG machine, HCAs and nurses (89.7% and 
82.1% of practices, respectively) were most often reported as the 
HCPs responsible for conducting ECGs. GPs conducted ECGs in only 
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12.8% practices. 81.3% of practices reported diagnosing AF in-
house and, in all those practices, GPs were responsible for making 
AF diagnoses. NPs were also reported to diagnose AF in 15.4% 
practices.  Only 37.5% practices reported always diagnosing AF in-
house. In practices that did not always make AF diagnoses most 
used other NHS services for this; 60% reported using an NHS 
hospital and 6.7% used other GP practices. 6.7% practices 
reported using private healthcare providers to diagnose AF and the 
remainder did not know or respond.    
 
6.5.4. Knowledge, skills and attitudes (KSA) relating to 
atrial fibrillation screening  
Table 6-1 presents the results for the knowledge and skills of HCPs 
for AF screening. There were no substantial differences between 
HCPs for performing pulse checks routinely and this was conducted 
by 95.8% GPs, 88.9% HCAs, 94.0% nurses and 100% NPs.  There 
were no substantial differences in how often pulse checks were 
performed by HCPs although a greater proportion of NPs reported 
always undertaking this activity. However, fewer HCAs (33.3% 
(95% CI 18.2-52.9)) were confident at performing pulse checks 
than other HCP groups. A greater proportion of non-GP HCPs were 
confident at performing 12-lead ECGs than GPs [Proportion (95% 
CI) for HCAs: 77.8% (56.7-90.4); nurses: 70.0% (54.4-82.0); 
NPs: 94.1% (66.0-99.2); GPs: 33.1% (23.7-44.0)]. Fewer nurses 
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and HCAs were confident at diagnosing AF using 12-lead ECG than 
GPs and NPs.  
Only 29.6% (95% CI 14.7-50.6) HCAs reported having excellent 
knowledge about identifying an irregular pulse, which was lower 
than other HCP groups [proportion (95% CI) for GPs 48.3 (38.7-
58.1); nurses: 46.0 (32.4-60.2); NPs 76.5 (46.5-92.4)]. Fewer 
non-GP HCPs reported having excellent or good knowledge for 
interpreting abnormal 12-lead ECGs, diagnosing and treating AF 
than GPs.  
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Table 6-1: Knowledge and skills in conducting atrial fibrillation screening actives by healthcare 
professionals 
Question Response GP 
(N=118) 
Healthcare assistant 
(N=27) 
Nurse 
(N=50) 
Nurse practitioner 
(N=17) 
P-value 
N 
(%)* 
95% C.I* N (%)* 95% C.I* N (%)* 95% C.I* N (%)* 95% C.I* 
Pulse checks 
 
Perform pulse 
checks 
Yes 113 
(95.8) 
89.9-98.3 24 
(88.9) 
69.3-96.7 47 
(94.0) 
82.3-98.1 17 
(100.0) 
- 0.210 
No 4 
(3.4) 
1.2-8.9 3 
(11.1) 
3.4-30.7 3  
(6.0) 
1.9-17.0 0  
(0.0) 
- 
How often pulse 
check performed 
Always 24 
(20.3) 
13.4-29.6 10 
(37.0) 
20.4-57.5 13 
(26.0) 
15.9-39.4 10 
(58.8) 
35.2-78.9 <0.00
1 
Often 64 
(54.2) 
45.5-62.7 7 
(25.9) 
11.2-49.2 24 
(48.0) 
35.5-60.8 6 
(35.3) 
19.3-55.5 
Sometimes 23 
(19.5) 
13.2-27.8 7 
(25.9) 
12.0-47.2 10 
(20.0) 
11.8-31.9 1  
(5.9) 
0.9-31.9 
Rarely 1 
(0.8) 
0.1-6.2 0  
(0.0) 
- 0  
(0.0) 
- 0  
(0.0) 
- 
Confidence in performing screening activities 
 
Identifying an 
irregular pulse 
Very 
confident 
99 
(83.9) 
77.0-89.0 9 
(33.3) 
18.2-52.9 36 
(72.0) 
55.6-84.1 17 
(100.0) 
- n/a 
Somewhat 
confident 
18 
(15.3) 
10.1-22.2 14 
(51.9) 
32.5-70.7 12 
(24.0) 
12.7-40.6 0  
(0.0) 
- 
Not confident 
at all 
0 
(0.0) 
- 3 
(11.1) 
3.8-28.5 1  
(2.0) 
0.3-13.9 0  
(0.0) 
- 
Performing 12-lead 
ECG 
Very 
confident 
39 
(33.1) 
23.7-44.0 20 
(77.8) 
56.7-90.4 35 
(70.0) 
54.4-82.0 16 
(94.1) 
66.0-99.2 <0.00
1 
Somewhat 53 35.3-54.9 3 3.4-30.7 10 10.8-34.0 1  0.8-34.0 
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confident (44.9) (11.1) (20.0) (5.9) 
Not confident 
at all 
25 
(21.2) 
15.4-28.5 2  
(7.4) 
1.7-26.6 4  
(8.0) 
2.9-20.0 0  
(0.0) 
- 
Deciding if ECG 
shows AF 
Very 
confident 
65 
(55.1) 
46.1-63.8 0  
(0.0) 
- 5 
(10.0) 
4.5-20.8 5 
(29.4) 
10.5-59.6 <0.00
1 
Somewhat 
confident 
50 
(42.4) 
33.6-51.6 5 
(18.5) 
8.4-35.9 19 
(38.0) 
25.9-51.8 5 
(29.4) 
12.5-54.8 
Not confident 
at all 
1 
(0.8) 
0.1-6.1 19 
(74.1) 
56.0-86.5 25 
(50.0) 
36.3-63.7 7 
(41.2) 
19.5-66.9 
Knowledge of performing screening activities 
 
Identifying an 
irregular pulse 
Excellent 57 
(48.3) 
38.7-58.1 8 
(29.6) 
14.7-50.6 23 
(46.0) 
32.4-60.2 13 
(76.5) 
46.5-92.4 n/a 
Good 58 
(49.2) 
39.4-59.0 11 
(40.7) 
21.7-63.0 24 
(48.0) 
35.5-60.8 4 
(23.5) 
7.6-53.5 
Fair 2 
(1.7) 
0.4-6.7 5 
(22.2) 
9.5-43.9 2  
(4.0) 
1.0-14.5 0  
(0.0) 
- 
Poor 0 
(0.0) 
- 1  
(3.7) 
0.5-23.5 0  
(0.0) 
- 0  
(0.0) 
- 
Non-existent 0 
(0.0) 
- 0  
(0.0) 
- 0  
(0.0) 
- 0  
(0.0) 
- 
Deciding the cause 
of an abnormal 12-
lead ECG 
Excellent 7 
(5.9) 
2.8-12.0 0  
(0.0) 
- 1  
(2.0) 
0.3-13.9 2 
(11.8) 
3.0-36.4 <0.00
1 
Good 56 
(47.5) 
38.8-56.3 1  
(3.7) 
0.6-20.7 6 
(12.0) 
4.9-26.4 3 
(17.6) 
5.8-42.6 
Fair 48 
(40.7) 
31.2-50.9 5 
(18.5) 
6.8-41.6 17 
(34.0) 
22.9-47.2 5 
(29.4) 
13.6-52.4 
Poor 5 
(4.2) 
1.5-11.7 7 
(25.9) 
13.5-44.0 17 
(34.0) 
21.4-49.3 7 
(41.2) 
21.9-63.7 
Non-existent 0 
(0.0) 
- 12 
(44.4) 
26.5-63.9 8 
(16.0) 
6.6-34.0 0  
(0.0) 
- 
Deciding if 12-lead 
ECG shows AF 
Excellent 31 
(26.3) 
17.8-37.0 0  
(0.0) 
- 1  
(2.0) 
0.3-12.9 2 
(11.8) 
2.7-38.8 n/a 
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Good 74 
(62.7) 
51.5-72.7 3 
(11.1) 
2.5-37.8 8 
(16.0) 
8.3-28.7 6 
(35.3) 
15.3-62.3 
Fair 11 
(9.3) 
4.7-17.8 7 
(25.9) 
13.5-44.0 20 
(40.0) 
29.6-51.4 4 
(23.5) 
9.9-46.4 
Poor 0 
(0.0) 
- 5 
(18.5) 
7.3-39.6 15 
(30.0) 
18.4-44.8 4 
(23.5) 
9.0-48.8 
Non-existent 0 
(0.0) 
- 9 
(33.3) 
16.9-55.1 5 
(10.0) 
4.1-22.3 1  
(5.9) 
0.8-34.0 
Deciding on 
treatment for AF 
Excellent 20 
(16.9) 
9.9-27.4 0  
(0.0) 
- 0  
(0.0) 
- 1  
(5.9) 
0.8-34.0 <0.00
1 
Good 66 
(55.9) 
46.3-65.2 1  
(3.7) 
0.5-23.5 8 
(16.0) 
7.7-30.3 4 
(23.5) 
7.1-55.4 
Fair 27 
(22.9) 
16.1-31.5 1  
(3.7) 
0.5-22.1 12 
(24.0) 
13.8-38.4 4 
(23.5) 
9.0-48.8 
Poor 2 
(1.7) 
0.4-7.0 3 
(14.8) 
5.6-34.0 16 
(32.0) 
20.0-47.0 6 
(35.3) 
15.3-62.3 
Non-existent 1 
(0.8) 
0.1-6.1 19 
(70.4) 
47.3-86.3 12 
(24.0) 
12.9-40.2 2 
(11.8) 
2.7-38.8 
*N=number of participants responding to question item; %=proportion of participants, adjusted for clustering by practice; 95% C.I= 
95% confidence interval for the proportion of participants; n/a=unable to calculate p-value to insufficient data within cells 
Missing data within question responses is present when the sum of column percentages <100% 
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Attitudes of HCPs about training for AF screening are presented in 
Table 6-2. More HCAs (48.1% (95% CI 30.6-66.2)) felt they would 
benefit from pulse palpation training than other HCPs (proportion 
(95% CI) for GPs: 7.6% (3.6-15.3); nurses: 18.0% (8.5-34.0); 
NPs: 0%]. All categories of HCPs felt they would benefit from ECG 
interpretation training, however, and there were no substantial 
differences between professional groups. However, a greater 
proportion of non-GP HCPs reported they would benefit from ECG 
interpretation training specifically for AF than GPs [proportion 
(95% CI) for GPs: 11.9% (6.8-20.0); HCAs: 37.0% (21.7-55.5); 
nurses: 44.0% (30.0-59.0); NPs 41.2% (21.9-63.7)]. More non-GP 
HCPs also felt they would be better at diagnosing AF if they 
received ECG interpretation training than GPs. Similar proportions 
of participants strongly agreed they would like to receive general 
ECG training across professional groups. However, more non-GP 
HCPs strongly agreed they would like to receive ECG training 
specifically for AF than GPs [proportion (95% CI) for GPs: 13.6 
(8.2-21.5); HCAs: 40.7% (24.2-59.7); nurses 38.0% (24.1-54.1); 
NPs: 29.4% (13.6-52.4); p<0.001). In contrast, fewer HCAs, 
nurses and NPs wanted to be involved in diagnosing AF than GPs. 
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Table 6-2: Attitudes of healthcare professionals about training for atrial fibrillation screening 
Question Response GP 
(N=118) 
Healthcare assistant 
(N=27) 
Nurse 
(N=50) 
Nurse practitioner 
(N=17) 
P-
value 
N (%)* 95% C.I* N (%)* 95% C.I* N (%)* 95% C.I* N (%)* 95% C.I* 
Benefit from pulse 
palpation training 
Strongly 
agree 
9  
(7.6) 
3.6-15.3 13 
(48.1) 
30.6-66.2 9 
(18.0) 
8.5-34.0 0  
(0.0) 
- n/a 
 
Agree 16 
(13.6) 
8.2-21.6 9 
(33.3) 
18.2-52.9 17 
(34.0) 
22.3-48.1 1  
(5.9) 
0.8-34.0 
Not sure 16 
(13.6) 
8.5-21.0 0  
(0.0) 
- 5 
(10.0) 
4.3-21.5 3 
(17.6) 
5.8-42.6 
Disagree 56 
(47.5) 
38.0-57.1 1  
(3.7) 
0.5-23.5 14 
(28.0) 
16.8-42.9 8 
(47.1) 
25.9-69.3 
Strongly 
disagree 
19 
(16.1) 
10.5-23.9 1  
(3.7) 
0.6-20.7 4  
(8.0) 
3.1-18.9 5 
(29.4) 
12.5-54.8 
Benefit from ECG 
interpretation 
training 
 
Strongly 
agree 
37 
(31.4) 
23.1-50.0 15 
(55.6) 
37.0-72.7 25 
(50.0) 
35.8-64.2 10 
(58.8) 
36.3-78.1  
n/a  
Agree 60 
(50.8) 
41.3-60.4 6 
(22.2) 
10.9-40.0 17 
(34.0) 
21.6-49.0 5 
(29.4) 
13.6-52.4 
Not sure 7  
(5.9) 
3.3-10.6 2  
(7.4) 
1.0-38.9 3  
(6.0) 
2.0-16.7 0  
(0.0) 
- 
Disagree 8  
(6.8) 
3.1-14.3 2  
(7.4) 
1.7-26.6 2  
(4.0) 
1.0-14.9 2 
(11.8) 
2.7-38.8 
Strongly 
disagree 
4  
(3.4) 
1.3-8.4 0  
(0.0) 
- 2  
(4.0) 
1.0-15.2 0  
(0.0) 
- 
Benefit for ECG 
interpretation 
training for AF 
 
Strongly 
agree 
14 
(11.9) 
6.8-20.0 10 
(37.0) 
21.7-55.5 22 
(44.0) 
30.0-59.0 7 
(41.2) 
21.9-63.7  
<0.00
1 
 
Agree 38 
(32.2) 
25.3-40.0 9 
(33.3) 
18.2-52.9 17 
(34.0) 
21.3-49.4 7 
(41.2) 
21.1-64.7 
Not sure 15 
(12.7) 
8.1-19.3 5 
(18.5) 
6.5-42.6 3  
(6.0) 
2.0-16.7 2 
(11.8) 
2.7-38.8 
Disagree 42 
(35.6) 
27.2-44.9 1  
(3.7) 
0.5-23.5 5 
(10.0) 
4.3-21.5 1  
(5.9) 
0.83-4.0 
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Strongly 
disagree 
7  
(5.9) 
3.0-11.4 0  
(0.0) 
- 2  
(4.0) 
1.015.2 0  
(0.0) 
- 
Better at diagnosing 
AF if received ECG 
interpretation 
training 
 
Strongly 
agree 
20 
(16.9) 
10.7-25.7 11 
(40.7) 
24.6-59.1 19 
(38.0) 
24.5-53.7 7 
(41.2) 
21.9-63.7  
<0.00
1 
 
Agree 31 
(26.3) 
19.6-34.2 5 
(18.5) 
7.7-38.2 20 
(40.0) 
27.2-54.4 8 
(47.1) 
25.9-69.3 
Not sure 22 
(18.6) 
11.3-29.2 5 
(18.5) 
7.0-40.7 4  
(8.0) 
2.9-20.4 1  
(5.9) 
0.8-34.0 
Disagree 35 
(29.7) 
21.1-39.9 2  
(7.4) 
1.7-26.6 3  
(6.0) 
1.9-17.0 1  
(5.9) 
0.8-34.0 
Strongly 
disagree 
8  
(6.8) 
3.5-12.7 1  
(3.7) 
0.5-23.5 3  
(6.0) 
1.9-17.0 0  
(0.0) 
- 
Would like ECG 
training (any 
condition) 
 
Strongly 
agree 
37 
(31.4) 
23.9-39.9 12 
(44.4) 
27.3-63.0 21 
(42.0) 
28.1-57.3 11 
(64.7) 
44.5-80.7  
n/a 
Agree 61 
(51.7) 
42.5-60.8 6 
(22.2) 
10.9-40.0 16 
(32.0) 
19.2-48.2 5 
(29.4) 
14.9-49.8 
Not sure 8  
(6.8) 
3.5-12.8 2  
(7.4) 
1.7-26.6 5 
(10.0) 
3.7-24.0 0  
(0.0) 
- 
Disagree 7  
(5.9) 
2.9-11.8 3 
(11.1) 
2.5-37.8 3  
(6.0) 
1.9-17.4 1  
(5.9) 
0.8-34.0 
Strongly 
disagree 
3  
(2.5) 
0.9-7.3 0  
(0.0) 
- 4  
(8.0) 
3.1-19.3 0  
(0.0) 
- 
Would like ECG 
training (AF) 
 
Strongly 
agree 
16 
(13.6) 
8.2-21.5 11 
(40.7) 
24.2-59.7 19 
(38.0) 
24.1-54.1 5 
(29.4) 
13.6-52.4 <0.00
1 
 Agree 33 
(28.0) 
21.4-35.6 7 
(25.9) 
13.5-44.0 14 
(28.0) 
17.3-42.0 9 
(52.9) 
31.0-73.8 
Not sure 21 
(17.8) 
11.5-26.5 3 
(11.1) 
3.6-29.7 5 
(10.0) 
4.6-20.4 2 
(11.8) 
2.7-38.8 
Disagree 38 
(32.2) 
23.1-42.8 2  
(7.4) 
1.8-25.4 8 
(16.0) 
8.3-28.7 1  
(5.9) 
0.8-34.0 
Strongly 
disagree 
8 (6.8) 3.4-13.2 0  
(0.0) 
- 3  
(6.0) 
1.9-17.0 0  
(0.0) 
- 
Would like to be Strongly 32 19.5-36.4 6 10.0-42.3 12 14.2-37.6 8 26.2-69.0 <0.00
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involved in 
diagnosing AF 
 
agree (27.1) (22.2) (24.0) (47.1) 1 
Agree 61 
(51.7) 
43.8-59.5 3 
(11.1) 
3.6-29.7 10 
(20.0) 
11.0-33.6 2 
(11.8) 
3.0-36.4 
Not sure 8  
(6.8) 
3.0-14.5 6 
(22.2) 
9.8-42.8 14 
(28.0) 
16.5-43.3 6 
(35.3) 
17.6-58.1 
Disagree 9  
(7.6) 
3.9-14.4 4 
(14.8) 
5.6-34.0 10 
(20.0) 
10.3-35.1 1  
(5.9) 
0.9-31.1 
Strongly 
disagree 
2  
(1.7) 
0.4-6.9 4 
(14.8) 
5.8-32.9 3  
(6.0) 
1.9-17.0 0  
(0.0) 
- 
*N=number of participants responding to question item; %=proportion of participants, adjusted for clustering by 
practice; 95% C.I= 95% confidence interval for the proportion of participants; n/a=unable to calculate p-value to 
insufficient data within cells 
Missing data within question responses is present when the sum of column percentages <100% 
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6.5.5. Facilitators and barriers to AF screening  
6.5.5.1. Quantitative results 
HCPs views on their potential roles in AF screening are presented in 
Table 6-3. Most participants reported having a likely role in 
performing pulse checks although a greater proportion of nurses 
and NPs reported having this role than other HCPs. More nurses 
and NPs also reported being very likely to have a role in conducting 
12-lead ECGs [proportion (95% CI) for GPs: 31.4% (23.1-41.0); 
HCAs: 48.1% (30.4-66.4); nurses: 70.0% (52.7-83.0); NPs 64.7% 
(39.9-83.5)]. Fewer non-GP HCPs reported having a future role in 
ECG interpretation and AF diagnosis than GPs.  
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Table 6-3: Perceived role of healthcare professionals in future atrial fibrillation screening 
Question Response GP 
(N=118) 
Healthcare assistant 
(N=27) 
Nurse 
(N=50) 
Nurse practitioner 
(N=17) 
P-
value 
N 
(%)* 
95% C.I* N 
(%)* 
95% C.I* N 
(%)* 
95% C.I* N 
(%)* 
95% C.I* 
Role in performing 
pulse checks 
Very likely 61 
(51.7) 
41.0-62.2 12 
(44.4) 
27.6-62.7 42 
(84.0) 
72.5-91.3 12 
(70.6) 
44.4-87.8 n/a 
 
Likely 37 
(31.4) 
22.9-41.3 7 
(25.9) 
11.2-49.2 6 
(12.0) 
5.8-23.3 2 
(11.8) 
1.6-52.3 
Unsure 9  
(7.6) 
3.9-14.4 6 
(22.2) 
9.8-42.8 0  
(0.0) 
- 0 
(0.0) 
- 
Unlikely 3  
(2.5) 
0.8-7.5 0 
(0.0) 
- 0  
(0.0) 
- 1 
(5.9) 
0.8-34.0 
Very unlikely 3  
(2.5) 
0.8-22.2 0 
(0.0) 
- 0  
(0.0) 
- 0 
(0.0) 
- 
Role in conducting 
12-lead ECGs 
 
Very likely 37 
(31.4) 
23.1-41.0 13 
(48.1) 
30.4-66.4 35 
(70.0) 
52.7-83.0 11 
(64.7) 
39.9-83.5 n/a 
 
Likely 29 
(24.6) 
17.1-33.9 6 
(22.2) 
9.6-43.3 4  
(8.0) 
2.9-20.0 3 
(17.6) 
4.0-52.2 
Unsure 6  
(5.1) 
2.3-11.0 4 
(14.8) 
6.1-31.7 4  
(8.0) 
3.0-19.3 0  
(0) 
- 
Unlikely 27 
(22.9) 
16.4-31.0 0  
(0) 
- 1  
(2.0) 
0.3-13.4 1 
(5.9) 
0.8-34.0 
Very unlikely 14 
(11.9) 
7.7-17.7 2 
(7.4) 
1.7-26.6 4  
(8.0) 
2.9-20.0 0  
(0) 
- 
Role in ECG 
interpretation for 
AF 
 
Very likely 71 
(60.2) 
48.8-70.5 2 
(7.4) 
1.7-26.6 7 
(14.0) 
6.4-27.8 5 
(29.4) 
12.5-54.8 <0.001 
 
Likely 37 
(31.4) 
22.8-41.5 2 
(7.4) 
1.7-26.6 8 
(16.0) 
8.1-29.1 4 
(23.5) 
8.3-51.0 
Unsure 6  
(5.1) 
2.3-10.8 9 
(33.3) 
18.9-51.7 18 
(36.0) 
24.4-49.5 3 
(17.6) 
5.8-42.6 
Unlikely 0  - 6 9.8-42.8 9 10.5-29.0 3 4.0-52.2 
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(0) (22.2) (18.0) (17.6) 
Very unlikely 0  
(0) 
- 6 
(22.2) 
10.4-41.1 6 
(12.0) 
5.4-24.5 0  
(0) 
- 
Role in diagnosing 
AF 
 
Very likely 69 
(58.5) 
46.9-69.2 0  
(0) 
- 5 
(10.0) 
3.7-24.1 5 
(29.4) 
12.5-54.8 n/a 
Likely 40 
(33.9) 
24.8-44.4 1 
(3.7) 
0.5-23.5 6 
(12.0) 
5.2-25.2 3 
(17.6) 
5.3-44.9 
Unsure 5  
(4.2) 
1.7-9.9 8 
(29.6) 
16.2-47.9 15 
(30.0) 
19.3-43.4 1 
(5.9) 
0.8-34.0 
Unlikely 0  
(0) 
- 3 
(11.1) 
2.5-37.8 11 
(22.0) 
11.8-37.2  6 
(35.3) 
15.3-62.3 
Very unlikely 0  
(0) 
- 13 
(48.1) 
30.5-66.3 11 
(22.0) 
12.0-36.8 0  
(0) 
- 
*N=number of participants responding to question item; %=proportion of participants, adjusted for clustering by 
practice; 95% C.I= 95% confidence interval for the proportion of participants; n/a=unable to calculate p-value to 
insufficient data within cells 
Missing data within question responses is present when the sum of column percentages <100% 
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6.5.5.2. Findings from open-ended questions 
There were 337 free-text responses from 171/212 (81%) 
respondents (105 GPs; 13 HCAs; 53 nurses). Around 20% 
responses identified no barriers to screening within current 
practice. Common themes for barriers, in all HCP groups, to AF 
screening were time to undertake screening, workload, lack of 
appointments, staffing levels within the practice, access to the 
required equipment, and available funding to conduct screening 
activities. [Comment 212 (GP): “we would require some form of 
extra resources to carry this out depending on the work required 
general practice is currently overstretched with work and 
conflicting demands”; Comment 219 (GP) “workload issues”; 
Comment 231 (GP): time, time, time, the waiting time for 
anticoagulation clinic would need to be reduced currently two to 
three weeks and GP carries responsibility for any adverse event; 
also who will find the money for new anticoagulants”. Comment 
311 (Nurse): “lack of appointments, too few nurses, extra load on 
all members of the team”]. Less common barriers included the 
perception that screening activities were not their current role, lack 
of space within the practice, lack of training, and the patient 
reluctance to screening.  
 
Only 10% of responses suggested there were no facilitators 
required for screening to be implemented within existing practice. 
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The most common theme identified as a facilitator for screening 
was additional training requirements; commonly reported 
requirements were training for conducting and interpreting 12-lead 
ECGs, the management of AF and undertaking pulse palpation. 
[Comment 57 (GP): “brief ECG update training and advice on 
management of AF once diagnosed”; Comment 69 (GP): “Training 
for practice nurses in AF diagnosis/management; written protocol 
pathway to aid above process”; Comment 99 (GP): “Further 
training on ECG interpretation. I am fairly confident that I can 
identify AF on an ECG but looking at ECG uncovers other 
abnormalities that I have less confidence in my interpretation”; 
Comment 151 (Nurse): “ECG training reading and interpretation of 
results”]. Less common facilitators to screening included provision 
or access to 12-lead ECGs and guidelines on AF screening.   
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6.6. Discussion 
6.6.1. Summary of principal findings 
This survey found that, even in this inner-city area, most 
respondents from practices believe they are able to perform and 
interpret ECGs in-house and were potentially well-equipped for 
future AF screening. Non-GP HCPs reported having less knowledge 
about ECG interpretation and the treatment of AF than GPs. 
However, non-GP HCPs more frequently reported they would 
benefit from ECG training specifically for diagnosing AF. All HCP 
groups reported they would like to receive training in ECG 
interpretation but this was specifically for AF diagnosis in non-GP 
groups. However, non-GP HCPs did not perceive themselves to 
have a future role in ECG interpretation or AF diagnosis. 
 
6.6.2. Strengths and limitations 
To my knowledge, this is the first study to ascertain the readiness 
for and views of HCPs regarding the introduction of AF screening in 
General Practices.  
 
A strength of this study was the high practice-level response rate: 
at least one GP responded from 81% of practices; therefore it is 
likely that representative estimates for existing methods for 
detecting AF within inner-city practices were ascertained. Whilst 
the response rate from individual participants was satisfactory 
 200 
(51%) there is a possibility that non-respondents’ knowledge, 
skills, attitudes and opinions might be different from those who 
completed questionnaires. For example, non-responders may have 
lower enthusiasm for AF screening and I may have overestimated 
HCP interest in this.  
 
Although findings are likely to represent the views of HCPs within 
inner-city practices of Nottingham City CCG, another limitation of 
this study is the generalisability of findings to professionals in other 
primary care settings, such as those working in rural settings. The 
prevalence of long-term conditions and associated health problems 
experienced by patients in Nottingham City CCG is similar to 
national average estimates. (207) Moreover, in 2014 Nottingham 
City CCG had similar ratios of GPs and nurses to patient population 
as the England average. (208) This suggests the burden of long-
term conditions and staffing available for managing these is similar 
to national estimates. Consequently, the views of HCPs in this 
study may be generalisable to professionals from other inner-city 
practices.  
 
HCPs working in the same practice may have similar abilities to 
detect AF and share similar opinions about screening; such 
clustering effects could have influenced the findings from the 
survey. However, this was allowed for in the quantitative analyses 
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by adjusting for the effects of clustering by practice and, 
consequently, the findings for these survey questions are likely to 
have greater precision. There remains the possibility of residual 
confounding as factors, such as time since ECG training, were not 
adjusted for in the analyses and could influence the outcomes in 
either direction. It is likely, however, that such effects were 
accounted for when adjusting for the effects of clustering by 
practice as GP practices often have in-house training and quality 
assurance processes. 
 
Although p-values were obtained to give an indication of true 
differences between HCP groups, the level of significance should be 
treated with caution given the number of statistical tests 
performed. Furthermore, this study was small in sample size and, 
combined with the lack of a power calculation, there is a limited 
ability to determine differences between HCPs groups.  
 
The survey ascertained information about methods for detecting AF 
in accordance with current recommendations – pulse palpation and 
12-lead ECG. (80) It is possible that some practices may be using 
other methods to detect patients with suspected AF (e.g. non-12-
lead ECGs) and information regarding practise using newer 
technologies is not known. 
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Another limitation to the survey is that data were ascertained for 
the perceived abilities of HCPs to undertake screening activities and 
there were no direct comparisons with objective information for the 
abilities of HCPs to detect or diagnose AF. The findings from 
research undertaken in chapter five of this thesis suggest that 
primary care professionals may under diagnose AF when 
interpreting ECGs; it is therefore possible that survey participants 
could have overestimated their competencies at undertaking such 
activities.  
 
Another limitation of this study was its cross-sectional design and 
the assumption that screening would be implemented within a 
primary care setting. The temporal relationship between HCPs 
views about screening and subsequent abilities to undertaken 
screening cannot be established.   
 
Finally, the survey ascertained both quantitative and qualitative 
data for the views of HCPs about the future implementation of AF 
screening. Although findings were consistent between both 
approaches there are methodological limitations of using open-
ended questions for qualitative data as part of a survey. Moreover, 
there were only three open-ended questions in the survey with 
limited space for free-text responses. The outcomes from open-
ended questions are more likely to provide an indication of views 
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expressed rather than deeper understanding of the opinions of 
HCPs about AF screening. Although surveys are a time-efficient 
method of data acquisition, the lack of investigator at survey 
completion does not enable probing/clarification of uncertain 
responses. Face-to-face qualitative research would therefore 
provide a greater in-depth exploration of the themes identified 
from the survey.  
 
6.6.3. Comparison with existing literature 
There have been few studies that have investigated the feasibility 
of conducting ECGs in primary care. Begg et al. undertook a cross-
sectional survey in the UK of HCPs in primary care (226 GPs, 13 GP 
registrars, five nurses) and secondary care physicians about ECG 
acquisition and interpretation. Of primary care respondents, 82% 
reported having an ECG machine at their practice and 82% 
reported nurses or HCAs as the HCP that performed ECGs. (209) 
These findings are consistent with the estimates from my survey 
and support the assertion that GP Practices are potentially well-
equipped for delivering AF screening as they have good access to 
ECGs. 
 
There have been very few studies that have investigated the 
competencies of HCPs in Primary Care for interpreting ECGs. Begg 
et al. also investigated the competencies of HCPs to interpret 
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ECGs. Survey participants were asked about their views about 
interpreting ECGs and they were provided six ECGs, with a variety 
of abnormalities, to interpret. (209) Approximately, 90% of HCPs 
in Primary Care interpreted less than five ECGs per week.  
Moreover, only 45% of respondents felt very or fairly confident at 
ECG interpretation but these findings were not provided according 
to professional groups.  There was also substantial variation in the 
accuracy of ECG interpretation by Primary Care professionals.  The 
findings by Begg et al. support the suggestion that training to 
improve the accuracy of ECG interpretation in Primary Care would 
be an important consideration if screening were implemented in 
this setting. 
 
The limited competencies of HCPs in Primary Care to undertake 
screening activities is consistent with findings of studies from other 
screening programmes. Patel et al. conducted a web-based survey 
of 147 General Practice surgeries in the East Midlands, UK about 
the Human Papilloma Virus (HPV) vaccine as part of cervical 
screening. (210) The survey explored practice nurse knowledge 
and attitudes towards HPV vaccine and self-perceived adequacy of 
HPV knowledge.  Patel et al. found that basic knowledge was 
lacking; 9.6% of respondents failed to identify HPV as a cause of 
cervical cancer and 62.8% nurses believed that HPV required 
treatment. Only 68% of nurses felt adequately informed about HPV 
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and the need to provide training was identified as an important 
facilitator to future screening. (210) 
 
There have also been very few studies that have investigated the 
opinions of HCPs in primary care about AF screening 
implementation. Studies of AF case finding in pharmacies have 
found that screening using single-lead ECGs was acceptable by 
community pharmacists and that and there was enthusiasm for 
screening within this setting. (140, 144) Since conducting my 
survey, Orchard et al. have published their findings of a cross-
sectional pilot study of AF screening. (211) Practice nurses from 
five GP practices in Australia screened patients using smart phone 
ECGs during influenza vaccination clinics.  As part of this study, 
practice nurses (n=7), GPs (n=5) and practice managers (n=5) 
were interviewed to ascertain their views about AF screening 
implementation. (211) Practice nurses felt confident at performing 
screening and enjoyed the extra interaction with patients. (211) 
GPs and practice managers were also positive about screening 
implementation. However, all professional groups identified key 
barriers as time and capacity to undertake screening. (211)  
 
The findings from the study by Orchard et al. and studies of 
screening implementation in pharmacies are consistent with the 
results of my survey where HCP groups were potentially 
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enthusiastic about screening but similar barriers to its 
implementation were identified.  
 
6.7. Conclusions 
Primary care is potentially well resourced and ready to deliver AF 
screening, with most healthcare professionals at surveyed practices 
perceiving they have the ability to detect pulse irregularities and 
perform 12-lead ECGs. Compared to GPs, other HCPs feel they 
have less knowledge and skills for interpreting 12-lead ECGs and 
diagnosing AF. Therefore GPs may be the appropriate professional 
group for diagnosing AF as part of screening. However, non-GP 
HCPs also reported they would like to gain skills in ECG 
interpretation. Therefore, nurses may have the greatest potential 
to up-skill and could have an important role in further supporting 
future AF screening.  
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Chapter 7. Summary and recommendations 
7.1. Summary and implications 
Screening for AF in primary care has been recommended; current 
guidance advocates using a two-stage approach for screening, 
where patients with pulse irregularities are identified and then AF is 
subsequently diagnosed or excluded using 12-lead ECG in those 
with suspected AF. (80, 108) The overall aim of this programme of 
research was to determine how AF screening might feasibly and 
effectively be introduced into primary care in the UK and research 
undertaken has progressed the understanding of this.  
 
The first systematic review (chapter four) identified four methods - 
pulse palpation, non-12-lead ECGs, modified blood pressure 
monitors and smart phone devices - for identifying patients with 
pulse irregularities caused by AF, and found that pulse palpation 
had the lower accuracy for detecting suspected AF than other 
methods due to its lower specificity. Pulse palpation would 
therefore result in greater false positive cases of suspected AF and 
more patients unnecessarily requiring 12-lead ECG than other 
methods.  
The findings from this review provide evidence on how the first-
step of proposed AF screening may be better organised and 
support the use of newer technologies to detect patients with pulse 
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irregularities attributable to AF as alternatives to pulse palpation. 
Greater accuracy of new technologies would reduce the number of 
unnecessary ECGs subsequently conducted would have an impact 
on reducing service utilisation (conducting and interpreting ECGs) 
and potential psychological harm to patients that are falsely 
identified as having suspected AF.  However, this study does not 
provide data for the effectiveness of new technologies to detect AF 
when compared to pulse palpation or the subsequent translation of 
findings to changes in stroke burden. 
 
Pulse palpation is considered a cheap and feasible method for 
detecting patients with an irregular pulse. (148) Any other method 
of detecting pulse irregularities caused by AF should, in addition to 
being cheap, be accurate, quick and simple for it to be a cost-
effective intervention in primary care. The review findings are 
supported by recent guidance from the National Institute for Health 
and Care Excellence (NICE) that advocate the use of an automated 
BP monitor for the detection of suspected AF in patients being 
screened or monitored for hypertension. (212) Modified blood 
pressure monitors were found to have a substantially greater 
accuracy for detecting pulse irregularities caused by AF than pulse 
palpation; such devices are likely to be a pragmatic alternative to 
pulse palpation as blood pressure checks are an integral 
component of existing cardiovascular screening programmes in 
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primary care. (213) Furthermore, automated devices would enable 
screening to be conducted by all healthcare professionals without 
the need for additional training, and could be used for all patients 
in the target screening population. However, to date there have 
been no economic analyses comparing alternative technologies to 
pulse palpation for detecting pulse irregularities attributable to AF 
and this would help to further inform optimal planning and service 
configurations of any future AF screening programme.  
 
The first systematic review also highlighted the potential utility of 
smart phone applications for detecting irregular pulses caused by 
AF. This method was found to have a similar diagnostic accuracy as 
blood pressure monitors. However, there were only two studies 
investigating smart phone applications and both were small in 
sample size. In addition, one of these studies investigated multiple 
software algorithms with different thresholds to determine a 
positive test result using the same cohort of patients; this reduces 
the internal validity of findings and the precision of point estimates 
for diagnostic accuracy of smart phone applications. Therefore, the 
findings for this method of identifying suspected AF should be 
interpreted with caution. If these findings, however, are replicated 
in larger studies that are representative of those targeted by 
screening, this raises the future possibility of using such 
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technologies within both the clinic and home settings for detecting 
AF. 
   
The second systematic review (chapter five) identified two methods 
- automated software and healthcare professional analysis - for 
interpreting 12-lead-ECGs for the diagnosis of AF. The review found 
that automated software analysis of ECGs had the greater 
specificity for AF diagnosis than healthcare professional ECG 
interpretation; software ECG interpretation would therefore result 
in the greatest number of true negative cases being identified and 
the lowest number of false positives.  
However, the sensitivities of automated software and healthcare 
professional ECG interpretation were similar and substantially lower 
than the respective specificities. Therefore, all methods of ECG 
interpretation would potentially result in excessive false negative 
diagnoses of AF.  Moreover, sub-group analyses found the accuracy 
of 12-lead-ECG interpretation in primary care was greater for GPs 
than nurses due to a lower specificity for nurse diagnosed AF.  
The specificities of methods of ECG interpretation suggest 
automated software would be a better method for ruling in AF; 
using healthcare professional ECG interpretation alone would result 
in greater false positive diagnoses of AF than software 
interpretation. This would result in potential treatment related and 
psychological harm to patients that are incorrectly diagnosed with 
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AF and inappropriately receive stroke preventative treatments. The 
lower sensitivities of all ECG interpretation methods suggest that 
there is the potential for excess false negative diagnoses of AF and 
patients incorrectly having AF ruled out, thus remaining at risk of 
stroke. However, the review did not provide evidence for the 
impact the sensitivities and specificities from different 
interpretation methods on the effectiveness and cost-effectiveness 
of screening. 
 
The findings from the second review also suggest the accuracy of 
interpreting ECGs and diagnosing AF in primary care would require 
improvement should screening be implemented within this setting.  
An alternative approach arising from the findings is the potential 
for combining software and healthcare professional interpretation 
of ECGs for the diagnosis of AF as part of screening. To date only 
one study has provided data for the accuracy of combining 
different methods for interpreting 12-lead-ECGs and diagnosing AF. 
(188) Mant et al. conducted secondary analyses of SAFE trial data 
and found that combining software and GP interpretation of 12-
lead ECGs did not result in an improvement in the sensitivity of 
diagnosing AF. (188) This study, however, did not combine other 
healthcare professionals’ (i.e. nurses) diagnoses of AF with 
interpretive software and so the accuracy of using other 
combinations for diagnosing AF is not known. The consistently high 
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specificity of automated software suggests it has potential utility 
for the triage of ECGs and exclusion of patients with normal ECG 
findings; this could be used to avoid physician interpretation of 
normal ECGs during AF screening, reducing the number of false 
positive diagnoses of AF. Furthermore, reducing the number of 
ECGs that require physician interpretation would also make 
screening more time efficient and potentially less costly. However, 
correctly diagnosing AF using software interpretation, either alone 
or in combination with GPs, has a limited sensitivity resulting in the 
potential for incorrect exclusion of AF, and interpreting ECGs to 
verify the presence of AF in this circumstance is likely to require 
additional interpretation from a competent healthcare professional. 
(80) Given the sensitivities of ECG diagnosis of AF in primary care 
were sufficiently low to give rise to substantial false negative cases 
of AF, it is conceivable that the skills of healthcare professionals in 
this setting would need improving to ensure the effectiveness of 
screening is not undermined. It would, however, be important to 
understand the current practise, skills and learning needs of 
primary care healthcare professionals before delivering any 
intervention to improve their abilities of accurately interpreting 
ECGs.  
 
The third study (chapter six) - a survey of healthcare professionals 
in primary care – was the first study that engaged GP and nurse 
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stakeholders about AF screening and. The survey ascertained data 
for the feasibility of implementing AF screening in General Practices 
and the views of healthcare professionals in primary care about 
screening. The survey found that screening could be feasibly 
implemented within primary care as GP practices had the facilities 
to conduct and interpret ECGs as part of routine practice.  
 
Screening for AF in primary care would result in a substantial 
increase in the number of ECGs conducted and that require 
interpretation. The findings from the survey suggest that non-GP 
healthcare professionals could have an important role in this. 
Although non-GP healthcare professionals reported more 
deficiencies in knowledge for ECG interpretation than GPs, they felt 
they would like to receive ECG training specifically for AF diagnosis.  
Furthermore, training to interpret ECGs and manage AF was 
identified as a facilitator for screening across all healthcare 
professional groups. Nurses may have the greatest potential for 
supporting AF screening. Nurses are having a greater role in 
managing long-term conditions, and research suggests that nurses 
prefer increased healthcare responsibilities, having an important 
role in disease management. (214, 215)  Studies have also found 
that, with appropriate training, the accuracy of ECG interpretation 
by nurses can be improved. (216, 217)  
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Paradoxically, in the survey nurses reported they would not have a 
future role in AF diagnosis and management despite reporting they 
would like to receive ECG interpretation training. This may be due 
to nurses sometimes seeing their role in clinical practice as vague. 
(218) A number of barriers to AF screening were also identified, 
particularly relating to lack of workforce and capacity to undertake 
screening, which may influence nurses’ lack of perceived role in 
future service delivery. The barriers to AF screening that the 
survey identified included lack of capacity, time, staff and funding 
to undertake screening activities within practices. Similar themes 
have been identified in studies investigating the introduction of 
screening for other conditions within primary care. (219-221) 
Furthermore, primary care in the UK is currently perceived to be in 
crisis, with surgeries facing cuts in funding, (222-224) poor 
recruitment, (225) and reduced job satisfaction reported by GPs. 
(222, 226) Any future AF screening programme would have 
financial and staffing implications to GP surgeries and overcoming 
these barriers, in addition to the facilitation of ECG interpretation 
training, would be imperative to ensure the successful 
implementation of this intervention.  
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7.2. Recommendations 
7.2.1. Recommendations for clinical practice  
Recommendation one: In the first stage of screening for AF, newer 
technologies, such as modified blood pressure monitors and non-
12-lead ECGs, could be used as alternatives to pulse palpation to 
detect pulse irregularities which may be caused by AF.  
 
As newer technologies were found to be more accurate than pulse 
palpation for detecting suspected AF using these technologies in AF 
detection is likely to be appropriate. New technologies could 
therefore be used for the first-step of AF screening if it were 
implemented.  
 
Recommendation two: In any screening programme, automated 
software analysis of 12-lead ECGs could be used to support 
healthcare professionals identify normal ECGs and also to rule in 
the presence of AF. 
 
Automated software analysis of 12-lead ECGs was found to have a 
greater specificity for AF diagnosis than other methods of ECG 
interpretation. This would result in those without AF being correctly 
identified alongside a low false positive rate of AF diagnoses. 
Therefore, a positive test result when diagnosing AF using 
automated ECG interpretation, in the context of a high specificity, 
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would also support healthcare professionals ruling in the presence 
of AF. However, the sensitivity of automated software analysis was 
not sufficiently high for this method to be reliably used in isolation 
to rule out AF, as the lower sensitivity would result in a high rate of 
false negative diagnoses of AF.    
 
Recommendation three: In a screening programme, practice 
nurses could be used to detect pulse irregularities caused by AF 
(the first-step of screening) and GPs could be used to interpret 
ECGs (the second-step of screening).  
 
Practice nurses were found to have confidence in undertaking AF 
screening activities, such as pulse palpation and performing 12-
lead ECGs, more often than GPs. Therefore, they could have a role 
in the first-step of AF screening where patients with an irregular 
pulse are identified. Of primary care professionals, GPs were found 
to have a greater confidence and accuracy for interpreting ECGs 
and diagnosing AF than nurses; GPs are therefore the most likely 
professional group to undertake the second-step of screening in 
primary care. However, it is likely that training would be required 
for GPs to ensure competencies in ECG interpretation are achieved.  
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7.2.2. Recommendations for research 
Recommendation 1: Studies of AF screening are required that 
compare the effectiveness and cost-effectiveness of newer 
technologies, such a modified blood pressure monitors and non-12-
lead ECGs, to pulse palpation for the detection of AF 
 
Although newer technologies were found to have a greater 
accuracy than pulse palpation for detecting suspected AF, there 
have been no studies comparing the effectiveness and cost-
effectiveness of such technologies to pulse palpation for detecting 
silent AF. Economic analyses should consider the greater yield of 
AF detection using new technologies and how this could offset the 
greater cost of implementing these into routine practice. This 
research would improve the understanding of how the 
recommended first-step of AF screening could be optimized. 
  
Recommendation 2: Studies are required that investigate 
improving the competencies of healthcare professionals in primary 
care to interpret 12-lead ECGs for the diagnosis of AF 
 
The accuracy of diagnosing AF using ECGs in primary care is likely 
to require improvement before screening could be implemented. 
This would be particularly important if nurses were to have a role 
in future AF screening; practice nurses perceived to have less 
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confidence, knowledge and skills than GPs to competently interpret 
ECGs and diagnose AF, and extending their role to undertake this is 
likely to require further training. Consequently, studies 
investigating methods of improving the abilities of GPs and/or 
nurses for interpreting 12-lead-ECGs are an important priority. This 
may include research that investigates combining healthcare 
professional and software ECG interpretation as automated 
software was found to have the greatest accuracy for determining 
normal ECGs. An important consideration when designing such 
research would be to ensure a high internal and external validity. 
The second systematic review undertaken in this thesis (chapter 5) 
found study quality – as assessed using the QUADAS-2 tool – was 
generally low. The QUADAS-2 tool could be used to inform the 
development of diagnostic accuracy studies to ensure the design, 
conduct and reporting of future research is of a high standard and 
translatable to different healthcare settings.   
 
Although many ECG training courses are available, to my 
knowledge there has been no systematic evaluation of the 
effectiveness of ECG training programmes to improve the accuracy 
of ECG interpretation by healthcare professionals in primary care. 
Indeed, such research would subsequently help inform how ECG 
interpretation and AF diagnosis could be quality assured as part of 
screening.  
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Recommendation 3: Studies are required that investigate the views 
of healthcare professionals in primary care from non-inner city and 
rural areas, and other key stakeholders, about AF screening  
 
The survey suggested it may be feasible to introduce screening 
within primary care and that healthcare professionals were 
enthusiastic about potential screening implementation. However, 
the generalisability of these findings would require testing in other 
practice settings. The survey also investigated healthcare 
professionals’ perceived knowledge and skills about AF screening 
and further research that objectively quantifies existing knowledge 
and skills would enable validation of the survey findings.  
 
Qualitative research would provide greater understanding of the 
views expressed by healthcare professionals in the survey about 
screening implementation. Although the survey used open-ended 
questions to help identify facilitators and barriers to screening, 
qualitative research methods would enable in-depth understanding 
of the themes identified.  
 
Furthermore, there has been a paucity of research investigating 
the views of other key healthcare professional groups such as 
Public Health England, NHS England and Clinical Commissioning 
Groups, and understanding the views of these stakeholders would 
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inform the development and implementation of future AF 
screening.  
 
Other stakeholders in AF screening are the service users. Although 
the literature review (chapter 2) identified some research about 
patient views of AF screening, there is little data on informed 
choice about AF screening. Such research would a provide greater 
understanding about the factors associated with patient 
engagement in AF screening programmes and help overcome 
patient related barriers to implementation. 
  
Recommendation 4: Studies are required that investigate long-
term clinical outcomes in patients with screen-detected AF 
 
The literature review from chapter two found only one study that 
reported clinical outcomes, other than new cases of AF, in those 
with screen-detected AF. Currently, AF screening studies report the 
stroke risk scores of people with screen-detected AF at the point of 
detection. However, there are no studies that report the 
subsequent change in long-term stroke burden as a consequence 
of treating those with screen-detected AF.   As screening aims to 
reduce the thromboembolic complications arising from silent AF, 
research that compares treatment provision and longer-term 
clinical outcomes, such as changes in stroke burden and 
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complications from the treatment, in those with screen-detected AF 
and those with AF detected from routine practice would be 
required.  
 
Recommendation 5: Studies are required that compare the 
effectiveness, cost-effectiveness and affordability of AF screening 
methods to usual care 
 
A finding from the literature review undertaken in chapter two was 
that there was a paucity of studies comparing the effectiveness of 
screening methods to usual care. Most studies of AF screening 
have been uncontrolled case finding studies and suggest silent AF 
exists and that it can be detected. Randomised trials of AF 
screening found screening, using pulse palpation and/or 12-lead 
ECG, to be more effective than usual practice at detecting new 
cases of AF.  As newer technologies are increasingly used to detect 
pulse irregularities caused by AF, randomised trial evidence is 
required that compares the effectiveness and cost-effectiveness of 
AF detection using such methods to AF detection that would arise 
from routine practice. Moreover, economic analyses that model the 
subsequent affordability and opportunity costs of screening if 
delivered at a population level would help inform the equitable 
delivery of healthcare services.   
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Recommendation six: Studies are required that investigate the 
effectiveness, cost effectiveness and subsequent affordability of AF 
screening in different target populations according to age 
 
Screening for AF has been recommended in patient’s ≥65 years of 
age. Although the literature review in chapter two found that most 
studies of AF screening included people ≥65 years, there were no 
studies that investigated the effectiveness and cost-effectiveness of 
screening by varying the age thresholds of inclusion. The 
prevalence of AF and the risk of stroke attributable to AF increase 
with age; it is therefore possible that screening could be more 
effective and cost-effective if the age threshold of including 
participants for screening is increased, and research investigating 
the impact of varying age thresholds would inform how screening 
could be optimally organised.  
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Appendices 
Appendix 1: Chapter 4 - Electronic search strategy 
Medline (1946 to March Week 2 2015) - search completed: 
16/03/2015 
 
Disease 
1) Atrial fibrillation – MESH - 27734 
2) Atrial fibrillation.mp - 35999 
3) Auricular fibrillation*.mp - 76 
4) Atrium fibrillation*.mp - 7 
5) Af.mp - 21099 
6) A-fib.mp – 38 
7) Atrial flutter – MESH - 2598 
8) Atrial flutter*.mp - 3593 
9) Auricular flutter*.mp - 6 
10) Irregular pulse.mp – 36 
11) Irregular pulse*.mp - 48 
12) Irregular heart*.mp - 123 
13) Heart beat*.mp - 2416 
14) Irregular rhythm*.mp – 84 
 
Screening 
15) Screen*.mp - 380961 
16) Diagnostic procedure.mp – 3307 
 243 
17) Diagnosis – MESH - 3858748 
18) Diagnos*.mp - 1234132 
19) Identif*.mp - 1480379 
20) Test*.mp - 1778554 
21) Detect*.mp – 1099413 
 
Device 
22) Electrocardiography – MESH - 72662 
23) Electrocardiogram*.mp - 19087 
24) Electrocardiograph*.mp - 76279 
25) Blood pressure monitors –MESH – 940 
26) Blood pressure monitor*.mp - 8977 
27) Blood pressure device*.mp - 142 
28) Ecg.mp - 27825 
29) Ekg.mp - 1339 
30) Holter.mp - 4738 
31) Event monitor*.mp - 638 
32) Pulse adj3 test*.mp - 682 
33) Pulse palpation.mp – 61 
34) Device*.mp - 182533 
35) Watch BP home A.mp – 0 
 
Professionals 
36) Physicians – MESH - 51096 
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37) Doctor*.mp – 58183 
38) Nurses – MESH - 42126 
39) Nurse*.mp – 166128 
40) Health personnel – MESH - 224026 
41) Healthcare worker*.mp - 4164 
42) Healthcare professional*.mp - 7882 
43) Primary Health Care – MESH - 63601 
44) Secondary Care – MESH - 137 
45) Hospitals – MESH - 105602 
46) General Practice- MESH – 36745 
 
Testing 
47) Accuracy.mp - 165781 
48) Sensitivity and Specificity – MESH – 387754 
49) Sensitivity.mp - 588915 
50) Specificity.mp – 564148 
51) Predictive value of tests- MESH – 129242 
52) Positive predictive value*.mp - 24040 
53) Negative predictive value*.mp – 24214 
 
Combining “OR” searches 
54) 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 
13 or 14 – 49725 
55) 15 or 16 or 17 or 18 or 19 or 20 or 21 – 6274796 
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56) 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 
32 or 33 or 34 or 35 – 280651 
57) 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 
46 – 520477 
58) 47 or 48 or 49 or 50 or 51 or 52 or 53 – 1057202 
59) 55 or 56 – 6340796 
 
Combination “AND” searches 
60) 54 and 57 and 58 and 59 – 83 
61) 54 and 58 and 59 – 4518 
62) Limit 60 to humans and all adults aged 19 plus – 63 
63) Limit 61 to humans and all adults aged 19 plus - 3194 
 
Embase (1980 to Week 11 2015) - searched completed: 
16/03/2015 
 
Disease 
1) Atrial fibrillation – MESH - 87943 
2) Atrial fibrillation.mp - 69156 
3) Auricular fibrillation*.mp - 922 
4) Atrium fibrillation*.mp - 87943 
5) Af.mp - 52764 
6) A-fib.mp – 162 
7) Atrial flutter – MESH - 9625 
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8) Atrial flutter*.mp - 6648 
9) Auricular flutter*.mp - 249 
10) Irregular pulse*.mp - 143 
11) Irregular heart*.mp - 332 
12) Heart beat*.mp - 9041 
13) Irregular rhythm*.mp – 227 
 
Screening 
14) Screen*.mp - 861041 
15) Diagnostic procedure - MESH – 12700923 
16) Diagnostic procedur*.mp – 92698 
17) Diagnosis – MESH - 4973477 
18) Diagnos*.mp - 3566708 
19) Identif*.mp - 2629324 
20) Test*.mp - 3521441 
21) Detect*.mp – 2120135 
 
Device 
22) Electrocardiography – MESH - 156369 
23) Electrocardiogram*.mp - 111191 
24) Electrocardiograph*.mp - 161434 
25) Blood pressure monitors –MESH – 543 
26) Blood pressure monitor*.mp - 26211 
27) Blood pressure device*.mp - 286 
 247 
28) Ecg.mp - 79109 
29) Ekg.mp - 7772 
30) Holter.mp - 17288 
31) Event monitor*.mp - 1242 
32) Pulse adj3 test*.mp - 1530 
33) Pulse palpation.mp – 142 
34) Device*.mp - 419080 
35) Watch BP home A.mp – 0 
 
Professionals 
36) Physician – MESH - 440074 
37) Doctor*.mp – 198770 
38) Nurse – MESH - 120534 
39) Nurse*.mp – 315282 
40) Health personnel – MESH - 988237 
41) Healthcare worker*.mp - 6651 
42) Healthcare professional*.mp - 14208 
43) Primary Health Care – MESH - 113103 
44) Secondary health Care – MESH - 1793 
45) Hospital – MESH - 749092 
46) General Practice- MESH – 70966 
 
Testing 
47) Accuracy.mp - 524616 
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48) Sensitivity and Specificity – MESH – 217170 
49) Sensitivity.mp - 970195 
50) Specificity.mp – 630639 
51) Predictive value - MESH – 66593 
52) Positive predictive value*.mp - 40792 
53) Negative predictive value*.mp – 41030 
 
Combining “OR” searches 
54) 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 
13 or  – 135741 
55) 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 – 15473280 
56) 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 
32 or 33 or 34 or 35 – 707833 
57) 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 
46 – 1928353 
58) 47 or 48 or 49 or 50 or 51 or 52 or 53 – 1689943 
59) 55 or 56 - 15623672 
 
Combination “AND” searches 
60) 54 and 57 and 58 and 59 – 842 
61) 54 and 58 and 59 – 8285 
62) Limit 60 to humans and all adult (<18 to 64 years) – 179 
63) Limit 60 to humans and all aged (<65+ years) – 195 
64) 62 or 63  - 263 
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65) Limit 61 to humans and all adult (<18 to 64 years) – 2620 
66) Limit 61 to humans and all aged (<65+ years) - 2234 
67) 65 or 66  - 3344 
 
CINAHL - search completed: 16/03/2015 
 
Disease 
( (MM "Atrial Fibrillation") OR "atrial fibrillation" OR (MH "Atrial 
Flutter") ) OR auricular fibrillation OR atrium fibrillation OR af OR a-
fib OR auricular flutter OR irregular pulse OR irregular heart OR 
irregular rhythm OR heart beat  
 
Above found 17,541 results 
 
Screening 
( (MM "Diagnosis+") OR "diagnosis" OR (MM "Diagnosis, 
Cardiovascular+") OR (MM "Diagnosis, Computer Assisted+") ) OR 
screen OR identify OR test OR detect OR procedure  
Above found 1,090,817 
 
Device 
( (MM "Electrocardiography+") OR "electrocardiography" OR (MM 
"Electrocardiography, Ambulatory") OR (MM "Cardiography, 
Impedance") ) OR electrocardiogram OR blood pressure monitor 
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OR blood pressure device OR ecg OR ekg OR holter OR event 
monitor OR pulse adj3 test OR pulse palpation OR device OR watch 
BP home A  
 
Above found 57,950 
 
Professionals 
( (MM "Physicians+") OR "physicians" ) OR doctor OR nurse OR 
health personnel OR healthcare worker OR healthcare professional 
OR primary health care OR secondary care OR hospital OR general 
practice  
 
Above found 496,183 
 
Testing 
( (MM "Sensitivity and Specificity") OR "sensitivity" ) OR accuracy 
OR specificity OR predictive value of test OR positive predictive 
value OR negative predictive value  
 
Above found 116,781 
 
Combination “AND” searches 
1) 1 AND 2 AND 3 AND 4 AND 5 – 24 
2) 1 AND 5 AND 6 – 638 
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LILACS - search completed:16/03/2015 
 
((atrial fibrillation*) OR (auricular fibrillation*) OR (Atrium 
fibrillation*) OR (AF) OR (A-fib) OR (Atrial flutter*) OR (Auricular 
flutter*) OR (irregular pulse*) OR (irregular heart*) OR (heart 
beat*) OR (irregular rhythm)) AND ((Accuracy*) OR (sensitivity) 
OR (specificity) OR (predictive value of test*) OR (positive 
predictive value*) OR (negative predictive value*)) AND 
((((Screen*) OR (diagnostic procedure) OR (diagnos*) OR 
(identif*) OR (test*) OR (detect*)) OR ((electrocardiograph*) OR 
(electrocardiogram*) OR (blood pressure monitor*) OR (blood 
pressure device*) OR (ecg) OR (ekg) OR (holter) OR (event 
monitor*) OR (pulse adj3 test*) OR (pulse palpation) OR (device*) 
OR (watch BP home A))))  AND (db:("LILACS")) = 61 
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Appendix 2: Chapter 4 - Data extraction table 
Category Data extracted 
 
Basic Study 
characteristics 
Author 
Year 
Title/question 
Design 
Years of enrolment 
Country of origin 
Funding source 
Participant’s 
characteristics 
Brief description of participants 
Inclusion criteria 
Exclusion criteria 
Baseline characteristics of participants 
Number of potential participants 
Number of participants who refused 
Number recruited 
Number lost to follow up/drop out 
Reasons for loss to follow up/drop out 
Comparator 
Intervention 
Device 
Manufacturer 
Diagnostic method and interpretation 
Threshold value 
 253 
Other information 
Experimental 
Intervention 
Device 
Manufacturer 
Diagnostic method and interpretation 
Threshold value 
Other information 
Other information Length of time between experimental 
intervention and comparator 
Results 
 
Sample size (if different to initial numbers) 
True positive 
False positive 
False negative 
True negative 
Sensitivity 
Specificity 
Positive predictive value 
Negative predictive value 
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Appendix 3: Chapter 5 - Electronic search strategy 
Medline (1946 to March Week 3 2014) - search completed: 
24/03/2014 
Disease 
1) (Heart) atrial fibrillation – MESH - 32301 
2) Atrial fibrillation.mp - 41749 
3) Auricular fibrillation*.mp - 1283 
4) Atrium fibrillation*.mp - 7 
5) Af.mp - 32254 
6) A-fib.mp – 36 
7) Atrial flutter – MESH - 4887 
8) Atrial flutter*.mp - 6326 
9) Auricular flutter*.mp - 410 
10) Irregular pulse.mp – 55 
11) Irregular pulse*.mp - 71 
12) Irregular heart*.mp - 155 
13) Heart beat*.mp - 3438 
14) Irregular rhythm*.mp – 132 
 
Screening 
15) Screen*.mp - 462367 
16) Diagnostic procedure.mp – 5624 
17) Diagnosis – MESH - 6340318 
18) Diagnos*.mp - 1845810 
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19) Identif*.mp - 1735408 
20) Test*.mp - 2643310 
21) Detect*.mp – 1479266 
 
Device 
22) Electrocardiography – MESH - 172776 
23) Electrocardiogram*.mp - 31874 
24) Electrocardiograph*.mp - 178114 
25) Blood pressure monitors –MESH – 1926 
26) Blood pressure monitor*.mp - 10505 
27) Blood pressure device*.mp - 199 
28) Ecg.mp - 43840 
29) Ekg.mp - 4459 
30) Holter.mp - 7862 
31) Event monitor*.mp - 708 
32) Pulse adj3 test*.mp - 1127 
33) Pulse palpation.mp – 82 
34) Device*.mp - 226332 
35) Watch BP home A.mp – 0 
 
Professionals 
36) Physicians – MESH - 83260 
37) Doctor*.mp – 81292 
38) Nurses – MESH - 68290 
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39) Nurse*.mp – 253375 
40) Health personnel – MESH - 357173 
41) Healthcare worker*.mp - 3968 
42) Healthcare professional*.mp - 7001 
43) Primary Health Care – MESH - 75611 
44) Secondary Care – MESH - 43 
45) Hospitals – MESH - 194688 
46) General Practice- MESH – 62966 
 
Testing 
47) Accuracy.mp - 192073 
48) Sensitivity and Specificity – MESH – 400650 
49) Sensitivity.mp - 743377 
50) Specificity.mp – 793646 
51) Predictive value of tests- MESH – 136172 
52) Positive predictive value*.mp - 25647 
53) Negative predictive value*.mp – 24978 
 
Combining “OR” searches 
54) 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 
13 or 14 – 70362 
55) 15 or 16 or 17 or 18 or 19 or 20 or 21 – 9651773 
56) 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 
32 or 33 or 34 or 35 – 436716 
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57) 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 
46 – 826469 
58) 47 or 48 or 49 or 50 or 51 or 52 or 53 – 1429831 
59) 55 or 56 – 9750420 
 
Combination “AND” searches 
60) 54 and 57 and 58 and 59 – 75 
61) 54 and 58 and 59 – 4475 
62) Limit 60 to humans and all adults aged 19 plus – 52 
63) Limit 61 to humans and all adults aged 19 plus - 2976 
 
After removing duplicates, these reduced to: 
 
62) 52 citations 
63) 2790 citations 
 
  
Embase (1980 to Week 22 2013) - searched completed: 
24/03/2014 
 
Disease 
1) (Heart) atrial fibrillation – MESH - 69630 
2) Atrial fibrillation.mp - 54189 
3) Auricular fibrillation*.mp - 884 
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4) Atrium fibrillation*.mp - 69636 
5) Af.mp - 45907 
6) A-fib.mp – 98 
7) Atrial flutter – MESH - 8403 
8) Atrial flutter*.mp - 5836 
9) Auricular flutter*.mp - 242 
10) Irregular pulse*.mp - 107 
11) Irregular heart*.mp - 247 
12) Heart beat*.mp - 7869 
13) Irregular rhythm*.mp – 176 
 
Screening 
14) Screen*.mp - 725649 
15) Diagnostic procedure - MESH – 11093533 
16) Diagnostic procedur*.mp – 85626 
17) Diagnosis – MESH - 4230862 
18) Diagnos*.mp - 2997012 
19) Identif*.mp - 2207650 
20) Test*.mp - 3018483 
21) Detect*.mp – 1845302 
 
Device 
22) Electrocardiography – MESH - 141891 
23) Electrocardiogram*.mp - 93464 
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24) Electrocardiograph*.mp - 146198 
25) Blood pressure monitors –MESH – 109 
26) Blood pressure monitor*.mp - 23151 
27) Blood pressure device*.mp - 260 
28) Ecg.mp - 65822 
29) Ekg.mp - 6484 
30) Holter.mp - 15340 
31) Event monitor*.mp - 1052 
32) Pulse adj3 test*.mp - 1375 
33) Pulse palpation.mp – 107 
34) Device*.mp - 334361 
35) Watch BP home A.mp – 0 
 
Professionals 
36) Physician – MESH - 325066 
37) Doctor*.mp – 176308 
38) Nurse – MESH - 100677 
39) Nurse*.mp – 277825 
40) Health personnel – MESH - 802719 
41) Healthcare worker*.mp - 5398 
42) Healthcare professional*.mp - 10331 
43) Primary Health Care – MESH - 98105 
44) Secondary health Care – MESH - 291 
45) Hospital – MESH - 585982 
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46) General Practice- MESH – 66974 
 
Testing 
47) Accuracy.mp - 444114 
48) Sensitivity and Specificity – MESH – 191084 
49) Sensitivity.mp - 837582 
50) Specificity.mp – 570265 
51) Predictive value - MESH – 34084 
52) Positive predictive value*.mp - 34537 
53) Negative predictive value*.mp – 34398 
 
Combining “OR” searches 
54) 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 
13 or  – 115107 
55) 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 – 13550282 
56) 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 
32 or 33 or 34 or 35 – 590094 
57) 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 
46 – 1596142 
58) 47 or 48 or 49 or 50 or 51 or 52 or 53 – 1466660 
59) 55 or 56 - 13677296 
 
Combination “AND” searches 
60) 54 and 57 and 58 and 59 –551 
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61) 54 and 58 and 59 – 6289 
62) Limit 60 to humans and all adult (<18 to 64 years) – 128 
63) Limit 60 to humans and all aged (<65+ years) – 134 
64) 62 or 63  - 179 
65) Limit 61 to humans and all adult (<18 to 64 years) – 2134 
66) Limit 61 to humans and all aged (<65+ years) - 1806 
67) 65 or 66  - 2646 
 
After removing duplicates, these reduced to: 
 
64) 116 citations 
67) 1362 citations 
  
CINAHL - search completed: 24/04/2014 
Disease 
( (MM "Atrial Fibrillation") OR "atrial fibrillation" OR (MH "Atrial 
Flutter") ) OR auricular fibrillation OR atrium fibrillation OR af OR a-
fib OR auricular flutter OR irregular pulse OR irregular heart OR 
irregular rhythm OR heart beat  
 
Above found 14,250 results 
 
Screening 
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( (MM "Diagnosis+") OR "diagnosis" OR (MM "Diagnosis, 
Cardiovascular+") OR (MM "Diagnosis, Computer Assisted+") ) OR 
screen OR identify OR test OR detect OR procedure  
Above found 917,175 
 
Device 
( (MM "Electrocardiography+") OR "electrocardiography" OR (MM 
"Electrocardiography, Ambulatory") OR (MM "Cardiography, 
Impedance") ) OR electrocardiogram OR blood pressure monitor 
OR blood pressure device OR ecg OR ekg OR holter OR event 
monitor OR pulse adj3 test OR pulse palpation OR device OR watch 
BP home A  
Above found 49,451 
 
Professionals 
( (MM "Physicians+") OR "physicians" ) OR doctor OR nurse OR 
health personnel OR healthcare worker OR healthcare professional 
OR primary health care OR secondary care OR hospital OR general 
practice  
 
Above found 451,595 
 
Testing 
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( (MM "Sensitivity and Specificity") OR "sensitivity" ) OR accucracy 
OR specificity OR predictive value of test OR positive predictive 
value OR negative predictive value  
 
Above found 81,595 
 
Combining “OR” Searches 
 
Screening + Device – 936,310 
 
Combination “AND” searches 
64) 1 AND AND 4 AND 5 AND 6 – 40 
65) 1 AND 5 AND 6 – 468 
 
Restricting for adult gives: 
1) 25 
2) 344 
 
After removing duplicates, the CINAHL search returned: 
1) 5 
2) 38 
  
LILACS - search completed:24/03/2014 
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((atrial fibrillation*) OR (auricular fibrillation*) OR (Atrium 
fibrillation*) OR (AF) OR (A-fib) OR (Atrial flutter*) OR (Auricular 
flutter*) OR (irregular pulse*) OR (irregular heart*) OR (heart 
beat*) OR (irregular rhythm)) AND ((Physician*) OR (Doctor*) OR 
(Nurse*) OR (health personnel) OR (healthcare worker*) OR 
(health care professional*) OR (primary health care) OR 
(secondary care OR hospital*) OR (general practice*)) AND 
((Accuracy*) OR (sensitivity) OR (specificity) OR (predictive value 
of test*) OR (positive predictive value*) OR (negative predictive 
value*)) AND (( 
((Screen*) OR (diagnostic procedure) OR (diagnos*) OR (identif*) 
OR (test*) OR (detect*)) OR ((electrocardiograph*) OR 
(electrocardiogram*) OR (blood pressure monitor*) OR (blood 
pressure device*) OR (ecg) OR (ekg) OR (holter) OR (event 
monitor*) OR (pulse adj3 test*) OR (pulse palpation) OR (device*) 
OR (watch BP home A))))  AND (db:("LILACS")) = 3 
 
((atrial fibrillation*) OR (auricular fibrillation*) OR (Atrium 
fibrillation*) OR (AF) OR (A-fib) OR (Atrial flutter*) OR (Auricular 
flutter*) OR (irregular pulse*) OR (irregular heart*) OR (heart 
beat*) OR (irregular rhythm)) AND ((Accuracy*) OR (sensitivity) 
OR (specificity) OR (predictive value of test*) OR (positive 
predictive value*) OR (negative predictive value*)) AND 
((((Screen*) OR (diagnostic procedure) OR (diagnos*) OR 
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(identif*) OR (test*) OR (detect*)) OR ((electrocardiograph*) OR 
(electrocardiogram*) OR (blood pressure monitor*) OR (blood 
pressure device*) OR (ecg) OR (ekg) OR (holter) OR (event 
monitor*) OR (pulse adj3 test*) OR (pulse palpation) OR (device*) 
OR (watch BP home A))))  AND (db:("LILACS")) = 20 
 
After removing duplicates compared to Medline and Embase, 
search 1 returns 3, search 2 returns 16. 
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Appendix 4: Chapter 6 - Healthcare professional survey 
 
  
 
 
 267 
 
 
 
 
 268 
 
 
 
 
 269 
 
  
 
 
 270 
 
 
 
 
 271 
 
 
 
 
 
 272 
 
 
 
 
 273 
 
 
 
 
 274 
 
 
 
 
 275 
 
 276 
Appendix 5: Research outputs 
Publications (peer reviewed) 
Taggar JS, Coleman T, Lewis S, Heneghan C, Jones M. Accuracy of 
methods for detecting an irregular pulse and suspected atrial 
fibrillation: A systematic review and meta-analysis. Eur J Prev 
Cardiol. 2016;23(12):1330-8. doi: 10.1177/2047487315611347. 
[Original research – Chapter 4] 
 
Taggar JS, Coleman T, Lewis S, Heneghan C, Jones M. Accuracy of 
methods for diagnosing atrial fibrillation using 12-lead ECG: A 
systematic review and meta-analysis. Int J Cardiol. 2015;184:175-
83. doi: 10.1016/j.ijcard.2015.02.014. [Original research – 
Chapter 5] 
 
Taggar JS, Coleman T, Lewis S, Jones M. Screening for Atrial 
Fibrillation - A Cross-Sectional Survey of Healthcare Professionals 
in Primary Care. PLoS One. 2016;11(4):e0152086. doi: 
10.1371/journal.pone.0152086 [Original research – Chapter 6] 
 
Taggar JS, Coleman T. Screening for atrial fibrillation in primary 
care: From recommendation to implementation. Eur J Prev Cardiol. 
2016;23(17):1880-1882 [Commentary] 
 
 
 277 
Abstract presentations 
Taggar J, Coleman T, Lewis S, Heneghan C, Jones M. Accuracy of 
methods for detecting Atrial Fibrillation: A systematic review.  
Society for Academic Primary Care Meeting. 9-11th July 2014, 
Edinburgh [Presentation] 
 
Taggar J, Coleman T, Lewis S, Heneghan C, Jones M. Accuracy of 
methods for diagnosing Atrial Fibrillation: A systematic review.  
Society for Academic Primary Care Meeting. 9-11th July 2014, 
Edinburgh [Presentation] 
 
Taggar JS, Coleman T, Lewis S, Jones M. Screening for Atrial 
Fibrillation - A Cross-Sectional Survey of Healthcare Professionals 
in Primary Care. Society for Academic Primary Care. Society for 
Academic Primary Care Annual Scientific Meeting. 6-8th July 2016, 
Dublin [Presentation] 
 
 
